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BACKGROUND 
Several mucosal routes, including nasal, buccal, rectal, ocular, pulmonary and vaginal 
routes,  have been investigated over the last decades as alternatives to oral and parenteral 
drug administration (Banga and Chien, 1988; Zhou and Li Wan Po, 1991b). With respect 
to the oral route, their major advantagesis the circumvention of the hepatic first pass 
metabolism and of chemical and enzymatic degradations that generally occur in stomach. 
Moreover, transmucosal drug administration can allow to avoid pain or discomfort 
caused by injections, when drugs are administered through parenteral routes and  
especially if multiple daily injections are required, thus increasing patient compliance.  
On the other side, the major disadvantage of transmucosal drug administration is 
represented by the presence of biological fluids and mucus that can remove drug systems 
from the application site, thus reducing the contact time between drug and mucosa and 
consequently, decreasing drug bioavailability. For this reason, in the recent years new 
muycoadhesive polymers (Peppas and Sahlin, 1996) were employed for the formulation 
of drug delivery systems able to increase their residence time and to improve drug 
bioavailability. Among these polymers, chitosancan adhere to mucosal surface thanks to 
its positive charge that can interact with negatively charged mucus. Moreover, chitosan 
can promote drug permeation through opening the thigh junction of mucosal membrane. 
These properties, in addition to other characteristics like biocompatibility, 
biodegradability and non- toxicity, allow to use this material for the formulation of 
several transmucosal drug formulations (Luppi, et al., 2010b).  
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SUMMARY 
In this project thesis, chitosan based mucoadhesive systems for buccal, vaginal and nasal 
drug administration were formulated and characterized in order to study their chemical-
physical properties and their ability to release drugs. 
In the paper 1, buccal films based on chitosan-gelatin complexes were prepared and 
loaded with propranolol hydrochloride. The complexes preapared with different amount 
of chitosan and gelatin, were characterized and studied in order to evaluate their physical-
chemical properties and their ability to release the drugand to allow its permeation 
through buccal mucosa. 
In the paper 2, vaginal inserts based on chitosan/alginate complexes were formulated for 
local delivery of chlorhexidine digluconate. Tests to evaluate the interaction between the 
polymers and to study drug release properties were performed, as well as the 
determination of antimicrobial activity against the patogens responsible of vaginitis and 
candidosis.  
In the project 3, chitosan based nanoparticles containing cyclodextrin and other 
excipients, with the capacity to modify insulin bioavailabity were formulated for insulin 
nasal delivery. Nanoparticles were characterized in terms of size, stability and drug 
release. Moreover,in vivo tests were performed in order to study the hypoglycemic 
reduction in rats blood samples.  
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1. ADMINISTRATION ROUTES 
Drugs can be introduced into the body by several routes, according to the physical-
chemical properties of drugs, the existence of preparations appropriate for their uses and 
the patient state (Fig. 1.1). In particular, they may be: 
 taken by mouth (orally); 
 given by injection into a vein (intravenously), into a muscle (intramuscularly), 
into the space around the spinal cord (intrathecally), or beneath the skin 
(subcutaneously); 
 placed under the tongue (sublingually); 
 inserted in the rectum (rectally) or in the vagina (vaginally); 
 placed in the eye (by the ocular route); 
 sprayed into the nose and absorbed through the nasal membrane (nasally); 
 breathed into the lungs, usually through the mouth (by inhalation); 
 applied to the skin (cutaneously) for a local (topical) or bodywide (systemic) 
effect; 
 delivered through the skin by a patch (transdermally) for a systemic effect. 
 
Fig 1.1 Schematic representation of several administration routes. 
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Each route has specific purposes, advantages, and disadvantages. 
1.1 Oral Route.The oral route is the most often used route, because it is convenient, safe 
and not expensive. Drugs can be administered orally as liquids, capsules, tablets, or 
chewable tablets and can be absorbed from the mouth until the intestine. Drugs, 
administered through oral route, pass through the intestinal wall and travels to the liver 
before they are transported via the bloodstream to its target site. The transit of drugs 
through the stomach and the liver can alter their physical-chemical structure, due to the 
presence of acidic medium in the stomach and of enzymatic process in the 
gastrointestinal tract and in the liver (first pass effect) that can metabolize or destroy 
many drugs. Consequently, a decreased amount of drugs reaches the bloodstream and  an 
increase in daily administration is often necessary to obtain the pharmacological effect, 
with a consequent decrease in patient compliance.  Moreover, in oral administration, food 
and other drugs in the digestive tract may affect the drug amount that is absorbed and the 
absorption velocity. For this reason, many drugs should be taken on an empty stomach, 
others should be taken with food, others should not be taken with certain other drugs. 
Some orally administered drugs, such as aspirin or non steroidal anti-inflammatory drugs,  
irritate the digestive tract and cause or aggravate preexisting ulcers. Finally, the oral route 
is not usable if the patient refuses to take it or vomits. 
 
The oral route can be used for a local or general treatment:  
 Local treatment: for the treatment of  intestinal infection or a parasitosis. In this 
case, drugs will not be absorbed or only poorly absorbed.  
 General treatment: it is the usual route of administration of drugs and in this case, 
drugs are absorbed and reach the bloodstream.  
 
At the stomach level, drugs absorption is favored by the great absorption area (about 
1m
2
), but the pH, approximately around 1-2,  can destroy drugs, especially peptide and 
proteins or drugs that are unstable under acidic conditions. Generally, only neutral 
molecules and not ionized acids in an acid pH are absorbed from the stomach.  
The majority of drugs are absorbed through intestinal mucosa, that is characterized by an 
high area surface (from 200 to 300m
2
), alkaline pH (from 6 to 8) and an  important blood 
irrigation (1 L/minute). In the portion of digestive tract, including the rectum, drug 
absorption is very variable.  
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Generally, neutral and liposoluble molecules, but not those completely insoluble in water, 
can be adsorbed by passive diffusion through the lipid bilayer; amino acids, sugars and 
certain peptides by secondary active transport; elements in the form of ions, cations and 
anions by complex mechanisms. 
Other routes of administration are required when the oral route cannot be used: for 
example, when a person cannot take anything by mouth, when a drug must be 
administered rapidly or in a precise or very high dose, or when a drug is poorly or 
erratically absorbed from the digestive tract(G.D. Anderson and  Russell P. Saneto 2012). 
 
1.2 Injection Routes: Administration by injection (parenteral administration) includes the 
subcutaneous, intramuscular, intravenous, and intrathecal routes. These routes are 
characterized by a low patient compliance due to the use of needles and the consequent 
discomfort caused by the injections.  
The subcutaneous route is used for many protein and peptidic drugs, for example insulin 
and heparin,that can be destroyed in the digestive tract if they aretaken orally. In this 
case, drug is administered through a needle, inserted into the fatty tissue beneath the skin. 
After the injection, drug moves directly into small blood vessels (capillaries) and carried 
away by the bloodstream or reaches the bloodstream through the lymphatic vessels. 
Certain drugs may be given by inserting plastic capsules under the skin (implantation), 
thus providing a long-term therapeutic effect (for example, etonogestrel that is implanted 
for contraception may last up to 3 years). 
For the intramuscular routedrugs are usually injected into the muscle of the upper arm, 
thigh, or buttock. This route is preferred to the subcutaneous route when larger volumes 
of a drug product are needed or when it is necessary to inject aqueous or oily solutions. 
Generally,a longer needle is used because the muscles lie below the skin and fatty tissues. 
Drug absorption depends primarily on the tissue vascularization. Recently, delayed 
preparations that gradually release forover one or many weeks the drugs from the 
anatomic site of injection into the circulation,have beenproduced. The intramuscular 
injection should not be made in a vessel, or in contact with a nerve. It is contra-indicated 
if the patient is undergoing anticoagulant therapy. 
For the intravenous route, a needle is inserted directly into a vein. A solution containing 
the drug may be given in a single dose or by continuous infusion, that is moved by 
gravity (from a collapsible plastic bag) or, more commonly, by an infusion pump through 
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thin flexible tubing to a tube (catheter) inserted in a vein, usually in the forearm. With an 
intravenous administration it is possible to deliver a precise dose quickly and in a well-
controlled manner throughout the body. It is also used for irritating solutions, which 
would cause pain and damage tissues if given by subcutaneous or intramuscular injection.  
It is very important to control the speed of administration to avoid the risks of severe 
reactions or to ensure the effective therapeutic concentration. Moreover,  the intravenous 
injection can be more difficult in obese person and in patient that refuses the needle. 
When given intravenously, a drug, delivered immediately to the bloodstream, tends to 
take effect more quickly than when given by any other route.  
For the intrathecal route, a needle is inserted between two vertebrae in the lower spine 
and into the space around the spinal cord. The drug is then injected into the spinal canal 
to produce rapid or local effects on the brain, spinal cord, or the layers of tissue covering 
them (meninges)-for example, to treat infections of these structures. A small amount of 
local anesthetic is often used to numb the injection site. Anesthetics and analgesics (such 
as morphine) are sometimes given by this way. 
1.3 Cutaneous Route. This route is often used to treat some superficial skin disorders, 
such as psoriasis, eczema, skin infections (viral, bacterial, and fungal), itching and dry 
skin.  
1.4 Transdermal Route: Some drugs are delivered bodywide through a patch on the skin 
without any injection. Through a patch, the drug can be delivered slowly and 
continuously for many hours or days or even longer, thus maintaining the levels of a drug 
in the blood relatively constant. Patches are particularly useful for drugs that are quickly 
eliminated from the body. However, patches may irritate the skin of some people and are 
limited by how quickly the drug can penetrate the skin.  
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2. TRANSMUCOSAL ROUTES 
 
Transmucosal routes involve the delivery of the drug through the mucosal linings of the 
nasal, rectal, vaginal, ocular and oral sites.  
Traditionally drugs are administered by oral and by parenteral routes. Although generally 
convenient, both routes have a number of disadvantages. In fact, in the case of oral 
administration drugs are exposed to the  harsh environment of the gastrointestinal tract 
and they are subject to the chemical and enzymatic degradation. Moreover, after 
gastrointestinal absorption the drug has to pass the liver, where, dependent on the nature 
of the drug, extensive first pass metabolism can take place with subsequent rapid 
clearance from the blood stream (Lalka et al., 1993; Taki et al., 1998). For 
macromolecular drugs  a low permeability across the gastrointestinal mucosa is also often 
encountered (Yamamoto et al., 2001; Pauletti et al., 1997). Parenteral administration 
avoids drug degradation in the gastrointestinal tract and hepatic first pass clearance but, 
due to pain or discomfort during injection, patient compliance is poor, particularly if 
multiple daily injections are required (Hinchcliffe and Illum, 1999). The  injections are 
responsible of several side effects like tissue necrosis and thrombophlebitis,leading to 
low patient acceptability (Zhou, 1994).  
For these reasons, several mucosal routes,including nasal, buccal, rectal, ocular, 
pulmonary and vaginal,have been investigated over the last decades as alternatives to oral 
and parenteral drug administration (Banga and Chien, 1988; Zhou and Li Wan Po, 
1991b). Their major advantage is the easy accessibility and circumvention of the hepatic 
first pass metabolism. In the following, a short overview over the different alternative 
mucosal drug delivery routes is given. 
 
2.1 Buccal route. The oral cavity is lined by a stratified squamous epithelium that is non-
keratinized in the buccal, lingual, and sublingual mucosa regions (Chien, 1995; 
Hoogstraate and Wertz, 1998). Although non-keratinized, the buccal mucosa contains 
intercellular lipids which are responsible for its physical barrier properties (Hoogstraate 
and Wertz, 1998; Shojaei, 1998), resulting in poor permeability for larger drugs, 
especially for peptides and proteins (Junginger et al., 1999; Veuillez et al., 2001). A more 
extended discussion on buccal mucosa as administration route will be madein the 
following chapters. 
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The sublingual epithelium is more permeable than the buccal one but the presence of 
saliva and the region motility can remove formulations from the absorption site (Shojaei, 
1998). The sublingual route is especially used to obtain a fast and immediate effect 
because drugs can be adsorbed directly into the small blood vessels that lie beneath the 
tongue, without first passing through the intestinal wall and liver.  
Dosage forms for buccal drug delivery include tablets, patches, films, lozenges, sprays, 
hydrogels, lollypops, chewing gums, powders, solutions (Hoogstraate and Wertz, 1998) 
and liposomal formulations (Veuillez et al., 2001). In order to enhance their permeation 
or to protect drugs from enzymatic degradations, absorption enhancer (Merkle et al., 
1992) and proteases (Bird et al., 2001; Veuillez et al., 2001; Walzer et al., 2002) can be 
used, while the use of bioadhesive formulations can improve the residence time inside the 
oral cavity (Shojaei, 1998; Veuillez et al., 2001; Langoth et al., 2003).  
 
2.2 Rectal Route. This route is preferable when people cannot swallow or have nausea or 
restrictions on eating. It is safe and convenient, especially for children, but the acceptance 
is low particularly among adults. The drugs are readily absorbed thanks the high 
vascularization of rectum tract and the thin wall. Moreover, the presence of a  
considerable protease activity and of bacterial flora (Lewin et al., 1986; Hacker et al., 
1991; Zhouand Li Wan Po, 1991b) can alter drug activity and additionally, the 
circumvention of the hepatic first pass metabolismby rectal administration is only partial 
and depends on the positioning and/or spreading ofthe drug formulation (de Boer and 
Breimer, 1997; Kurosawa et al., 1998).Generally, drugs are administered with a 
substances that dissolve or liquefy after it is inserted into the rectum (Lejus et al., 1997; 
Jensen and Matsson, 2002). Traditional rectal dosage forms are suppositories, unguents 
and creams, as well as enemas.More recent studies have evaluated thermogelling dosage 
forms (Miyazaki et al., 1998), gels(de Leede et al., 1986), osmotic mini pumps 
(Teunissen et al., 1985) and hard gelatincapsules (Eerikainen et al., 1996) as rectal drug 
delivery systems.  
 
2.3 Vaginal Route. This route can be used for local delivery of some drugs, such as 
antibacterial, antifungal, antiprotozoal, antiviral, labor-inducing, spermicidal agents, 
prostaglandins and steroids (Vermani and Garg, 2000) or to obtain a systemic drug 
absorption. In fact, vagina is characterized by a large surface area with high permeability 
and a high vascularization, so that can be used for administration of  steroids (Ho et al., 
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1976; Alvarez et al., 1983). The vaginal route has also the potential for uterine targeting 
of active agents such as progesterone and danazol (Bulletti et al., 1997; Cicinelli et al., 
1998). However, changes of vaginal characteristics with age, stage of menstrual cycle, 
infections, and sexual arousal (Vermani and Garg, 2000) can influence the drug 
absorption. Moreover, vaginal flora can potentially contribute to enzymatic drug 
degradation in addition to the membrane-bound enzymes of the vaginal mucosa (Chien, 
1995; Vermani and Garg, 2000). Limitations of systemic vaginal drug delivery next to the 
physiological barriers are also the gender specificity and the relatively low 
convenience.Drugs may be administered vaginally to women as creams, gels, tablets, 
capsules, pessaries, foams, films, tampons, vaginal rings and douches (Vermani and 
Garg, 2000). A more extended discussion on vaginal mucosa as administration route will 
be madein the following chapters. 
 
2.4 Ocular Route. This route is typically used for a local drug delivery, especially for the 
treatment of glaucoma or ocular infection and inflammation. Drugs are mixed with 
excipients in order to obtain several formulations, such as  liquid, gel or ointment. Liquid 
eye drops are relatively easy to use but may run off the eye too quickly to be absorbed 
well. Gels and ointment formulations keep the drug in contact with the eye surface longer 
but they may blur vision. Solid inserts, which release the drug continuously and slowly, 
are also available, but they may be hard to put in and keep in place.  Fluids, introduced 
into the eye, arerapidly drained from the precorneal area to the nasal cavity and throat; a 
consequence of this mechanism is the low bioavailability. For this reason, in order to 
increase drug absorption, inactive substance that increase fluid viscosity or mucoadhesive 
polymers can be used. Novel formulations include drops, suspensions, oily drops, 
unguents and mucoadhesive ocular delivery systems such as solutions and microparticle 
suspensions, in-situ gelling systems triggered by pH, temperature or ions, colloidal 
delivery systems such as liposomes and nanoparticles and ocular inserts (Le Bourlais et 
al., 1995). Ocular inserts can be divided into non-erodible (Chetoni et al., 1998; 
Kawakami et al., 2001) and erodible inserts. Erodible ocular inserts, which do not need to 
be removed mechanically from the eye, have been prepared by powder compression from 
poly(ethylene oxide) (Di Colo et al., 2001), from bioadhesive mixtures of poly(ethylene 
oxide) with chitosan hydrochloride (Di Colo et al., 2002), and from mixtures of 
Carbopol® 974P with drum dried waxy maize starch (Ceulemans et al., 2001; 
Weyenberg et al., 2003). Finally, ocular inserts have also been prepared by freeze-drying 
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aqueous solutions of water soluble polymers such as HPMC resulting in a sponge-like 
structure (Diestelhorst et al., 1999; Lux et al., 2003). 
Recently, this route has been investigated for the systemic delivery of peptides and 
proteins. Already in 1931, ocular administration of insulin produced sustainedlowering of 
the blood glucose level in proportion to the dose instilled (Christie and Hanzal,1931). 
However, systemic drug absorption afterocular instillation takes place across the nasal 
mucosa after drainage via the nasolachrymalduct (Lee et al., 2002). In addition, 
drugabsorption via the cornea is relatively low due to the lipophilicity of the corneal 
epithelium,dilution of the drug in the tear fluid (reflex tearing and reflex blinking) and 
drug binding toproteins in tear fluid and the presence of enzymes can alter drug activity 
(Zhou and Li Wan Po,1991b).  
 
2.5 Nasal Route. The nasal route of administration has received a great deal of attention 
in recent years as a convenient and reliable method not only for local but also for 
systemic administration of drugs (Schipper et al., 1991; Sakar, 1992; Merkus and 
Verhoef, 1994; Kublik and Vidgren, 1998; Marttin et al., 1998; Davis, 1999; Hinchcliffe 
and Illum, 1999; Martini et al., 2000; Chow et al., 2001; Illum, 2003). Drug is absorbed 
through nasal mucosa, that show a large surface area and a great vascularization, and 
directly enters the blood stream.The nasal cavity offers a number of unique advantages 
such as easy accessibility, good permeability especially for lipophilic, low molecular 
weight drugs, avoidance of harsh environmental conditions and hepatic first pass 
metabolism, potential direct delivery to the brain. The ciliary movement and the 
considerable enzyme activity can remove the formulation from the site absorption and 
can destroy the drug. Nevertheless, a number of approaches have been used to 
overcomethese limitations such as the use of bioadhesive formulations to increase the 
nasal residencetime of dosage forms (Morimoto et al., 1991; Soane et al., 2001), addition 
of absorptionenhancers to increase the membrane permeability (De Ponti, 1991; Merkus 
et al., 1993; Illum,1999, Natsume et al., 1999), and the use of protease/peptidase 
inhibitors to avoid enzymaticdegradation of peptide and protein drugs in the nasal cavity 
(Morimoto et al., 1995; Dondetiet al., 1996). Several nasal dosage forms are under 
investigation including solutions (drops or sprays), gels, suspensions and emulsions, 
liposomal preparations, powders and microspheres,as well as inserts. A more extended 
discussion on nasal mucosa as administration route will be madein the following 
chapters. 
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2.6 Inhalation. Usually, this route is used to administer drugs that act specifically on the 
lungs, such as aerosolized antiasthmatic drugs in metered-dose containers, and to 
administer gases used for general anesthesia. The interesting properties of the lung, such 
as the large surface area of about 150 m
2
 and an extremely well vascularized thin 
epithelium, lead many authors to study this route for the systemic drug delivery lung (Qiu 
et al., 1997; Adjei and Gupta,1998; Edwards et al., 1998).Drugs administered by 
inhalation through the mouth must be atomized into smaller particles than those 
administered by the nasal route, so that the drug can pass through the windpipe (trachea) 
and into the lungs. How deeply into the lungs they go depends on the size of the droplets 
and smaller droplets go deeper. Moreover, the particle size should be in the aerodynamic 
diameter window of 0.5 - 5 μm, ideally 2 - 3 μm, for deep lung delivery to avoid loss of 
delivered particles by impaction onto the mucus lined epithelia. The aerodynamic 
diameter relates the geometric particle diameter and the particle mass density. Thus, large 
porous particles are effective means for drug delivery to the alveolar region (Edwards et 
al., 1997; Vanbever et al., 1999; Crowder et al., 2002). In addition, the high humidity in 
the airways furthers particle agglomeration, thus decreasing the delivery efficiency due to 
hygroscopic growth (Malcolmson and Embleton, 1998; Crowder et al., 2002).  
Drug administration through this route must be carefully monitored to ensure that a 
person receives the right amount of drug within a specified time. In addition, specialized 
equipment may be needed to give the drug by this route.  
A number of technologies for the delivery of drug formulationshave been developed 
(Martini et al., 2000): (i) pressurized metered dose inhalers usingpropellants to deliver 
micronized drug suspensions (Autohaler®, Spacehaler®), (ii) dry powderinhalers which 
dispense micronized drug particles with/without carrier (lactose) byinhalation activation 
(Spinhaler®, Rotohaler®, Diskhaler®), and (iii) nebulizers and aqueousmist inhalers 
which aerosolize drug solutions using compressed air or ultrasound 
(AERx®,Respimat®).  
A prolonged drug delivery can be obtained using polymeric particle 
formulations(Kawashima et al., 1999; Zhang et al., 2001) and mucoadhesive formulations 
(Takeuchi et al.,2001) but the accumulation of polymeric material in the alveoli has to be 
taken into consideration as well asthe possible delivery related development of fibrosis. 
Finally, the lungs contain high levels ofhydrolytic and other enzymes, which can become 
significant absorption barriers to drugs,although the metabolic activity of the lung is 
much lower than in the gastrointestinal tract (Adjei, 1997). 
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3. BUCCAL ROUTE 
 
Delivery of drugs to the oral cavityhas attracted particular attention due to its potential for 
high patientcompliance and unique physiological features. 
Within the oral mucosalcavity, the delivery of drugs is classified into two categories: (i) 
localdelivery,which is drug delivery into the oral cavityand (ii) systemic delivery either 
via the buccal mucosa,through the mucosal membranes lining the cheeks or 
sublingualmucosa, through the mucosal membranes lining the floor of the mouth. The 
sublingual mucosa is more permeable because more thin than the buccal mucosa and 
because it shows a considerable surface are and a high blood flow. It is used when a rapid 
onset is desired; in particular, for the treatment of acute disorders. It  is not always useful, 
because the constant washing effect of saliva, the tongue activity and the lack of an 
expanse immobile mucosa limit the permanence of the dosage form at the administration 
site.  
The buccal mucosa offers many advantages: 
a) a smooth and relatively immobile surface, 
b) suitability for the placement and removal of controlled-release systems, 
c) high patient compliance, 
d) relatively permeable in comparison to the other mucosal tissues, 
e) drugs can be administered to unconscious and trauma patients, 
f) avoidance of first-pass effect that leads to significant reduction in dose. 
However, buccal drug delivery shows the following limitations: 
a) drug chemical modification due to saliva enzymes activity, 
b)  involuntary swallowing and constant salivary scavenging canresult in drug loss 
fromthe site ofabsorption, 
c) relatively small absorption area and the barrier property of the buccalmucosa 
contribute to the inherent limitations of this delivery route, 
d) drug selection for oral transmucosal delivery is limited by thephysico-chemical 
properties of the drugs themselves and only few milligrams of drug can cross the 
oral mucosa (Harris and Robinson, 1992; Junginger et al., 1999; N. Salamat-
Miller et al., 2005; Shojaei A.H, 1998, Viralkumar F. et al., 2011 and Ghandi et 
al., 1994). 
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3.1 Anatomy and nature of oral cavity 
The oral cavity may be divided in two regions: the outer oral vestibule, boundedby the 
lips and cheeks; the oral cavity itself, the border being formed by the hard andsoft palates, 
the floor of the mouth and tonsils (Shojaei A.H, 1998; Satheesh Madhav et al., 2009; 
Salamat-Miller et al., 2005 and Ghandi et al., 1994). 
 
 
Fig. 3.1 Anatomy of oral cavity.  
(http://www.cancer.gov/cancertopics/pdq/treatment/lip-and-oral-
cavity/Patient/page1/AllPages) 
 
The oral cavity comprises lips, cheek, tongue, hard palate, soft palate and floor of the 
mouth (Fig. 3.1) and its lining, referred to as the oral mucosa(including buccal, 
sublingual, gingival, palatal and labial mucosa).  
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Fig. 3.2 Oral mucosa (Viralkumar F. et al., 2011) 
The oral mucosa is made up of a layer of stratified squamous epithelium with closely 
compacted epithelial cells; their function is to protect the underlying tissue against 
potential harmful agents in the oral environment and from fluid loss (Fig. 3.2). Beneath 
the epithelium are the basement membrane, lamina propria and submucosa.  
Three types of oral mucosa can be found in the oral cavity: the lining mucosa, the 
masticatory mucosa and the specialized mucosa approximately 60%, 25% and 15% of the 
total oral mucosal surface, respectively. The lining mucosa is found in the outer oral 
vestibule (buccalmucosa) and the sublingual region (floor of the mouth) and it has a non-
keratinized epithelium, which sits on a thin and elastic lamina propria and a submucosa. 
The masticatory mucosa is found on the hard palate (the upper surface of the mouth) and 
the gingiva (gums) that are particularly susceptible to the stress and it consist of an 
epithelium with keratinized cells, a thick lamina propria and the underlying periosteum. 
In the dorsum of the tongue there is a  specialized gustatorymucosa, with both keratinized 
and some non-keratinized cells. The keratinized epithelia contain neutral lipids like 
ceramides and acylceramides which have been associated with the barrier function. These 
epithelia are relatively impermeable to water. In contrast, non-keratinized epithelia, such 
as the floor of the mouth and the buccal epithelia do not contain acylceramides and only 
have small amounts of ceramide. 
The most important sites for drug delivery are the buccal and the sublingual membranes 
that show a total area of 5.02cm
2
 and 26.5cm
2
, respectively. 
The oral mucosal thickness varies depending on the site: thebuccalmucosameasures at 
500-800 μm,while themucosal thickness ofthe hard and soft palates, the floor of the 
mouth, the ventral tongue andthe gingivae measure at about 100-200 μm.  
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3.1.1 Composition of Mucus Layer : 
The epithelial surface is covered by a thin, continuous layer gel, called mucus that shows 
a mean thickness from about 50-450 μm(Satheesh Madhav et al., 2009). It is secreted by 
the goblet cells lining the epithelia or by special excessive glands with mucus cell acni. 
Mucus is composed of water (95%),glycoproteins,known as mucins,lipids (0.5-3.00%), 
mineral salts (1%) and free proteins (0.5-1.0%). Mucus protects and hydrates the oral 
cavity and plays an important role in bioadhesion of mucoadhesive drug delivery 
systems. At physiological pH, the mucus network carries a negative charge (due to the 
sialic acid and sulfate residues) and can form a strongly cohesive gel structure with the 
bioadhesive system.  
3.1.2 Salivary secretion : 
Saliva protects all tissues of oral cavity fromabrasion by rough materialsand from 
chemicals,aids the digestion of foods, lubricates the food for mastication and swallowing.  
Saliva is an aqueous fluid with 1% organic and inorganic materials and is secreted by 
perotid, sublingual and sub-mandibularglands. The salivary pH rangesfrom 5.5 to 7 
depending on the flow rate. The amount of saliva in the oral cavity is around 1.1 ml, 
although the daily salivary production is between 0.5 and 2 l .  
Saliva provides a water rich environment of the oral cavity where the pharmaceutical 
formulations must be dissolved to provide drug release. However, the presence of saliva 
can dilute the drug and remove the formulation form the site absorption before effective 
absorption occurs through the oral mucosa, thus also reducing the amount of permeated 
drug.  
3.1.3 Blood Supply to Oral Mucosa: 
The blood supply to the oral cavity tissue is delivered via the external carotid artery 
which branches into the maxillary, lingual and facial arteries. Blood from the capillary 
beds is collected by three main veins that finally flow into the internal jugular vein. Thus 
delivery of drugs via the oral mucosa drains directly to the systemic circulation and the 
hepatic first passmetabolism is avoided. 
3.2 Oral drug delivery 
Buccal cavity can be used for local and systemic drug delivery. 
Local drug delivery. Buccal local administration is used for the treatment of topical 
pathologies such oral infections, dental caries, mouth ulcers andstomatitis. 
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Systemic delivery. Buccal administration is an effective way to systemically delivery of 
drugs as an alternative to oral and intravascular routes, thanks to interesting buccal 
mucosa properties. 
3.2.1 Mechanism of drug absorption 
Drugs can cross the oral mucosa through different routes.One route involves the 
paracellular pathway(also called extracellular route) and consist in drug passage through 
the inter-cellular space; while the other route, the transcellular (also called intracellular 
route),  involvesits passage into and across the cell. 
The hydrophilic nature of the paracellular spaces and cytoplasmprovides a permeability 
barrier to lipophilic drugs but can be favorable for hydrophilic drugs. In contrast, the 
lipophilic cell membrane offers a preferable route for lipophilic drugs compared to 
hydrophilic compounds (Fig. 3.3).  
 
 
Fig. 3.3 Buccal mucosa and mechanism of drug absorption 
3.2.2 Barriers to drug absorption 
Drug permeability is influenced by the structure and the function of the several oral 
cavity regions. In particular, the permeability of the oral mucosa decreases in this order: 
sublingual greater than buccal and buccal greater than palatal (Satheesh Madhav et al., 
2009); this behavior is due to the different mucosa thickness and degree of keratinization. 
Generally, the permeability decreases with the increase of thickness and keratinization 
degree.  Moreover, the most important barrier to drug absorption is represented by the 
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intercellular lipid materials derived from the so-called membrane coating granules 
(MCGs),  spherical or oval organelles, 100–300 nm in diameter, that migrate to the apical 
surface of the cell where their membranes fuse with the cell membranes and the lipid 
content is extruded in the extracellular space.  
The membrane coating granules of keratinized epithelium are composed of lamellar lipid 
stacks, whereas the non-keratinized epithelium contains membrane coating granules that 
are non-lamellar. The membranecoating granule lipids of keratinized epithelia include 
sphingomyelin,glucosylceramides, ceramides and other non-polar lipids. However, 
fornon-keratinized epithelia, the major membrane coating granule lipidcomponents are 
cholesterol esters, cholesterol and glycosphingolipids.  
3.2.3 Crucial factors for buccal drug delivery 
For buccal administration, the design of a dosage form is influenced by several aspects, 
such as the physical-chemical and organoleptic drug properties, formulation 
characteristics and physiological conditions(Shojaei A.H, 1998; Satheesh Madhav et al., 
2009).  
Drug and system characteristics: 
Molecular size and weight influence the diffusivity of the drug through theepithelial layer 
and generally, the larger the molecule the more difficult it is to moveabout, and the lower 
will be the diffusivity. Hydrophilic drugs andsmall molecules (<75-100 Da) appear to 
cross oral mucosa rapidly, althoughpermeability falls off rapidly as molecular size 
increases. The pKa of the drug plays also an important role in its absorption across the 
lipid membranes of the oral mucosa; in fact, drugs ionized at the oral cavity pH (around 
6.8) can difficulty cross the oral mucosa.  
The organoleptic properties of a drug and the type of delivery system can influence the 
patient compliance or the acceptance of the product. The design of a drug delivery system 
is also influenced by the area surface in contact with the formulation (about 2cm
2
); for 
this reason a drug delivery system for buccal administration, that is  easily applied, can 
deliver only small amount of drug (10-20 mg).Therefore, buccal drug delivery is suitable 
only for drugs whose daily dose is in the orderof a few mg. 
Finally, idealformulation and its degradation products should be non-toxic, nonirritant 
and free from leachable impurities.  
Physiological conditions.The formulation of a drug delivery system must take into 
account that the presence of saliva and the swallowing can remove the formulation from 
the absorption site; moreover, the buccal mucosa is relatively permeable due to the 
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presence of MCGs. For this reason, generally mucoadhesive polymers and absorption 
enhancers can be used in order to increase residence time formulation and drug 
absorption (Mizrahi and Domb, 2008). Thebioadhesion performance should not be 
impacted by surroundingenvironmental pH(Sudhakar et al., 2009). 
Another barrier to the drug permeability across buccal epithelium is enzymatic 
degradation due to esterases, carbohydrases and phosphatases contained in saliva.  
 
3.3 Oral transmucosal dosage forms 
Several buccal drug delivery devices have been developed by many researchers either for 
local or systemic actions(Satheesh Madhav et al., 2009 and Viralkumar F. et al., 2011). 
They are broadly classified into (i) Solid dosage forms (ii) Semi-solid dosage forms (iii) 
Liquid dosage forms.  
3.3.1 Solid buccal adhesive dosage forms 
They are dry formulations which achieve bioadhesion via dehydration of the local 
mucosal surface. 
Buccal Tablets and lozenges 
Tablets and lozengeshave been the most commonly investigated dosage forms for buccal 
drug delivery (Llablot at., 2002); these dosage forms, when exposed to saliva rapidly 
dissolve and  the total amount of the drug that can be delivered is limited. For this reason,  
mucoadhesive polymers can be used in order to increase the residence time of the 
formulation inside the oral cavity.Buccal mucoadhesive dosage forms can also be 
categorized into three types on the basis of geometry. Type I is a single layer device with 
multidirectional drug release that is characterized by a great loss of drug in the oral cavity 
due to the saliva washing effect and swallowing (Fig. 3.4 a,d). In the type II devices, an 
impermeable backing layer is superimposed on top of the drug-loaded bioadhesive layer, 
creating a double-layered device, preventingdrug loss from the top surface of the dosage 
form into the oral cavity (Fig. 3.4b, c). Type III is a unidirectional release device, from 
which drug loss is minimal, since the drug is released from the side adjacent to the buccal 
mucosa(Fig. 3.4e and f). This can be achieved by coating every face of the dosage form, 
except the one that is in contact with the buccal mucosa(Rossi et al., 2005).The 
bioadhesive polymers can be incorporated into a matrix containing the active agent and 
excipients and perhaps a second impermeable layer to allow unidirectional drug delivery. 
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The most important disadvantage of solid dosage forms is the poor patient compliance 
especially for children.  
 
Fig. 3.4 Schematic representation representation of different types of matrix tablets 
designed for buccaldrug delivery system (Rossi et al., 2005) 
 
Bioadhesive micro/nanoparticles 
Recently, different studies have demonstrated the interesting properties of micro and 
nanoparticulate systems in buccal drug delivery (Kockisch et al., 2004 and 2003; 
Holpuch et al., 2010).Bioadhesive micro/nanoparticles have the advantage of being 
relatively small and more likely to be acceptable by the patients but their physical 
properties enable them to make intimate contact with a lager mucosal surface area. These 
are typically delivered as an aqueous suspension or are incorporated into a paste or 
ointment or applied in the form of aerosols  
3.3.2 Semi-solid dosage forms 
Medicated chewing gums 
Chewing gum is one of the modern approaches to oral transmucosal drug delivery and is 
a useful means for systemic drug delivery. These formulation are convenient and can 
deliver the drug for an extended period of time, increasing drug bioavailability. Some 
commercial products are available in the market, such as the caffeine chewing gum (Stay 
THEORETICAL SECTION-BUCCAL ROUTE 
Angela Abruzzo-University of Bologna Pag. 34 
 
Alert®) that was developed for alleviation of sleepiness and nicotine chewing gums (e.g., 
Nicorette® and Nicotinelle®) for smoking cessation. 
Adhesive Gels 
Various adhesive gels may be used to deliver drugs via the buccal mucosa and allow 
sustained release. They may deliver variable amount of drug in comparison with a unit 
dosage formand as a result have limited uses for drugs with narrow therapeutic window; 
another limitation of semisolid dosage forms is the low retention time into the oral cavity. 
Gel forming bioadhesive polymers has been used to adhere to the mucosal surfaces for 
extended periods of time and provide controlled release of drug at the site of absorption 
(Perioli et al., 2008).  
3.3.3 Buccal patches/films 
Patches are laminates, 1-3 cm
2
 in size, consisting of an impermeable backing layer, a 
drug-containing reservoir layer from which the drug is released in a controlled manner, 
and a bioadhesive surface for mucosal attachment. Flexible films/patches have been 
prepared either by solvent casting or hot melt extrusion technique to deliver drugs 
directly to a mucosal membrane. Compared to semisolid dosage forms, they offer 
advantages in delivering a measured dose of drug to the site.In general, oral mucosal 
patches can be classifiedinto three categories: patches with a dissolvable matrix, patches 
with anon-dissolvable backing and patches with a dissolvable backing.Patches with a 
dissolvable matrix are designed to release drug into theoral cavity. They work similarly 
to, and share many of the limitationsof, the solid dose form. The mucoadhesive layer, 
either in the drugmatrix or attached to drug matrix as an additional layer, prolongs 
theduration of drug matrix in the oral cavity. Therefore, compared withother open dosage 
forms, these types of patches are longer acting andcan potentially deliver more drug. 
Patches with non-dissolvablebacking are usually designed for systemic delivery. Since 
they areclosed systems and the formulations are protected from saliva, thedrug 
concentration is controlled and drug is continuously deliveredfor 10 to 15 h (Viralkumar 
F. et al., 2011). Recently, different authors have investigated buccal patch/film properties 
for drug delivery and a great attention has been focused on the possibility to deliver drugs 
through buccal route (Burgalassi et al., 1996; Cheng, et al., 1997 and 1993; Reinhold & 
Hans, 1989; Peh, et al., 1999; Kohda et al., 1997; Remuñán-et al., 1998and 1996). 
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3.3.5 Liquid formulations 
Liquids have been investigated primarily to coat the mucosaand act as a protectant or a 
vehicle for drug delivery in the treatment oflocal disorders, including motility 
dysfunction and fungal infections. The major limitation of these preparations is thelow 
residence time in buccal cavity due to washing effect of saliva.   
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4. VAGINAL ROUTE 
 
Vagina represents an interesting site of drug delivery thanks its unique features that can 
be exploited in order toachieve desirable therapeutic effect (Woolfson, et al., 
2000).Traditionally,vaginal route is used mainlyfor the local pharmacological effect and 
for the treatment of infections pathologies and inflammations. Recently, vagina was also 
considered tobe an organ capable to ensure a systemic drug absorption thanks to mucous 
permeability anddense network of blood vessels. Moreover, systemic drug administration 
can allow to avoid the first pass metabolism, gastrointestinal irritation and side effect at 
gastrointestinal tract and is characterized by an easily administrationand the possibility to 
rapidly remove the drug delivery system. 
However drug delivery through this route having several disadvantages like  
a) low bioavailability,  
b) gender specificity, 
c) culture sensitivity, 
d) personal hygiene, 
e) local irritation and  influence of sexual inter course, 
f) changes of physiological conditionand estrogen concentration . 
 
4.1 Anatomy and physiology of vagina 
Vagina is an important organ of the reproductive tract with a major role in reproduction. 
As reported in literature(Alamdar H. and Fakhrul A, 2005;Richardson et al., 1992;J. 
Paavonen, 1983), vagina is a slightly S-shaped fibromuscular collapsible tubes between 6 
and 10 cm long extending from cervix of the uterus to thevestibule.It presents two 
distinctpositions; a lower convex portion and a wider upperportion that lies in an almost 
horizontal plane atstanding position of subject. The angle betweenupper and lower axes is 
about 130 degree. As the vagina enters the pelvis, it passes through two diaphragms: the 
urogenital and the pelvic diaphragms. The women ofreproductive age having numerous 
folds in vagina,named ―rugae‖, which provide distensibility, supportas well as increase 
surface area of vaginal wall (Fig. 4.1). 
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Fig. 4.1 Vagina anatomy 
 
The vaginal histology is mainly consisting of four distinct layers. The superficial layer 
consists of anon-secretory stratified squamous epithelium and protects vaginal cavity 
from organisms that can invade or access the basement membrane/capillary bed; its 
thickness varies with age, menstrual cycles and several hormonal activities. The next is 
lamina propria or tunica, made of collagen and elastin, which contains a rich supply of 
vascular and lymphatic channels. The muscular layer is based on smooth muscle fibers 
running in both circular and longitudinal directions. The final layer consists of areolar 
connective tissue and a large plexus of blood vessels. An estimated cell turnover of 
vagina is about 10-15 layer in order of 7 days. 
Vaginal tissue does not contain fat cells, glands or hair follicles, but it secrets a large 
amount of fluid containing transudates through the epithelium, cervical mucus, 
exfoliating epithelial cells, secretions of the Bartholin‘s and Skene‘s glands, leukocytes, 
endometrial and tubal fluids. The cervical mucus contains inorganic and organic salts, 
mucins, proteins, carbohydrates, urea and fatty acids (lactic and acetic acids). Vaginal 
secretions are influenced by the estrogens amount, menstrual cycle and the sexual 
stimulation; generally, they increase with the increase of hormones and sexual activity. 
Women of reproductive age produce fluid at a rate of 3-4 g/4 h, while the discharge 
produced by postmenopausal women is reduced by 50%. Lactic acid, present in the 
cervical mucus, is produced from glycogen by the Lactobacillus acidophilusand is 
responsible component able to maintain the vaginal pH between 3.8 and 4.8. Moreover, 
the vaginal pH is influenced by menstruation and acts of coitus, so that menstrual cycle 
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and sexual activity, as well as the high activity of enzymes, can potentially affect short- 
and long-term stability of intravaginal delivery systems and devices. 
4.1.1 Innervation and blood supply. 
Vagina is mainly consisting of two type of nervesupply. The peripheral nerve is the most 
important and supply to the lower quarter of the vagina making it ahighly sensible area. 
The other one is an autonomic fiber that isnot very sensitive topain or temperature. In 
addition, there are few sensory fibers in the upper vagina, making it a relatively 
insensitive area. For this reason, women rarely feel localized sensations or any 
discomfort when using vaginal products such as tampons, suppositories or vaginal rings. 
Moreover, the presence of smooth elastic fibers in the muscular coat vagina makes it a 
site with an excellent elasticity.  
As regard the vascular supply of vagina, the uterine artery, the pudendal artery and the 
middle and inferior hemorrhoidal arteries cover the vagina. The vaginal, uterine, 
vescical, and rectosigmoid veins from the middle and upper vagina provide drainage to 
the inferior vena cava, which bypasses the hepatic portal system. In this way, drugs 
absorbed from the vagina do not undergo first-pass metabolism because blood leaving 
the vagina enters the peripheral circulation via a rich venous plexus, which empties 
primarily into the internal iliac veins. Moreover, the presence of an extensive vascular 
connections between the vagina and uterus allows to hypotize a ―first uterine pass 
effect‖ when hormones are administered vaginally (Bulletti et al., 1997; Cicinelli et al, 
1998).  
4.1.2 Vaginal pH 
The vaginal pH of healthy women of reproductiveage is acidic (pH 3.8-4.8); this value is 
maintainedby lactobacilli that convert glycogen ofexfoliated epithelial cells into lactic 
acid(Richardson et al., 1992). The pHchanges with age, stages of menstrual cycle, 
infectionsand sexual arousal. Menstrual, cervicaland uterine secretions, and semen act as 
alkalizingagents and increase pHto levels, where protective lactobacilli cannot survive 
(Sjorberg, et al., 1988).Female hygiene products and douches wash away a variety of the 
vaginal defenses and can promote colonization of bacteria or alter vaginal pH, allowing 
pathogenic bacteria and yeast to proliferate. Tampons or any absorbent material become 
media for bacterial colonization and growth. 
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4.1.3 Microflora 
The vaginal flora is a dynamic system and is influencedby factors such as the glycogen 
contentof epithelial cells, glucose, pH, hormonal levels,trauma during sexual 
intercourse, birth-controlmethod, age and antimicrobial treatment.Lactobacillus is the 
mostprevalent organism in the vaginal environmenttogether with many other facultative 
and obligateaerobes and anaerobes; they are beneficial for vaginal health becausethey 
compete with exogenous microbes for nutrients. Moreover, they produce  lactic acid and 
hydrogen peroxide from glycogen thus maintaining pH to acidic values thus protecting 
vagina from bacteria and yeast proliferation. In fact, hydrogen peroxide is toxic to 
othermicroorganisms that produce little or no hydrogen peroxide and its production 
make the environment less hospitable toother microbes such as Escherichia coli (E. 
coli), Group BStreptococcus and even human immunodeficiency virus(HIV). 
The vaginal microflora alteration leads to a decrease of hydrogen peroxide and to an 
increase of bacterial vaginosis or candidosis onset. Generally, the alteration of 
microflora depends on the estrogen production, sexual activity and hygiene products 
use. For example, high levels of estrogen during pregnancy result in athick epithelium, 
high levels of lactobacilli and a low pH. 
4.2 Vaginal drug delivery 
The vagina has been studied as a favorable site for the local andsystemic delivery of 
drugs, specifically for female-related conditions. 
4.2.1 Local delivery. Traditionally, the vaginal cavity has been used for the delivery of 
locally acting drugs such as antibacterial, antifungal, antiprotozoal, antiviral, labor-
inducing and spermicidal agents, prostaglandins and steroids. In particular, local drug 
delivery was used for the treatment of vaginal candidiasis that is the most common 
gynaecological infections, caused by the presence ofCandida albicans (Nyririesy et 
al.,2001; Sobel, 1988; Das Neves et al, 2008) and for the treatment of aerobic vaginitis 
that is accompanied by the presence of enteric commensals or pathogens,especially 
Escherichia coli and Streptococcus galactiae (Donders et al., 2002; Donders etal., 2011). 
Several drug delivery systems were studied for local drug delivery (Dobaria et al.m 2009, 
Kast et al., 2002; Shaaban et al., 2011; Garg et al., 2010; Furneri et al., 2008).In this 
thesis project, a pharmaceutical formulation for local drug delivery was formulated and 
more details will be discuss in the experimental section.  
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4.2.2 Systemic drug delivery. Becauseof its large surface area, rich blood supply and 
permeabilityto a wide range of compounds including peptides andproteins, the vagina has 
great potential alsofor systemic delivery (Benziger and Edelson, 1983). It offers a 
favorable alternative to the parenteralroute for some drugs such as bromocriptine 
(Varmesh et al., 1988), propranolol (Patel et al., 1984), oxytocin, calcitonin (Sayani and 
Chien, 1996), human growth hormone (Dezarnaulds and Fraser, 2003),insulin (Ning et 
al., 2005).However, despite all these advantages,the vagina has not been extensively 
explored for systemicdelivery because of gender specificity and cyclic variations. 
The vaginal route has also potential for the uterine targeting ofactive agents such as 
progesterone and danazol (Cicinellli et al., 1998). 
4.2.3 Mechanism of drug absorption 
The drug transport across vaginal membrane mainly takes place by three major ways: 
transcellularly, via concentration dependent diffusion through the cells; paracellularly, 
mediated via tight junctions; vesicular or receptor mediated transport(Alamdar H. and 
Fakhrul A, 2005). 
Drug absorption from vaginaldelivery systemtakes place in two mainsteps: drug 
dissolution in vaginal lumen and membranepenetration (in the case of systemic 
absorption). Any factors related to physiology orformulation that affects the above 
mentioned steps canpotentially alter the release and the absorption profile. Some of the 
factors which influence the drugabsorption are discuss in the following portion. 
4.2.4 Factors Affecting Vaginal Absorption of Drugs 
Physico-chemical Factors 
The physico-chemical properties of drugs and polymers like lipophilicity, ionization, 
molecular weight, surface charge and chemical nature can influence the vaginal drug 
absorption.  
Physiological Factors 
Physiological factors like changes in thethickness of epithelium layer, cyclic changes,  
hormones, volume of vaginalfluid, alteration of vaginal pH and sexual arousal, asdescribe 
earlier, can potentially affect drug release fromany intravaginal delivery system and also 
alter its rateof absorption(Alamdar H. and Fakhrul A, 2005). The high volume of 
vaginalfluid may remove drug from the vaginal cavitywithsubsequent reduction of drug 
absorption. Changes in the pH ofvagina canalter degree of ionization of weakelectrolytic 
drugs and affect the release profile of pHsensitive drugs. 
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4.3 Vaginal dosage forms 
For local action, a vaginal drug delivery system should distribute uniformly throughout 
the vaginal cavity. Several delivery systems can be used for local treatment; in particular, 
dosage forms can be classified into solid, semisolid and liquid dosage forms.  Recently, 
new formulations such as  vaginal rings have been studied especially for a systemic drug 
absorption. 
4.3.1Tablets and Suppositories 
A large number of intravaginal delivery systems are also available in the form of tablets 
and suppositories. Vaginal tablets contain components as like conventional oral tablets 
and are easy to manufacture and insert. Generally, mucoadhesive polymers are sometimes 
used in order to increase the vaginal residence time. These formulations can be used for 
local delivery of drug such as miconazole for vaginal candiasis and progesterone for 
hormonal replacementtherapy (Vukovic et al., 1977; Cicinelli et al, 1988). Inserts can be 
also used for vaginal drug delivery, thanks to their interesting properties such as the 
unique dosage form and the accurate dosage (Luppi et al., 2010a; Rabl et al., 2002). 
4.3.2 Creams and Gels 
They aremainly used for topical delivery of contraceptives andantibacterial drugs. These 
delivery systems are messyto use, uncomfortable, may not provide an exact dosebecause 
of non-uniformity and leakage. The desirable properties of vaginally administered creams 
or gels are acceptability and feasibility. They must be non-toxic and non irritating to the 
mucus membrane.  
Several studies investigated creams and gels for local drug delivery (DuBouchel et al., 
1998; Cruz and Uckun, 2001; Shettly et al., 2001; Rabl et al., 2002). Most of these 
conventional vaginal formulationsare associated with several disadvantages such as the 
low retention to the vaginal epithelium, leakage and messiness and poor patient 
compliance.  
4.3.3 Vaginal Ring 
Vaginal rings are circular ring type drug deliverydevices designed to release drug in a 
controlled releasefashion after insertion in the vagina(Alamdar H. and Fakhrul A, 2005). 
This type ofdosage forms can becontrolled by the user, does not interfere with coitusand 
allows continuous delivery of microbicidalcompounds. They are 5.5 cm in diameter with 
acircular cross section diameter of 4-9 mm. Drugs can be homogeneously dispersed, only 
on the surface ring or in the total area of the system in order to obtain a faster and 
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immediate release or a controlled drug release over time. Moreover, a vaginal ring 
sandwich or reservoir types of system have been developed in order to obtain a constant 
release of drug. Sandwich type devices consistof a narrow drug containing layer located 
below thesurface of the ring and positioned between a nonmedicatedcentral core and a 
non-medicated outerband. In reservoir type of rings, drugs are dispersed ina central core, 
which is than encapsulated by a drugfree layer. In a single ring, it is possible to have 
several cores of different drugs and thereby allowing administration of several drugs from 
the same device. Rate of drug release can be modified by changing the core diameter or 
thickness of the non-medicated coating. Several rings havebeen studied in recent years 
with different polymers such as ethylene vinyl acetate that provides increased flexibility, 
improved optical properties,  greater adhesion and increased impact and puncture 
resistance (Roumen and Dieben, 1999; Laarhoven et al., 2002; Harwood and Mishell, 
2001;Ballagh,2001).  
Vaginal rings are mainly used forcontraceptive and hormonal replacement therapy. 
Formost contraceptive application the ring is placed invagina for 21 days followed by a 
week of ring freeperiod. Nuvaring is one of the example ofcontraceptive ring available in 
US market(Nova´k et al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THEORETICAL SECTION-NASAL ROUTE 
Angela Abruzzo-University of Bologna Pag. 43 
 
5.NASAL ROUTE 
5.1 Introduction 
 
The nose as drug delivery site has a number of unique features related to its anatomy 
andphysiology. Conventionally, the nasal  route has been used for local delivery of drugs 
for treating nasal allergy, nasal congestion or nasal infections. However, the interesting 
properties of nasal mucosa, such as the large surface area, the avoidance of the first pass 
effect, the high permeability and vascularization lead to take into account the nasal route 
as a potential route for the systemic drug delivery(Hinchcliffe and Illum, 1999). 
Moreover, the concentration-time profiles achieved after nasal administration are often 
similar to those after intravenous administration, resulting in a rapid onset of 
pharmacological activity.  
The advantages of nasal drug delivery can be summarized as follow:  
a) large nasal mucosal surface area for drug absorption, 
b) rapid drug absorption via highly vascularized mucosa, 
c) rapid onset of action, 
d) ease of administration, 
e) avoidance of the gastrointestinal tract and first pass metabolism, 
f) possible transport directly into systemic circulation and CNS, 
g) lower dose/reduced side effects, 
h) improved convenience and compliance, 
i) self-administration. 
Moreover, nasal drug delivery shows the following limitations: 
a) volume that can be delivered into nasal cavity is restricted to 25-200 μl, 
b) not feasible for high molecular weight more than 1kDa, 
c) adversely affected by pathological conditions, 
d) ciliary movement and enzymatic inhibition can limit drug permeability, 
e) nasal irritants drugs cannot be administered through this route. 
The following sections will therefore give an introduction to the anatomyand physiology 
of the human nose. 
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5.2 Anatomy and physiology of nose 
Human nasal cavity fills the space between the base of the skull and the roof  of the 
mouth; above, it is supported by the ethmoid bones and, laterally, by the ethmoid, 
maxillary and inferior conchae bones. The lateral walls of the nasal cavity include a 
folded structure which enlarges the surface area in the nose to about 150 cm
2
. This folded 
structure includes three turbinates, the superior, the median and the inferior (Gizurarson, 
1990; Illum, 1996). The human nasal cavity is divided by middle (or nasal) septum into 
two symmetrical halves, each one opening at the face through nostrils and extending 
posterior to the nasopharynx (Fig. 5.1). Both symmetrical halves consist of four areas 
(nasal vestibule, atrium, respiratory region and olfactory region) that are distinguished 
according to their anatomic and histological characteristics (Merkus andVerhoef, 
1994Mygind and  Dahl, 1998 andMerkus andVerhoef, 1998). 
 
Fig. 5.1 Structure of nose(http://www.pharmainfo.net/pharma-student-magazine/drug-
delivery-nasal-route) 
 
Nasal vestibule is the most anterior part of the nasal cavity, just inside the nostrils, 
covered by a stratified squamous and keratinized epithelium with sebaceous glands. Here, 
there are nasal hairs, also called vibrissae, which filter the inhaled particles.   
Atrium is the intermediate area between nasal vestibule and respiratory region. Its 
anteriorsection is constituted by a stratified squamous epithelium and the posterior area 
by pseudostratified columnar cells presenting microvilli. 
The Respiratory Region  
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The nasal respiratory region, also called conchae, is the largest part of the nasal cavity 
and it isdivided in superior, middle and inferior turbinates which are projected from the 
lateral wall. These specialized structures are responsible for humidification and 
temperature regulation ofinhaled air.  
The nasal respiratory mucosa (Merkus and Verhoef, 1994, Mygind and Dahl, 1998), 
considered the most important section for delivering drugssystemically, is constituted by 
the epithelium, basement membrane and lamina propria (Fig. 5.2).  
 
 
Fig. 5.2 Representation of nasal mucosa. (http://www.nozami.com/what.php) 
 
The respiratory epithelium, 100µm in thickness, is composed of four types of cells, 
namely basal cells, non-ciliated and ciliated columnar cells and goblet cells.  
Basal cells, which are progenitors of the other cell types, lie on the basement membrane 
and do not reach the airway lumen. 
All columnar cells are covered on their apical surface with 300 microvilli, expansions 
that enhance the respiratory surface area, thus  promoting exchange processes across the 
epithelium and that prevent drying surface, retaining moisture. Columnar cells are 
divided intociliated and non-ciliated cells. The ciliated cells are covered by fine 
projections, called cilia, 0.2 - 0.3 μm wide and 5 μm in length (100-300 cilia for every 
ciliated cells). Below the respiratory epithelium is a thick lamina propria, composed of a 
loose mesh of fibroelastic tissue with many blood vessels, nerves and glands. These 
submucosal glands possess both serous and mucous secretory cells and release directly 
onto the surface of the epithelium. 
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The globet cells secrete granules filled with mucin, a glycoprotein that determine the 
viscosity of the mucus. Mucus (or nasal secretion) is a complex mixture of materials, 
consisting of approximately 95% water, 2% mucin, 1% salts, 1% of other proteins such as 
albumin, immunoglobulins, lysozymes, lactoferrin and <1% lipids (Kaliner et al., 1984). 
Mucus is present in two layers (5 µm in thickness) on the epithelium, a viscous and dense 
gel layer, the ‗mucus blanket‘ (gel layer, 2-4 mm thickness) that floats on the serous fluid 
layer (‗sol layer‘, 3-5 mm thickness). The viscous gel layer is moved along by the hook 
shaped cilia termini during the energy dependent ‗effective stroke‘ phase of the ciliary 
motion. Cilia are up to 7mm in length when fully extended but can fold to half this length 
during the recovery stroke where the hook terminus detaches from the gel layer and 
moves immersed in the sol layer in the opposite direction to the gel layer movement. The 
cilia of the columnar cells move with regular and symmetric beats at a frequency of about 
10 Hz in the lower sol phase (Sleigh et al., 1988, Duchateau et al., 1985).Hence the 
mucus moves only in one direction from the anterior to the posterior part of the nasal 
cavity to the nasopharynx (Fig. 5.3). 
The velocity of mucous transport is approximately 5- 8 mm/min (Procter et al., 1973; 
Andersen and Procter, 1983), thus renewing the nasal mucus layer every 10 - 20 min. 
The combined action of mucus layer and cilia is called mucociliary clearance, that is an 
important nonspecific physiological defense mechanism of the respiratory tract to 
protect the body against noxious inhaled materials. On the other hand, the mucociliary 
clearance is responsible for the generally observed rapid clearance of nasally 
administered drugs from the nasal cavity to the nasopharynx. To overcome the rapid 
removal of nasally administered drugs, the concept of bioadhesion can be applied. 
Thebaseline pH in the human nasal cavity is approximately 6.3, ranging from 5.2 - 
8.1(Washington et al., 2000a). 
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Fig. 5.3 Nasal clearance mechanism 
(http://wwwtest.valois.com/pharma/en/publication/illustration.php) 
 
5.2.1 Vasculature and innervation. The lamina propria under the nasal epithelium and the 
basement membrane are rich in blood vessels and have an extensive blood supply (about 
40 ml/min/100g, Bende et al., 1983) as well as a large lymph drainage system, 
particularly inthe respiratory region of the nasal cavity (Hinchcliffe and Illum, 1999). 
Three types of blood vesselscan be distinguished(Mygind and Dahl,1998): 
(i) Cavernous venous sinusoids are specialized vessels adapted to the functional 
demandsof the nose with respect to heating and humidification of inhaledair.  
(ii) Arterio-venous anastomoses allow the blood to bypass the capillaries. Their role 
is probably related to the temperature and water control. At least 50% of the blood flow is 
normally shunted through arterio-venous anastomoses (Anggard, 1974). 
(iii) Nasal vasculature shows cyclic changes of congestion (nasal cycle, every 3- 7 
h). Different to the gastrointestinal tract, the venous blood draining from the nose passes 
directlyinto the systemic circulation, thereby circumventing hepatic first pass elimination. 
The lamina propria of the nasal mucosa embeds also nerves. Afferent nerve fibers run in 
thetrigeminal nerve. Stimulation of the trigeminus in the nasal mucosa results in the 
sneezing reflex (Faller, 1988). There is a rich parasympathetic innervation of the glands. 
Nervous stimulation of the glandular cholinoceptors causes marked hypersecretion and is 
often part ofthe reflex arc. Nasal blood vessels are both sympathetically and 
parasympathetically innervated, but are mainly controlled by sympathetic fibers (Mygind 
and Dahl, 1998). 
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5.2.2 The Olfactory Region. It islocated on the roof of the nasal cavities, just below the 
cribriform plate of the ethmoid bone, which separates the nasal cavities from the cranial 
cavity. The olfactory epithelial layer predominantly contains three cell types: the 
olfactory neural cells, the subtentacular (also known as supporting) cells and the basal 
cellsthat are progenitor cells (of supporting cells) and also provide mechanical support 
via anchorage to other cells. The olfactory epithelium is a gateway for the non-invasive 
delivery of therapeutic agents to CNS thanks to a neuronal connection between the nasal 
mucosa and brain, thus providing a provide a unique pathway. The intraneuronal pathway 
involves axonal transport and require to hours or days for drugs to reach different brain 
regions, while the extraneuronal pathway probably relies on the bulk flow transport 
through perineural channelsand allows therapeutic agents to reach the CNS within 
minutes.  
In this area there are also small serous glands (glands of Bowman) producers of 
secretions acting as a solvent for odorous substances (Fig. 5.4). 
 
 
 
Fig. 5.4 Nose to brain delivery 
(http://www.medicalook.com/human_anatomy/organs/Olfactory_sense.html) 
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5.3 Intranasal drug delivery 
In the nasal drug delivery, several  factors, such as the nature of pathologic condition 
(acute or chronic) and intended effects of drug treatment (local, systemic or at CNS), can 
be taken into account.  
5.3.1Local delivery 
Intranasal local administration of medicines is thenatural choice for the treatment of some 
topical nasal disorders, such as rhinosinusitis. In these cases, intranasalroute is the 
primary option for drug deliverybecause it allows a rapid symptom relief with amore 
favorable adverse-event profile than oral or parenteral routes (Salib et al 2003).  
5.3.2Systemic delivery 
The intranasal administration is an effective wayto systemically delivery of drugs as an 
alternativeto oral and intravascular routes. Actually, it seemsto present fast and extended 
drug absorption and it has been supported by many studiesplanned to compare intranasal 
drug deliveryagainst oral and parenteral administration. Consequently, the number of 
drugsadministered as nasal formulations intended toachieve systemic effects has widely 
increased (Illum 2002; Leonard et al., 2007; Illum 2004; Heidari et al., 2006; Ugwoke et 
al.,2000; Wang et al., 2006; Yu et al., 2004). 
5.3.3 Mechanism of drug absorption through nose 
The first step in the absorption of drug from the nasal cavity is passage through the 
mucus; generally, small unchanged particles easily pass through this layer. Subsequently, 
there are several mechanisms for absorption through the mucosa (Fig. 5.5). These include 
transcellular or simple diffusion across the membrane, responsible for the transport of 
lipophilic drugs, paracellular transport via movement between cell and transcytosis by 
vesicle carriers. Drugs also cross cell membranes by an active transport route via carrier-
mediated means or transport through the opening of tight junctions (Illum, 2003; Arora et 
al., 2002). 
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Fig. 5.5 Drug absorption through nasal mucosa. 
(http://wwwtest.valois.com/pharma/en/publication/illustration.php) 
 
5.3.4Barriers for nasal delivery 
Low bioavailability. Bioavailability of polar drugs is generally low, about 10% for low 
molecular weight drugs and not above 1% for peptides such as calcitonin and insulin due 
to the low membrane permeability. Polar drugs with molecular weights below 1000 Da 
generally pass the membrane using the paracellular route. Although tight junctions are 
dynamic structures and can open and close to a certain degree when needed, the mean 
size of these channels is of the order of less than 10 Å and the transport of larger 
molecules is considerably more limited. Larger peptides and proteins are able to pass the 
nasal membrane using an endocytotic transport process but only in low amounts (Illum, 
2003). Nasal absorption of such polar drugs can be greatly improved by co administration 
of absorption enhancing agents (see chapter 7). 
Mucociliary clearanceThe mucociliary clearance can remove formulation form the 
absorption site, thus decreasing drug bioavailability, especially in the case of liquid 
formulations or formulations without mucoadhesive polymers. In fact,it has been shown 
that for both liquids and powder formulations, which are not bioadhesive, the half life for 
clearance is of the order of 15- 30 min (Pires et al., 2009). For this reason, the use of 
bioadhesive excipients in the formulations can be an approach to overcome the rapid 
mucociliary clearance.  
Enzymatic Degradation. The enzymatic degradation due to the presencein the lumen of 
the nasal cavity ofexo-peptidases, such as mono and diaminopeptidases and endo-
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peptidases,can degrade drugs leading to their  low bioavailability The use of enzyme 
inhibitors may be an approach to overcome this barrier (Illum, 2033).  
 
5.4 Crucial factors for nasal formulations 
Drug absorption through nasal mucosa must take into account the deposition of drug and, 
consequently, the deposition area, that is mainly dependent on the delivery system and 
the delivery device. The selection of delivery system depends upon the drug used, 
therapeutic indication, patient population and, last but not least, marketing preferences. 
Moreover, some of the physico-chemical characteristics of the drug formulation and 
physiological factors must be considered prior to designing an intranasal delivery system 
(Pires et al., 2009). 
5.4.1 Physicochemical properties of drugs and delivery systems 
Physicochemical properties are one of the important aspects in design of nasal 
formulation. In particular,  increasing drug lipophilicity, the nasal absoption of the 
compound normally increases. In fact, lipophilic compounds tend to readily cross 
biological membranes via the transcellular route and diffuse into and traverse the cell in 
the cell cytoplasm.Unionized forms of drug are well absorbed compared with ionized 
forms of drug. Moreover, absorption decreases significantly if the molecular weight is 
greater than 1,000 Daltons except with the use of absorption enhancers (Illum, 2003). 
It has been reported that particles greater than 10 μm in size are deposited in the nasal 
cavity. Particles that are 2 to 10 μm can be retained in the lungs, and particles of less than 
1 μm are exhaled.  
Additionally, drug delivery systems deposited in the nasal cavity need to dissolve in order 
to release the drug and to increase drug bioavailability (Pires et al., 2009). 
Generally,solvents or co-solvents such as glycols or small quantities of alcohol can be 
used in order to increase drug solubility. 
The delivery volume is limited by the size of the nasal cavity. An upper limit of 25 
mg/dose and a volume of 0.1-0.2 ml/nostril have been suggested.  
Drug formulation should be isotonic in order to avoid cilliary activity inhibition. 
Deposition of the formulation in the anterior portion of the nose provides a longer nasal 
residence time and better absorption, while a rapid elimination of the formulation occurs 
if the dosage form is deposited in posterior chamber of nasal cavity. The site of 
deposition is dependent on the delivery device mode of administration andphysico-
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chemical properties of drug molecule. Drug absorption depends upon the vasoconstriction 
and vasodilatation of these blood vessels. 
5.4.2 Physiological factors 
The absorption of drugs is influenced by the residence time of drug formulation inside the 
nasal cavity. The mucociliary clearance removes the formulation from the absorption site 
and generally bioadhesive polymers can be used in the formulation in order to increase 
the residence time in the nasal cavity.  
Several enzymes that are present in the nasal mucosa might affect the stability of drugs. 
For example, proteins and peptides are subjected to degradation by proteases and amino-
peptidase at the mucosal membrane. 
Finally,intranasal pathologies such as allergic rhinitis, infections or previous nasal 
surgery may affect the nasal mucociliary transport process and/or capacity for nasal 
absorption. During the common cold, the efficiency of an intranasal medication is often 
compromised. Nasal pathology can also alter mucosal pH and thus affect absorption of 
drugs.  
 
5.5 Nasal formulations 
5.5.1 Liquid dosage forms. Liquid dosage forms either in form of soluble, suspended or 
colloidal systems are normally used for formulating nasal delivery systems and included 
drops, sprays, nano and microemulsions and nanoparticles. They are rapidly removed 
from the nasal cavity due to the clearance mucociliary and are characterized by a lack of 
dose precision, even if innovative and precise dispositive for the systems deposition are 
used. Liquid formulation show also a low stability and generally, preservatives must be 
used.  
5.5.2 Semisolid dosage forms. Semi-solid systems, including ointments and liquids 
containing polymers able to gel at particular pH changes, are usually employed for 
designing the nasal drug delivery systems. These systemsshow a greater viscosity with 
respect to liquid formulations and can remain inside the nasal cavity for a greater time.  
5.5.3Solid dosage forms 
Nasal powders  
The advantages of a nasal powder dosage form are the absence of preservative and 
superior stability of the drug in the formulation. However, the suitability of the powder 
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formulation is dependent on the solubility, particle size, aerodynamic properties and nasal 
irritancy of the active drug and/or excipients. An additional advantage of this system is 
local application of drug, but nasal mucosa irritancy and metered dose delivery are some 
of the aspects that must be taken into account. 
5.5.4 Novel drug formulations 
Novel drug formulation for intranasal drug delivery include liposomes, microspheres and 
nanoparticles. These systems canbe formulated incorporating inside the system  
enzymatic inhibitors,nasal absorption enhancers or/and mucoadhesivepolymers in order 
to improve the stability,membrane penetration and retention time in nasalcavity.  
Liposomes 
Liposomes are phospholipids vesicles composedby lipid bilayers enclosing one or more 
aqueouscompartments and wherein drugs and othersubstances can be included. 
Liposomal drugdelivery systems present various advantages suchas the effective 
encapsulation of small and largemolecules with a wide range of hydrophilicity and pKa 
values (Law et al., 2001; Wyas et al., 1995). 
Microspheres 
Microsphere technology has been widely appliedin designing formulations for nasal drug 
delivery. Microspheres are usuallybased on mucoadhesive polymers (chitosan,alginate), 
which present advantages for intranasaldrug delivery. Furthermore, microspheres 
mayalso protect the drug from enzymatic metabolismand sustain drug release, prolonging 
its effect (Gavini et al., 2006). 
Nanoparticles 
Recently, much attention has been given tonanotechnology in many areas. Nanoparticle 
systems are being investigated to improve drugdelivery and intranasal drug 
administration.Nanoparticles are solid colloidal particles withdiameters ranging from 1-
1000 nm. Theyconsist of macromolecular materials in which the active substance 
isdissolved, entrapped, encapsulated, adsorbed orchemically attach. Nanoparticles may 
offer several advantages due to their small size,but only the smallest nanoparticles 
penetrate themucosal membrane by paracellular route and in alimited quantity because 
the tight junctions are inthe order of 3.9-8.4 Å (Fernandez- Urrusuno et al., 1999a and 
1999b). 
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5.6 Delivery of Peptide and Non-Peptide Drugs for Systemic Effect through Nasal 
Route 
Most peptides and proteins, being hydrophilic polar molecules of relatively high 
molecular weight, are poorly absorbed across biological membranes with bio-availability 
obtained in the region of 1–2% when administered as simple solutions. But for certain 
peptide drugs such as insulin which does not have the luxury of wide therapeutic index it 
is essential to develop the novel formulation strategies. Different studies have been 
performed to evaluate the possibility to deliver insulin through nasal route. In particular, 
several drug delivery systemwere formulated and their delivery properties were evaluated 
from different point of view (Pillion et al., 1994; Bechgaard et al., 1996; Leary et al., 
2005; Leary et al., 2006; Khafagy et al., 2009; Callens et al., 2003). 
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6. CHITOSAN 
6.1 Chitosan and chitin 
Chitosan is currently receiving a great deal of attention for medical and pharmaceutical 
applications due to itsinteresting properties. Indeed, chitosan is known for its 
biocompatibility allowing its use in various medicalapplications such as topical ocular 
application (Felt et al., 1999), implantation (Patashnik et al., 1997) or injection (Song et 
al., 2001). Moreover, chitosan can be considered as biodegradable because it is 
metabolized by certain human enzymes, e.g. lysozyme (Muzzarelli, 1997; Koga and 
Chen, 1998) and it can act as a penetration enhancer by opening epithelial tight-junctions  
(Junginger and Verhoef,1998; Kotze et al., 1998). Due to its positive charges at 
physiological pH, chitosan is also bioadhesive, thus increasing retention time at the site of 
application  (He et al., 1998; Calvo et al., 1997) and has bacteriostatic effects (Liu et al., 
2001). Finally, chitosan is abundantin nature and its production is of low cost and is 
ecologically interesting (Peter, 1995). In medical and pharmaceutical applications, 
chitosan is used as a component for the preparation of several drug delivery systems; in 
particular, our research group have investigated chitosan properties when it is formulated 
as hydrogels and in different dosage forms (Cerchiara et al., 2003a; 2003b; 2008; Bigucci 
et al., 2008a; 2008b; Luppi et al.,2009; 2010a; 2010b). 
Chitosan (Fig. 6.1) is a polysaccharide formed primarily of repeating units of β-(1→4)-2-
amino-2-deoxy-D-glucose (or D-glucosamine).  
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Fig. 6.1 Chitosan structure 
Chitosan is the N-deacetylated derivative of chitin (Fig. 6.2), the most ubiquitous natural 
polysaccharide after cellulose,which is the main component of the exoskeleton of 
crustaceans, such as shrimps (Muzzarelli, 1973). 
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Fig. 6.2 Deacetylation process of chitin to obtain chitosan 
 
Chitin is composed of 2-acetamido-2-deoxy-β-d-glucose through a β (1→4) linkage and 
can be degraded by chitinase (Dutta et al., 2002). It may be regarded as cellulose with 
hydroxyl at position C-2 replaced by an acetamido group and like cellulose, it functions 
naturally as a structural polysaccharide. Chitin is a white, hard, inelastic, nitrogenous 
polysaccharide. Chitin is present as ordered crystalline microfibrils forming a complex 
structure with proteins, minerals, and lipids and possesses three polymorphic forms (R, β, 
λ), where R is the most common structure, corresponding to a tightly compacted 
orthorhombic cell of alternate sheets of parallel and antiparallel chains. Commercial 
chitin is effectively isolated from crustacean shells after chemical treatments that lead to 
reduction in chitin molecular weights; but these methodologies do not allow the recovery 
of products such as protein hydrolyzates and pigments and can generate undesirable 
corrosive side products. Alternatively, biological approaches for chitin recovery have 
been proposed and among them, lactic acid fermentations (LAFs) are promising because 
minerals (calcium carbonate) are solubilized in situ and endogenous proteases are 
adequately activated for deproteinization.  
Generally, alkali are used to simultaneously remove the protein and deacetylates chitin 
and allow to dissolve calcium carbonate which is present in crab shells in high 
concentrations. Then, chitin is deacetylated in order to obtain chitosan. Chitosan 
parameters such as molecular weight (MW) and degree of deacetylation (DD), 
representing the proportion of deacetylated units, are determined by theconditions 
selected during its preparation and are responsible of chitosan properties.The conditions 
employed for deacetylation of chitin, such as temperature, alkali concentration, time and 
the acidic depolymerisation can decrease the DD (Sorlier et al., 2001) and theMW (Dong 
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et al., 2001). For example, chitin is deacetylated in 40% sodium hydroxide at 120°C for 
1–3 h,leading to 70% deacetylated chitosan.Moreover, chemical deacetylation conducted 
under heterogeneous conditions at high temperature during a short period of time is faster 
in amorphous regions, whereas homogeneous deacetylation, at relatively low 
temperatures and extended time, results in random distribution of deacetylated residues in 
the polymer backbone. In both cases, high deacetylation can be successfully achieved but 
with remarkable reduction in molecular weight. It has been suggested that the initial 
crystalline structure of the chitin is an important parameter during deacetylation and 
affects final chitosan structure as well as molecular mass and the DA. Therefore, this will 
influence its solubility, reactivity for chemical modification as well as biological, 
mechanical and rheological properties.  
6.1.1 Chitosan solubilization 
The solubilization occurs by protonation of the -NH2 function on the C-2 position of the 
d-glucosamine repeat unit, whereby the polysaccharide is converted to a polyelectrolyte 
in acidic media (chitosan pKb= 6.3; Lee et al., 1999).This characteristic can allow to use 
chitosan in different applications; in particular, it can be used as flocculants for protein 
recovery, as components to obtain solutions, gels, or films and fibers.  
Chitosan solubility dependson its average DA, molecular weight, distribution of the 
acetyl groups and on pH and ionic concentration of solution used to chitosan dissolution. 
Generally, chitosan is characterized by typical degrees of deacetylation between 70 and 
95% and molecular weights between 10 and 1,000 kDa and a low molecular weight can 
allow to obtain a fast chitosan dissolution. Moreover, chitosan can be dissolved in acetic 
acid or hydrochloric acid, pH and the pK of the acid influencing chitosan solubility. 
Finally, a salting-out effect was observed in excess of HCl (1 M HCl), making it possible 
to prepare the chlorhydrate form of chitosan.  
6.2 Chitosan hydrogels 
Peppas (Peppas, 1986) defined hydrogels as ―macromolecular networks swollen in water 
or biological fluids‖. Hydrogels are often divided intothree classes depending on the 
nature of their network,namely entangled networks, covalently crosslinked networksand 
networks formed by physical interactions. Thelatter class contains all the intermediary 
cases situatedbetween the two other classes representing the extremes(Ross-Murphy, 
1994). However, with respect to chitosan hydrogels, thisclassification is not entirely 
suitable and it can be suggested the following modified classification for 
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chitosanhydrogels; i.e. a separation of chemical and physicalhydrogels. Chemical 
hydrogels are formed by irreversiblecovalent links, as in covalently crosslinked 
chitosanhydrogels. Hydrogels formed by the addition of acrosslinker, namely covalently 
and ionically crosslinkedhydrogels are characterized by apotential toxicity of free 
unreacted covalent crosslinkers thatrequired a purification step during the manufacturing 
ofhydrogels. For this reason the development of alternative types of hydrogelswas 
desirable (Berger et al., 2004); in particular,hydrogels formed by directinteraction 
between polymeric chains without the additionof crosslinkers is  advantageous. In 
physical hydrogels, chitosan can form reversible links such as ionic interactions, as 
inionically crosslinked hydrogels and polyelectrolyte complexes(PEC), or secondary 
interactions as in chitosan/polyvinyl alcohol (PVA) complexed hydrogels, 
graftedchitosan hydrogels and entangled hydrogels. The entangledchitosan hydrogels 
show a limited use due to their lack ofmechanical strength and their tendency to 
dissolve.Moreover, they do not exhibit characteristics that allow anefficient control of 
drug delivery or the modification ofproperties in response to changes in their physico-
chemicalenvironment, such as pH or temperature. 
6.3 Polyelectrolyte complexed hydrogels 
As described before, polyelectrolyte complex networks are formed mixing oppositely 
charged polyelectrolytesthat can interact in solution thanks to the formation of ionic 
interactionsand without the use of covalent cross-linkers. The reaction isgenerally 
performed in aqueous solution, thus favoring biocompatibility and avoiding 
purificationbefore administration. For this reason, in general, these polymeric networks or 
hydrogels are well tolerated, biocompatible and are more sensitive to changes in 
environmental conditions (Long et al., 1996; Wang et al., 1997; Takahashi et al., 1990; 
Berger et al., 2004). They are characterized by a hydrophilic microenvironment with a 
high water content and electrical charge density and exhibit interesting swelling 
characteristics. 
The formation and stability of these polyelectrolyte complexes depend on many factors 
such as the degree of ionization, the density of the charges, the charge distribution of the 
oppositely charged polyelectrolytes, the concentration of the polyelectrolytes, their 
mixing ratio, the mixing order, the duration of the interaction, the nature of the ionic 
groups, the position of the ionic groups on the polymeric chains, the molecular weight of 
the polyelectrolytes, the polymer chain flexibility as well as the temperature, ionic 
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strength and pH of the reaction medium. When the polyelectrolyte complex contains 
equal amounts of each opposite charge, it is usually insoluble and precipitate out of 
solution upon formation (Berger et al., 2004), due to its zero net charge. On the other 
hand, when in the mixed solution there is an excess of one charge (either positive or 
negative), a non-stoichiometric complex is formed that are usually soluble.  
Chitosan can easily form polyelectrolyte complexes through the electrostatic attraction 
between the cationic amino groups on the C2 position of the repeating glucopyranose 
units of chitosan and the anionic groups of the other polyelectrolyte, even if other 
secondary binding interactions (Lee et al., 1999) can be occurred. In this way, chitosan 
that normally is dissolved in the stomach can be used for formulation of new drug 
delivery systems and it is also possible to maintain its interesting properties of 
biocompatibility and biodegradability. Generally, the formation of PEC can induce a 
conformational change of chitosan that  has a rigid, stereo-regular structure containing 
(Berger et al., 2004).  
The most commonly used polyanions are polysaccharides bearing carboxylic groups such 
as alginate (Kim et al., 1999), pectin (Bigucci et al, 2008b; Luppi et al., 2010a; Yao et al., 
1997)or xanthan (Dumitriu and Chournet, 2000). Proteins, such as collagen (Taravel and 
Domard, 1996) and synthetic polymers, such as PAA (Wang et al., 1997) or even DNA 
(Borchard, 2001)have also been investigated.  
In order to form a PEC, the pH solution values must be in the vicinity of the pKa interval 
ofthe two polymers, thus obtaining a great ionization of the two polymers. During 
complexation, polyelectrolytes can either coacervate or form a more or less compact 
hydrogel or precipitate. Precipitation can beavoided if electrostatic attraction is weakened 
by the addition of salts, such as NaCl, that reducestheattraction between the oppositely 
charged polyelectrolytes. 
6.3.1 Properties and medical applications 
As PEC hydrogels are formed by ionic interactions, theyexhibit pH- and, to a minor 
extent, ion-sensitive swelling. Inaddition, they have a high water content and 
electricalcharge density and allow the diffusion of water and/or drugmolecules (Berger et 
al., 2004). Therefore,chitosan hydrogels formed by PEC are well toleratedsystems and 
can be used in various applicationssuch as drug delivery systems, in cell culture and 
enzymeimmobilization or for tissue reconstruction and woundhealingmanagement. 
PEC exhibit pH-sensitive swelling not onlyin acidic but also in basic conditions. pH of 
physiological fluids can modify the charge balance inside the gel andtherefore the degree 
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of interaction between the two polymers and the swelling properties. In particular, in 
acidic medium, the polyacid is neutralized and due to the free ammonium groups of 
chitosan, freepositive charges appear inside the gel and the consequent entry of water 
causes swelling(Fig. 6.3). On the other hand, in basic medium themechanism is the same 
but swelling is induced by the freenegative charges of the polyacid. If swelling 
becomestoo important, dissolution of the complex can occur at certainpH values if the 
global charge density of one of the polymersis no longer sufficiently high to ensure 
complexation (Berger et al., 2004). 
 
Fig. 6.3 Swelling properties of PEC in mediawith different pH (Berger et al., 2004). 
6.4 Polyelectrolyte Complexes Chitosan/gelatin and Chitosan/alginate 
As described before, chitosan can ionically interact with different polymers, natural and 
synthetic. In particular, in this thesis project chitosan/gelatin and chitosan/alginate were 
taken into account in order to obtain drug delivery system. These complexes were  
studied in terms of chemical-physical properties and of their ability to control drug 
release. 
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6.4.1 Chitosan-gelatin polyelectrolyte complex 
Gelatin is a heterogeneous mixture of protein fractions consisting of single or multi-
stranded polypeptides (Fig. 6.4), obtained by partial hydrolysis of animal collagen 
derived from skin, white connective tissues and bones. In nature there are two types of 
gelatin: type A gelatin, derived from pig skin by means of acid hydrolysis and type B 
gelatin, obtained from alkaline hydrolysis of cattle hides and bones [49]. The isoelectric 
point of gelatin is around a pH value of 4.7 and the formation of polyelectrolyte 
complexes is obtained in pH interval between this value and 6.3 that correspond to 
chitosan pKb (Yin et al., 2005). Chitosan-gelatin polyelectrolyte complex was used to 
obtain sponges containing tramadol hydrochloride; these formulations allow to obtain a 
control of drug release which followed Higuchi‘s diffusion mechanism over a 12 h 
periodand showed improved mechanical properties compared to sponges containing 
chitosan alone (Foda et al., 2007).  
 
Fig. 6.4 Gelatin structure. 
 
6.4.2 Chitosan-alginate polyelectrolyte complex 
Alginates are natural polysaccharide polymers isolated from brown seaweed such as 
Laminaria hyperborea, Ascophyllum nodosum and Macrocystis pyrifera(Oliveira et al., 
2009; Sankalia et al., 2007). The seaweed is extracted with a dilute alkalinesolution 
which solubilizes the alginic acid.Free alginic acid is obtained on treatment ofthe 
resulting thick and viscous mass with mineral acids and then converted to asalt, such as 
sodium alginate, that is the major form currentlyused. 
 
THEORETICAL SECTION-CHITOSAN AND OTHER MATERIALS 
Angela Abruzzo-University of Bologna Pag. 62 
 
 
Fig. 6.5 Alginate structure 
 
Alginic acid (Fig. 6.5) is a linear polymer consistingof D-mannuronicacid (M) and L-
guluronic acid (G) residues that are arranged in the polymer chain in blocks, M and G 
blocks. In particular, M and G residues in alginatesare joined together in a blockwise 
fashion-homopolymeric M blocks (MMMMM) and Gblocks (GGGGG) or 
heteropolymeric blocks of altering M and G (MGMGMG).In the polymerchain the 
monomers tends to find their most energetically favorable structure. For G-G itis the 1C4 
chair form linked together with an α-(1→4) glycosidic bond. For M-M it is the 4C1chair 
form linked together with a β-(1→4) glycosidic bond. The rather bulky carboxylic 
groupis responsible for an equatorial/equatorial glycosidic bond in M-M and an 
axial/axial glycosidicbond in G-G and an equatorial/axial glycosidic bond in M-G. The 
result of this is a buckledand stiff polymer in the G-block regions and a flexible, ribbon-
like polymer in the M-block andMG-block regions (Fig. 6.6).  
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Fig. 6.6 Alginate block types 
 
The proportion and distribution of these blocks (Fig. 6.6) determine the chemicaland 
physical properties of the alginate molecules. 
The chemical composition of alginates varies accordingto seaweed species and even 
within different parts of the same plant, even if a selection of manufacture process allows 
to obtain alginates with constant properties in a wide range of grades.The block structure 
distribution of an alginate extracted from brown algae is determinedby alginate 
biosynthesis in the brown algae and its genetical and environmental control. Thepathway 
of alginate biosynthesis in brown algae ends up with poly(mannuronate), the 
homopolymerof M, as an obligate intermediate. An epimerase is then acting on the 
polymer level andworks along the polymer chain in controlling the epimerization from M 
to G in certain regionsof the polymer. As a rule of the thumb, one can say that the 
transformation from M to G willbe more and more complete as the plant tissue grows 
older.  
Hydration of alginic acid leadsto the formation of a high-viscosity ‗‗acid gel‘‘ due to 
intermolecular binding; water molecules are physically entrapped inside thealginate 
matrix, but are still free to migrate. Moreover, monovalent metal ions form soluble salts 
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withalginate whereas divalent and multivalent cations(except Mg
2+
) form gels or 
precipitates(Tønnesen and Karlsen, 2002). The variouscations show different affinity for 
alginate andselective ion binding is the basis for the ability ofalginate to form ionotropic 
hydrogels (Fig. 6.7). Alginateswith a high content of guluronic acid blocks givegels of 
considerably higher strength compared toalginates rich in mannuronate, as the G 
residuesexhibit a stronger affinity for divalent ions than the M residues. 
 
Fig. 6.7Binding mode between Ca
2+
 ions and alginate 
 
Calcium and sodium alginate are the most extensively studied due to their properties such 
as the non-toxicity and biocompatibility (Tønnesen and Karlsen, 2002). In particular, 
sodium alginate can be used as a bindingand disintegrating agent in tablets, as 
asuspending and thickening agent in water-misciblegels, lotions and creams, and as a 
stabilizer foremulsions.  
 
An important characteristic of alginate is represented by the presence of carboxylic acid 
groups of manuronic and guluronic acid units that can be present under ionized form and 
can interact electrostatically with the positively charged amino groups of chitosan to form 
a polyelectrolyte complex (Hamman, 2010). Alginate is one of the most studied anionic 
polyelectrolytes in complexation with chitosan. The polyelectrolyte complex formed 
between these two polymers is still biodegradable and biocompatible, but mechanically 
stronger at lower pH values where chitosan dissolves (Hein et al., 2008). Moreover, 
chitosan-alginate polyelectrolyte complexes are less degraded by lysozymes with respect 
chitosan alone (Li et al., 2009) and they can be used in tissue engineering for scaffolds 
and support materials (Li et al., 2009). It has been shown that charge ratio, molecular 
weight, ionic strength, pH, mixing order, as well as speed and diameter of the dispersing 
element, influence the particle size, particle surface charge (zeta potential) and stability of 
alginate-chitosan polyelectrolyte complexes (Sætheret al., 2008). 
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6.5 Cyclodextrins 
CDs are useful pharmaceutically because they can interact with drug molecules to form 
inclusion complexes (1:1), thus improving their physicochemical and biological 
properties. In particular, the complex formation can enhance drug solubility, physical and 
chemical stability, thus resulting in greater biological performance (Uekama et al., 1994; 
Loftsson, 1995; Albers and Muller, 1995; Loftsson and Brewster, 1996;  Challa et al., 
2005). The complex formation is already widely used in many industrial products, 
technologies and analytical methods as well as in pharmaceutical fields. Cyclodextrin 
complexation with drugs can protect them against oxidation, light induced reactions, 
decomposition and thermal decomposition; it can also improve their solubility and 
stability.  Moreover, it was demonstrated that they can increase dramatically the loading 
capacity of carriers such as liposomes, nanospheres and microspheres (Dunchene and 
Ponchel, 1999; Duchene et al., 1999). Cyclodextrins are used in food formulations for 
flavour protection and delivery. Artificial flavours are volatile oils or liquids and 
complexation with cyclodextrins provide a promising alternative to the conventional 
encapsulation technologies used for flavour protection. In cosmetic field, the major 
benefits of cyclodextrins in this sector are stabilization, odour control and improvement 
upon conversion of a liquid ingredient to a solid form. It is also possible to eliminate or 
reduce undesired tastes or odours and microbiological contaminations.  
The CDs of biomedical and pharmaceutical interest are cyclic oligosaccharides made up 
of six to eight dextrose units joined through one to four bonds. They are crystalline, 
homogeneous, non-hygroscopic substances, which are torus-like macro-rings built up 
from glucopyranose units.The α-cyclodextrin comprises 6 glucopyranose units, β-CD 
comprises 7 such units and γ-CD comprises 8 such units(Fig. 7.1).  
 
Fig. 6.8Cyclodextrin structure 
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As a consequence of the 4C1 conformation of the glucopyranose units, all secondary 
hydroxyl groups are situated on one of the two edges of the ring, whereas all the primary 
ones are placed on the other edge. Cyclodextrin rings are amphipathic with the wider rim 
displaying the 2- and 3-OH groups and the narrower rim displaying 6-OH group on its 
flexible arm. These hydrophilic groups are on the outside of the molecular cavity whereas 
the inner surface is hydrophobic lined with the ether-like anomeric oxygen atoms and the 
C3-H and C5-H hydrogen atoms. 
The C-2-OH group of one glucopyranoside unit can form a hydrogen bond with the C-3-
OH group of the adjacent glucopyranose unit. In the βCD molecule, a complete 
secondary belt is formed by these H-bonds, therefore the βCD is a rather rigid structure. 
This intramolecular hydrogen bond formation is probably the explanation for the 
observation that βCD has the lowest water solubility of all CDs. 
 
6.5.1 Cyclodextrin derivates 
In the cyclodextrins every glucopyranose unit has three free hydroxyl groups which all 
differ in their functions and reactivity. The relative reactivities of C(2) and C(3) 
secondary, and the C(6) primary hydroxyls depend on the reaction conditions (pH, 
temperature, reagents). In β-CD 21 hydroxyl groups can be modified substituting the 
hydrogen atom or the hydroxyl group with a large variety of substituting groups like 
alkyl-, hydroxyalkyl-, carboxyalkyl-, amino-, thio-, tosyl-, glucosyl-, maltosyl-, etc. 
groups, thousands of ethers, esters, anhydro- deoxy-, acidic, basic, etc. derivatives can 
be prepared by chemical or enzymatic reactions. The aim of such derivatizations may 
be: 
 to improve the solubilityof the CD derivative (and itscomplexes) 
 to improve the fitting, and/or the association between the CD and its guest, with 
concomitant stabilization of the guest. 
 
6.5.2 Cyclodextrin inclusion complexes 
In an aqueous solution, the slightly apolar cyclodextrin cavity is occupied by water 
molecules which are energetically unfavored (polar-apolar interaction), and therefore 
can be readily substituted by appropriate ―guest molecules‖ which are less polar than 
water. The dissolved cyclodextrin is the ―host‖ molecule, and part of the ―driving force‖ 
of the complex formation is the substitution of the high-enthalpy water molecules by an 
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appropriate ―guest‖ molecule. Most frequently the host:guest ratio is 1:1, however 2:1, 
1:2, 2:2, or even more complicated associations and higher order equilibria exist, almost 
always simultaneously. The inclusion complexes formed can be isolated as stable 
amorphous or microcrystalline substances. The association of the CD and guest (D) 
molecules and the dissociation of the CD/guest complex formed, is governed by a 
thermodynamic equilibrium. Upon dissolving these complexes, an equilibrium is 
established very rapidly between dissociated and associated species, and this is expressed 
by the complex stability constant Ka. The most important primary consequences of 
stirring a poorly soluble guest with an aqueous CD solution are as follows: 
a) The concentration of the guest in the dissolved phase increases significantly, while the 
concentration of the dissolved free CD-decreases. This latter point is not always true, 
because ionized guests or hydrogen-bond establishing (e.g. phenolic) compounds may 
enhance the solubility of the CD. 
b) The spectral properties of the guest are modified. For example, the chemical shifts of 
the anisotropically shielded atoms are modified in the NMR spectra. Also when achiral 
guests are inserted into the chiral CD cavity, they become optically active, and show 
strong induced Cotton effects on the circular dichroism spectra. Sometimes the maximum 
of the UV spectra are shifted by several nm. 
c) The reactivity of the included molecule is modified. In most cases the reactivity 
decreases, i.e. the guest is stabilized, but in many cases the CD behaves as an artificial 
enzyme, accelerating various reactions and modifying the reaction pathway. 
d) The diffusion and volatility (in case of volatile substances) of the included guest 
decrease strongly. 
e) The complexed substance is effectively protected against any type of reaction, except 
that with the CD-hydroxyls, or reactions catalyzed by them. 
f) Sublimation and volatility are reduced to a very low level. 
g) The complex is hydrophilic, easily wettable and rapidly soluble. 
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6.6Kinetics of Hydrogel Swelling 
 
The favorable property of these hydrogels is their ability to swell when put in contact 
with an aqueous solution. The water attacks the hydrogel surface and penetrates into the 
polymeric network. Regularly, the meshes of the network in the rubbery phase start 
expanding, allowing other solvent molecules to penetrate within the hydrogel network. 
Therefore, the unsolvated glassy phase is separated from rubbery hydrogel region with a 
moving front.  
One of the very important features of hydrogel swelling is the rate of swelling or swelling 
kinetics, that aredetermined by the  sample/particle size, porosity extent and the type of 
the porous structure. In particular, hydrogels may be divided into four main classes: a) 
non-porous that have molecular size pores equal to the macromolecular correlation length 
(10-100 Å); micro-porous (100-1000 Å); macro-porous (0.1-1 μm) and super-porous 
hydrogels (SPHs) that is usually in the range of several hundred micrometers, 
characterized by a rapid uptake of water into the porous structure.  
The most important parameters that define the structure and properties of swollen 
hydrogels are the polymer volume fraction in the swollen state, ν2,s, the effective 
molecular weight of the polymer chain between cross-linking points, Mc, and the 
correlation distance between two adjacent cross-links, ξ. The polymer volume fraction in 
the swollen state (ν2,s) describes the amount of liquid that can be imbibed in hydrogels 
and is defined as a ratio of the polymer volume (Vp) to the swollen gel volume (Vg).  
 
ν2,s = Vp / Vg 
 
Swelling is a continuous process of transition from unsolvated glassy or partially rubbery 
state to a relaxed rubbery region. Although penetrant sorption by rubbery polymers may 
be described by Fickian transport with a concentration dependent diffusion coefficient, 
this description usually is not successful for glassy polymers that are influenced by the 
glass transition temperature (Tg) in the delivery process. In particular, it is possible to 
distinguish the Fickian or Case I transport, which appears when the Tg of polymer is well 
below the medium temperature and a non-Fickian diffusion, which appears when the Tg 
of polymer is well above the experimental temperature. 
In the first case, the polymer chains have a high mobility and the water penetrates easily 
in the rubbery network. Therefore, the solvent diffusion rate, Rdiff, is clearly slower than 
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the polymer chain relaxation rate, Rrelax, (Rdiff << Rrelax). In the second  situation, the 
polymer chains are not adequately mobile to permit urgent penetration of water into the 
polymer core. Depending on the relative rates of chain relaxation and diffusion, they 
commonly classified the non- Fickian diffusion to two subsections: "Case II transport" 
and "anomalous transport". Case II transport is dominated when the diffusion is very 
rapid compared to relaxation (Rdiff >> Rrelax), with relaxation occurring at an 
observable rate. The anomalous transport is observed when the diffusion and relaxation 
rates are comparable (Rdiff ≈ Rrelax). Since most polymers swell when they are in 
contact with certain solvents, Fick's laws can be used. 
 
A simple and useful empirical equation is commonly used to determine the mechanism of 
diffusion in polymeric networks: 
(Mt/M =͚k*t n)   
The constants k and n are characteristics of the solvent-polymer system. The diffusional 
exponent (n) is dependent on the geometry of the device as well as the physical 
mechanism of solute uptake or drug release.  
By determining the diffusional exponent, information about the physical mechanism 
controlling solute uptake or about drug release from a particular device can be obtained 
(Table 1). For a film, n = 0.5 indicates Fickian diffusion, n > 0.5 indicates anomalous 
transport and n = 1 implies case II (relaxation-controlled) transport.  
 
Table 1 Drug transport mechanisms and diffusional exponents for hydrogel slabs 
 
The Fickian diffusion, actually, refers to a situation where water penetration rate in the 
gels is less than the polymer chain relaxation rate. Therefore, n = 0.5 indicates a perfect 
drug transport mechanisms and diffusional exponents for hydrogel slabs. Nevertheless, 
when the water penetration rate is much below the polymer chain relaxation rate, it is 
Type of 
transport 
Diffusional 
exponent (n)  
Time 
dependence 
Fickian 
diffusion 
n= 0.5 t 
1/2
 
Anomalous 
transport 
0.5 < n < 1 t 
n-1
 
Case II transport  n= 1 Time 
dependent 
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possible to record the n values below 0.5. This situation, which is still regarded as Fickian 
diffusion, is named as "Less Fickian" behaviour. 
The previously discussed power law equation , even though effectively describes the 
major portion of the swelling behaviour , fails to give a precise analysis above Mt /M͚ = 
0.60. To obtain a better model beyond 60%, the Berens-Hopfenberg proposed the 
following differential equation: 
 
dMt/ dt = k2 (M  ͚  –Mt) 
 
where k2 (min-1) is the relaxation rate constant. 
 
For the case of anomalous transport, Peppas et al. developed the following model to 
describe the release behavior of dynamically swelling hydrogels 
 
Mt/ M  ͚ = k1t+k2t ½  
 
This expression describes the release rates in terms of relaxation-controlled transport 
process (k1t) and the diffusion-controlled process (k2 t 
1/2
). 
The exponent  (n) is also influenced by the matrix geometry of the delivery systems 
(Table 2).  
 
Table 2 Matrix geometry influence on diffusional exponent 
 
The diffusional Deborah number (De), which relates water motion to the rate of polymer 
relaxation, and the swelling interface number (Sw), which measures water penetration 
into a network relative to diffusion of a dispersed drug out of the polymer, are the two 
dimensionless parameters that describe the dominant behavior of swelling-controlled 
systems. 
Matrix 
Geometry 
Diffusion-
controlled delivery 
system (Case I) 
Swelling-controlled 
delivery system 
(Case II) 
Slab n= 0.5 n= 1 
Cylinder n= 0.45 n= 0.89 
Spere n= 0.43 n= 85 
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Deborah number, De(δr), is used to relate the relaxation time of polymeric chains and the 
drug diffusion time. δr is the gel layer thickness which is defined as δ(t)- δg(t), where δ(t) 
is the distance from the gel/water edge to the centre of the hydrogel, and δg(t) is the 
distance from the centre of the hydrogel to the interface between glassy and rubbery 
regions of the material 
De = λ/t = λD/ δ(t)2 
The swelling interface number  
Sw = V δ(t) /D  
where V is the velocity of swelling process and D is the drug diffusion. 
If the swelling process is subjected by water diffusion (De<<1 or Sw>>1) the Fickian 
diffusion dominates the drug release process. If the swelling process is controlled by the 
relaxation time (De>>1 or Sw<<1), the Case II transport is dominated and results in zero-
order release kinetics.  
During the swelling process, it is possible to distinguish three front: the diffusion front, 
that is characterized by the movement of drug inside the gel system; the swelling front 
that is the limit between the polymers in the glass state and rubbery state; the erosion 
front that is represented by the limit where polymer, after reaching the critic water 
concentration (disentanglement concentration), start to disaggregate (Fig. 6.8) 
 
 
Fig. 6.9Schematic illustration of a swellable tablet during radial drug release.
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8. BIOADHESION 
 
Conventional formulations are characterized by a low retention time at the absorption site 
due to the biological fluids that rapidly remove the systems or reduce their contact time 
with biological surface, with the consequent decrease of drug bioavailability. For this 
reason, the recent research is increasinglyfocused on the use of bioadhesive/ 
mucoadhesive polymers that can increase the residence time of the formulations, thus 
allowing a greater contact with the mucous membrane and improving drug 
bioavailability. This feature can allow to decrease the drug administration frequency and 
to increase patient compliance.  
Bioadhesion can be defined as the state in which two materials, at least one of which is 
biological in nature, are maintained together for a prolonged time period by means of 
interfacial forces (Smart, 2005). It is also defined as the ability of a material (synthetic or 
biological) to adhere to a biological tissue for an extended period of time, thereby 
increasing drug bioavailability and promoting local or systemic effects (Woodley, 2001).  
Bioadhesive systems applied to mucous membrane are frequently defined as 
mucoadhesive, but the terms are interchangeable (Leung, Robinson, 1990). Mucosal 
membranes of human organism are characterized by an epithelial layer whose surface is 
covered by mucus. The mucus contains glycoproteins, lipids, inorganic salts and 95% 
water by mass, making it a highly hydrated system. Mucin is the most important 
glycoprotein of mucus and its main functions are protecting and lubricating the 
epithelium. Mucus thickness can vary from 50-450 μm in the stomach to less than 1 μm 
in the oral cavity (Smart, 2005). Different dosage forms can interact with mucin and the 
mucus component, for example with ionic interaction, or they can be hydrated by mucus 
thus allowing an entanglement process between the formulation and mucin chains.  
 
8.1 Mechanism of mucoadhesion 
When a drug delivery system comes into contact the mucosal surface, attraction and 
repulsion force are established, but  for a mucoadhesive to be successful, the attraction 
forces must dominate. 
It was possible to consider the  mucoadhesion as a process based on different stages: 
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Stage-1 Involves an intimate contact between a bioadhesive system and a mucosal 
membrane; this depend by the bioadhesive and membrane wetting and by the swelling of 
bioadhesive. 
Stage-2: After contact is established, penetration of the bio-adhesive into the surface of 
the tissue takes place. These two stage represent the contact step. In some cases, such as 
for ocular or vaginal formulations, the delivery system is mechanically attached over the 
membrane. In other cases, the deposition is promoted by the aerodynamics of the organ to 
which the system is administered, such as for the nasal route. 
Stage-3: Inter penetration of the chains of the bioadhesive with those of the mucous takes 
place. In this step there was a consolidation of linkage between drug delivery system and 
mucosal surface(Fig. 8.1). 
 
 
Fig. 8.1 Steps of mucoadhesion process (Carvalho et al., 2010) 
 
Essentially, there are two theories explaining the consolidation step: the diffusion theory 
and the dehydration theory. According to diffusion theory, the mucoadhesive molecules 
and the glycoproteins of the mucus mutually interact by means of interpenetration of their 
chains and the building of secondary bonds (Smart, 2005). In particular, polymers with 
hydrogen bonds building groups (–OH, –COOH), with an anionic surface charge, high 
molecular weight, flexible chains and surface-active properties can establish a chemical 
and mechanical contact with mucus thus increasing mucoadhesion process.  
According to dehydration theory, materials that are able to readily gelify in an aqueous 
environment, when placed in contact with the mucus can cause its dehydration due to the 
difference of osmotic pressure. In fact the difference in concentration gradient can favor 
the entry of water into the formulation until the osmotic balance is reached, promoting the 
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mixture of formulation and mucus and consequently ensuring the consolidation step. 
However, the dehydration theory is not applicable for solid formulations or highly 
hydrated forms (Smart, 2005).  
8.2 Mucoadhesion theories 
There are six classical theories adapted from studies on the performance of several 
materials and polymer-polymer adhesion which explain the phenomenon (Hägerström, 
2003; Huang et al., 2000; Smart, 2005).  
8.2.1 Electronic theory 
This theory is used when mucoadhesive material possesses electrical charges that are 
opposed to those of biological membrane; in this case, both materials come into contact 
and transfer electrons leading to the building of a double electronic layer at the interface, 
where the attractive forces within this electronic double layer determines the 
mucoadhesive strength.  
8.2.2 Adsorption theory 
According to this theory, after an initial contact between two surfaces, the materials 
adhere because of two types of chemical bonds. In particular, it is possible to distinguish 
primary and secondary chemical bonds. The first are covalent in nature and  undesirable 
in bioadhesion because their high strength may result in permanent bonds, while the 
secondary chemical bonds  include electrostatic forces, Vander Waals forces and 
hydrogen and hydrophobic bonds. 
8.2.3 Wetting theory 
Wetting theory is predominantly applicable to liquid bioadhesive systems and analyses 
adhesive and contact behavior in terms of a liquid or a paste to spread over a biological 
system (Smart, 2005). 
8.2.4 Diffusion theory 
According to this theory, the polymer chains and the mucus mix to a sufficient depth, to 
create a semipermanent adhesive bond(Fig. 8.2). In particular, the polymer chains 
penetrate the mucous; the exact depth of penetration depends on the diffusion co-
efficient, time of contact and flexibility and nature of the mucoadhesive chains, mobility 
and contact time (Huang et al., 2000; Lee, Park, Robinson, 2000; Smart, 2005).  
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Fig. 8.2 Diffusion theory 
 
According to the literature, the depth of interpenetration required to produce an efficient 
bioadhesive bond lies in the range 0.2-0.5 μm. This interpenetration depth of polymer and 
mucin chains can be estimated by equation 
L = (t* Db)1/2 
where t is the contact time, and Dbis the diffusion coefficient of the mucoadhesive 
material in the mucus. The adhesion strength for a polymer is reached when the depth of 
penetration is approximately equivalent to the polymer chain size.  
8.2.5 Fracture theory 
This theory is the most-used theory in studies on the mechanical measurement of 
mucoadhesion. It analyses the force, Sm, required to separate two surfaces after adhesion 
is established (Smart, 2005) that is  calculated by the ratio of the maximal detachment 
force, Fm, and the total surface area, A0, involved in the adhesive interaction. 
Sm  = Fm/A0 . 
It has been demonstrated that the rupture rarely occurs at the surface, but near it or at the 
weakest point, which can be the interface itself, the mucus layer or the hydrated region of 
the mucus, as illustrated in Figure (Smart, 2005).  
Since the fracture theory is concerned only with the force required to separate the parts, it 
does not take into account the interpenetration or diffusion of polymer chains. 
Consequently, it is appropriate for use in the calculations for rigid or semi-rigid 
bioadhesive materials, in which the polymer chains do not penetrate into the mucus layer.  
8.2.6 Mechanical theory 
Mechanical theory considers adhesion to be due to the filling of the irregularities on a 
rough surface by a mucoadhesive liquid. Moreover, such roughness increases the 
interfacial area available to interactions thereby aiding dissipating energy and can be 
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considered the most important phenomenon of the process (Peppas, Sahlin, 1996; Smart, 
2005).  
 
It is unlikely that the mucoadhesion process is the same for all cases and therefore it 
cannot be described by a single theory. In fact, all theories are relevant to identify the 
important process variables (Lee, Park, Robinson, 2000). 
8.3 Factors affecting muco/ bioadhesion 
Mucoadhesion can be influenced by several factors affecting the polymers or the 
environment or the physiological properties.  
In particular, polymers related factors regard the molecular weight, its flexibility and 
spatial conformation. High molecular weight polymers are generally used for 
mucoadhesion and it seems that the bioadhesive force increases with molecular weight of 
the bioadhesive polymer, up to 10,000 and that beyond this level there is no much effect. 
Hydrogen bonding due to presence of hydrophilic groups such as -COOH or -OH, plays a 
significant role in mucoadhesion.  
The polymer nature influences the degree of swelling in water which in turn determines 
interpenetration of polymeric molecules within the mucus. To allow chain 
interpenetration, the polymeric molecule must have an adequate length. Size and 
configuration of the polymer molecules are also important factors. 
Flexibility is an important factor for interpenetration and entlanglement. As water soluble 
polymers become cross-linked, the mobility of individual polymer chain decreases. As 
the cross-linking density increases, the effective length of the chain which can penetrate 
into the mucous layer decreases and mucoadhesive strength is reduced. 
The pH of the environment influences the charge on the surface of both mucus and the 
polymers. In particular, mucus contains sialic acid and sulphate residues of the 
glycoprotein that are negatively charged under physiological conditions; these negatively 
charges can interact with polymers through several strengths.   
The physiological factors are principally related to the natural turnover of mucin 
molecules from the mucus layer. The mucin turnover limit the residence time of the 
mucoadhesives on the mucus layer, but mucin turnover also results in substantial 
amounts of soluble mucin molecules. These molecules interact with mucoadhesives 
before they have chance to interact with the mucus layer. 
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Moreover, the physicochemical properties of mucus are known to change during diseased 
states such as common cold, gastric ulcers, ulcerative colitis, cystic fibrosis, bacterial and 
fungal infections of the female reproductive tract and inflammatory conditions of the eye. 
If the mucoadhesives are to be used in the diseased states, the mucoadhesive property 
needs to be evaluated under the same conditions. 
 
8.4 Mucoadhesive materials 
Mucoadhesive materials interact with the mucus layer covering the mucosal epithelial 
surface and the main molecules constituting a major part of mucus. They can be synthetic 
or natural polymers and can be water-soluble and water insoluble polymers. Water 
insoluble polymers are swellable networks, jointed by cross-linking agents, or highly 
polar to ensure a good hydration and consequently an optimal fluidity that permits the 
mutual adsorption and interpenetration of polymer and mucus to take place.  
An ideal mucoadhesive polymer has the following characteristics: 
1. The polymer and its degradation products should be nontoxic  
2. It should be non-irritant to the mucous membrane. 
3. It should preferably form a strong non-covalent bond with the mucin-epithelial 
cell surfaces. 
4. It should adhere quickly to most tissue and should possess some site-specificity. 
5. The polymer must not decompose on storage or during the shelf life of the 
dosage form. 
6. The cost of polymer should not be high so that the prepared dosage form 
remains competitive. 
 
Generally, mucoadhesive materials can be divided into first and second generation 
materials.  
The first generation mucoadhesive materialsare natural or synthetic hydrophilic 
molecules containing numerous organic functions that generate hydrogen bonds such as 
carboxyl, hydroxyl and amino groups, which do not adhere specifically onto several 
surfaces and the most known examples are carbomers, chitosans, alginates and cellulose 
derivatives. These polymers can be subdivided into three classes: cationic, anionic and 
nonionic. Cationic molecules, such as chitosan, are positively charged at physiological 
pH and can interact with the mucus surface. In particular, an electrostatic interactions of 
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the amino groups (or positive charge) with the sialic groups of mucin in the mucus layer 
can occur. Chitosan has been extensively investigated as a drug delivery mucoadhesive 
systems (Woodley, 2001; Bravo-Osuna et al., 2007; Luppi et al., 2010b).  
In the case of anionic molecules, mucoadhesion results from physical-chemical 
processes, such as hydrophobic interactions, hydrogen and van der Waals bonds, which 
are controlled by pH and ionic composition (Woodley, 2001) and from  interpenetration  
of polymers chains (Luppi et al., 2010a).  
Nonionic polymers, including hydroxypropylmethylcellulose, hydroxyethylcellulose and 
methylcellulose, present weaker mucoadhesion force compared to anionic polymers 
(Mortazavi, Moghimi, 2003).  
 
Studies on novel mucoadhesive systems involve the use of multifunctional materials.  
These novel multifunctional mucoadhesive systems are classified as second generation 
polymers (Lee, Park, Robinson, 2000). They are an alternative to non-specific 
bioadhesives (Smart, 2005) because they bind or adhere to specific chemical structures on 
the cell or mucus surface. Good examples of these molecules are lectins, invasins, 
fimbrial proteins (Woodley, 2001), and those obtained by the addition of thiol groups to 
known molecules (Bravo-Osuna et al., 2007).  
 
8.5 Methods of analyzing mucoadhesion 
No technology has still been developed specifically to analyze mucoadhesion. Most of 
the tests available were adapted from other preexisting techniques but are useful and 
necessary for selecting the promising candidates as mucoadhesives as well as in 
elucidating their mechanisms of action.  
8.5.1 Tests measuring mucoadhesive strength 
Most in vitro/ex vivo methodologies found in the literature are based on the evaluation of 
mucoadhesive strength, that is, the force required to break the binding between the model 
membrane and the mucoadhesive. Depending on the direction in which the mucoadhesive 
is separated from the substrate, is it possible to obtain the detachment, shear and rupture 
tensile strengths (Carvalho et al., 2010).  
The force most frequently evaluated in such tests is rupture tensile strength (Bromberg et 
al., 2004; Bruschi et al., 2007; Luppi et al., 2010 a). Generally, the equipment used is a 
texture analyzer or a universal testing machine that measure the force required to remove 
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the formulation from a model membrane. The model membrane can be a disc composed 
of mucin (Bruschi et al., 2007), a piece of animal mucous membrane, generally porcine 
nasal mucus (Luppi et al., 2010a) or intestinal mucus from rats (Bromberg et al., 2004).  
8.5.2 Rheological methods 
This category of methods are all carried out in vitro and were first proposed by Hassan 
and Gallo (1990), who used viscosimetric assays to macroscopically analyze the 
formulation-mucin interaction. From this test, it is possible to obtain the mucoadhesion 
force by monitoring the viscosimetric changes of the system constituted by the mixture of 
the polymer chosen and mucin. The energy of the physical and chemical bonds of the 
mucin-polymer interaction can be transformed into mechanical energy or work. This 
work, which causes the rearrangements of the macromolecules, is the basis of the change 
in viscosity.  
Rheological tests are performed totally in vitro and consequently are conducted in 
combination with the rupture tensile strength test, most frequently used in studies on 
mucoadhesion. Moreover, it is applicable to semi-solids and liquids. 
8.5.3 Tests analyzing molecular interactions involved in mucoadhesion 
In order to study mucoadhesion process form a microscopical point of view, several tests 
analyzing the molecular interactions involved in mucoadesion are used.   
The use of low frequency dielectric spectroscopy represents an attempt to study gel-
mucus interactions near the molecular level. It evaluates the possible physic-chemical 
interactions between molecules and glycoproteins of the mucus at the interface, which is 
considered the step preceding the formation of bonds during the mucoadhesion process. 
This technique involves the study of material response to the application of an electrical 
field. A sinusoidal voltage is applied throughout the sample and the response is measured 
in function of the frequency. From the responses, the impedance or permittivity of the 
sample is obtained and the property of charges changing in the system can be determined 
(carvalho et al., 2010). This technique can provide information about the compatibility 
between mucus and mucoadhesive system by means of the evaluation of the movement of 
the charged particles.  
Another test was applied for the analysis of mucoadhesion by Takeuchi et al. (2005). 
This test is based on the passage of a mucin suspension through a sensor containing the 
immobilized polymer. When a mucin particle binds to the polymer at the sensor, both the 
solute concentration and the refraction index on this surface undergo changes, where the 
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interaction is quantitatively evaluated and reproduced on a diagram. The sensor is a chip 
with a glass surface covered in a fine gold layer, where functional groups are introduced 
and the polymer is attached (Takeuchi et al., 2005).  
8.5.4 In vivo tests 
Säkkinen et al. (2006) applied gamma scintigraphy to analyze mucoadhesion in vivo of 
chitosan within the gastrointestinal tract. Gamma scintigraphy allows the immediate 
visualization of all the formulation transit, with low exposure of the subjects to radiation. 
The study emphasized the importance of in vivo studies, because although chitosan 
exhibits an outstanding mucoadhesion capacity in vitro, the retention time at the 
absorption site in the human gastrointestinal tract was relatively short and not sufficiently 
reproducible (Säkkinen et al., 2006). The gastrointestinal transit time in animals can also 
be evaluated in a non-invasive way, in which the release systems can be formulated with 
opaque radioisotopes and signals can be followed by X-rays, without affecting normal 
gastrointestinal motility (Chowdary, Rao, 2004).  
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AIM OF THE THESIS 
 
The aim of this thesis was the formulation of new chitosan based delivery systems for 
transmucosal drug administration. With respect to the oral route, the transmucosal route, 
such as buccal, vaginal and nasal routes, allowsthe circumvention of the hepatic first pass 
metabolism and of chemical and enzymatic degradations that generally occur in the 
stomach. Moreover, transmucosal drug administration can allow to avoid pain or 
discomfort caused by injections, when drugs are administered through parenteral routes 
and  especially if multiple daily injections are required, thus increasing patient 
compliance. On the other side, the major disadvantage of transmucosal drug 
administration is represented by the presence of biological fluids and mucus that can 
remove drug systems from the application site, thus reducing the contact time between 
drug and mucosa and consequently, decreasing drug bioavailability. For this reason, in 
this study, the investigation of chitosan delivery systems as mucoadhesive formulations 
able to increase drugs residence time and to improve their bioavailability, was taken into 
account. 
Polyelectrolyte complexes were prepared with chitosan and polyanions such as gelatin 
and alginate. Several parameters of production process were evaluated in order to obtain 
a final drug delivery system (buccal films and vaginal inserts) able to interact with 
water,to adhere with mucosal surface and to deliver the selected drugsover the time. 
Results related to these aims are shown in the following papers (N°1 and 2): 
 
Mucoadhesive chitosan/gelatin films for buccal delivery of propranolol hydrochloride. 
Carbohydrate Polymers, 2012, 87, 581-588. 
Reproduced with permission. License number: 3042490426245; Carbohydrate polymers;  
Elsevier 
 
Chitosan/alginate complexes for vaginal delivery of chlorhexidine digluconate. Original 
Research Article. 2013, 91(2), 651-658. DOI information: 10.1016j. 
carbopol.2012.08.074.  
Reproduced with permission. License number: 3042500670157, Carbohydrate polymers; 
Elsevier. 
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Finally, chitosan was employed for the preparation of nanoparticles intended for insulin 
nasal delivery. This research was conducted in Santiago di Compostela under the 
supervision ofProf. Marcos-García Fuentes and Prof. Maria José Alonso. In particular, 
nanoparticles were prepared with chitosan and cyclodextrin including different amount of 
two excipients with the capacity to modify insulin bioavailabity. I will disclose the names 
of these formulation components due to IP issues and I will call them with the codenames 
C1 and C2. Nanoparticles were characterized in terms of size, PDI, zeta potential and 
stability and the influence of these excipients on drug release and permeation were 
evaluated. These results are shown in the paper N°3: 
 
4. Chitosan-cyclodextrin nanoparticles containing two excipients with the capacity 
to modify insulin bioavailabity. In preparation 
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MUCOADHESIVE CHITOSAN/GELATIN FILMS FOR 
BUCCAL DELIVERY OF PROPRANOLOL 
HYDROCHLORIDE 
 
 
 
 
 
 
 
 
Abruzzo A., Bigucci F., Cerchiara T., Cruciani F., Vitali B., Luppi B. Mucoadhesive 
chitosan/gelatin films for buccal delivery of propranolol hydrochloride. Carbohydrate 
Polymers, 2012, 87, 581– 588 
 
 
License number: 3042490426245; Carbohydrate polymers, Elsevier 
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Abstract 
 
The aim of this work was to develop and characterize chitosan/gelatin films as innovative 
mucoadhesive system for buccal delivery of propranolol hydrochloride. FT-IR and TGA 
analysis confirmed the interaction between chitosan and gelatin. The presence of higher 
chitosan amounts in chitosan/gelatin films allowed the lowest percent water-uptake 
ability (235.1±5.3%) and the highest in vivo residence time in the buccal cavity (240±13 
minutes). Moreover, the presence of mannitol in the formulation allowed 80% drug 
permeation through porcine buccal mucosa in 5 hours. This behaviour suggests that the 
application of four and two films containing 5 mg of propranolol hydrochloride could be 
suitable for achieving the proposed daily dose for hypertension and atrial fibrillation 
treatment, respectively. Another interesting aspect of chitosan/gelatin films was their 
compatibility with buccal microflora in the absence of drug and their ability to determine 
growth inhibition for pathogen bacteria, but not for probiotic species, when loaded with 
drug. 
 
Keywords: Chitosan/gelatin complexes; Buccal delivery; Mucoadhesive films; 
Propranolol hydrochloride. 
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1. Introduction 
 
Buccal route offers several advantages than oral route (Harris and Robinson, 1992) due 
tothe high total blood flow which ensures systemic bioavailability, avoiding first-pass 
hepatic metabolism and gastrointestinal drug degradation (Junginger et al., 1999; 
Salamat-Miller et al., 2005). Moreover, it is easily accessible for self-medication and 
suitable for dosage forms administration and removal. However, the accidental 
swallowing of delivery systems and the continuous dilution of the released drug by saliva 
could determine a low residence time of formulation in buccal cavity and, consequently, a 
low drug bioavailability (Shojaei, 1998).For this reason, various bioadhesive buccal 
formulations (Sudhakar et al., 2006), such as tablets(Llabot et al., 2002), gels (Pelin et al., 
2004; Mortazavi, 2002), patches (Burgalassi et al., 1996; Reinhold and Hans, 1989; 
Cheng et al., 1997; Wong et al., 1999), and films (Kohda et al., 1997;Remuñán-López, 
1998), have been developed using mucoadhesive polymers which can establish a strong 
adhesive contact with the buccal mucosa, allowing to increase residence time of delivery 
systems and to optimize drug bioavailability. In particular, mucoadhesive buccal films 
can ensure an accurate drug dosing with respect to liquid formulations and gels, which 
can be easily washed away by saliva, and can be more comfortable with respect to 
conventional solid formulations. In fact, films are flexible and elastic, so that patient 
compliance is increased and also adequately strong to withstand breakage, caused from 
mouth movements (Peh and Wong, 1999). 
In this study the properties of films based on chitosan/gelatin polyelectrolyte complexes 
were investigated. Chitosan, a N-deacetylated product of the polysaccharide chitin, shows 
interesting biological properties, including biocompatibility, non-toxicity, 
biodegradability and mucoadhesivity (Koga, 1998; He et al., 1998; Muzzarelli, 1997; 
Luppi et al., 2010a). Chitosan is also a promising matrix carrier for sustained drug release 
and it possesses excellent film-forming properties (Remuñán-López and Bodmeier, 
1996). At pH below its pKa, chitosan is a polycation and has been used extensively to 
prepare ionically crosslinked hydrogels with anionic polymers (Hamman, 2010, Berger et 
al., 2004; Meshali and Gabr, 1993). In this study, type B gelatin was used as anionic 
polymer. Type B gelatin is a heterogeneous mixture of protein fractions consisting of 
single or multi-stranded polypeptides and it is derived from alkaline hydrolysis of cattle 
hides and bones (Hamman, 2010).  
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Propranolol hydrochloride is a β-blocker almost completely absorbed although it shows a 
low bioavailability due to extensive first-pass metabolism, so that only 25% 
approximately reaches systemic circulation (Reiter, 2004). It is used clinically for 
hypertension, angina, postinfarction, sinus tachycardia, arrhythmias, and obstructive 
cardiomyopathy. Because of differences in clearance and variation in drug binding there 
is a wide range of effective oral dosage. In particular, for hypertension treatment, the 
initial average daily dose of propranolol hydrochloride is 40 mg twice daily, while for 
atrial fibrillation, the initial usual dose is 10 mg three or four times daily. Considering 
drug oral bioavailability of approximately 25%, for hypertension treatment and for atrial 
fibrillation, the anticipated buccal doses of drug are 10 mg twice daily and 7.5-10 mg 
daily, respectively. 
The aim of this work was to develop mucoadhesive chitosan/gelatin films able to easily 
administer propranolol hydrochloride by buccal route, allowing suitable drug permeation. 
In particular, their use for chronic treatment can be suggested due to their tolerability and 
compatibility with buccal mucosa. 
 
2. Materials and methods 
 
2.1 Materials 
Type B gelatin from bovine skin (~225 Bloom, isoelectric point in the range of pH 4.5-
5.5) was obtained commercially from Sigma-Aldrich (USA); chitosan (Mr. 150,000; 
deacetylation degree 84%; pKa 6.3) and propranolol hydrochloride were obtained 
commercially from Fluka (Milan, Italy). All other chemicals and solvents were of 
analytical grade and purchased from Carlo Erba (Milan, Italy). Water-uptake, 
mucoadhesion, release and permeation studies were carried out in aqueous buffers with 
the following compositions (g) per liter of distilled water: 2.38 Na2HPO4·10H2O, 0.19 
KH2PO4, 8.0 NaCl for buffer solution pH 7.4; 4.609 KH2PO4, 16.748 Na2HPO4·12H2O 
adjusted with hydrochloric acid to pH 6.8. 
 
2.2 Preparation of chitosan/gelatin complex buccal films 
As described in Cheng M. et al., (2003), known amounts of chitosan and gelatin were 
dissolved separately in 1% w/v acetic acid and water, respectively. Then chitosan 
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solution and gelatin solution were mixed obtaining two final polymeric concentrations, 
F1 (1% w/v) and F2 (2% w/v) and different weight mixing ratios. The mixing ratio r (i.e. 
the percentage of gelatin in the mixture) was defined as: 
r = Wg/(Wc+Wg); 
where Wc and Wg were the weights of chitosan and gelatin, respectively.  
 
50 mL of the final mixture were cast into a petri dish (11 cm in diameter) and dried at 50 
°C for 24 h through casting-solvent evaporation method. Loaded films were prepared by 
the same procedure, adding a known amount of propranolol hydrochloride into the 
polymeric solutions, in order to obtain films containing 1.67 mg/cm
2
. 
Mannitol, a hydrophilic absorbing material, was added to F1 polymeric solutions 
obtaining Fm films (1.55 mg/cm
2
 of mannitol). 
Films were washed with 80% ethanol until neutrality (pH=7), cut into appropriate sizes, 
packed in aluminium foil and stored at 4°C for further studies. 
 
2.3 FT-IR spectroscopy, Thermogravimetric analysis (TGA) and Differential Scanning 
Calorimetry (DSC) 
To verify interactions between chitosan and gelatin, FT-IR spectroscopy (FT-IR-4100 
spectrophotometer recorded with a Jasco, 650-4000 cm
−1
) and TGA (Mettler TA 4000 
apparatus equipped with a TG 50 cell on 8-10 mg samples; β=10 K min−1, static air 
atmosphere, 30-400°C temperature range) of unloaded films, chitosan and gelatin 
powders and their physical mixture were performed. Measurements were carried out at 
least in triplicate (relative standard deviation ± 5%). To verify the absence of crystal drug 
in films, thermal analysis were performed using a thermocryostat (Mettler 821e/800/847) 
connected to the thermal analyzer (Mettler- Toledo S.p.a., Novate Milanese, 
Italy).Samples of loaded films and propranolol hydrochloride powder (about 5 mg) were 
sealed in a 30 μL aluminium pan and were scanned between 30°C and 340°C at a heating 
rate of 10°C/min.  
 
2.4  Characterization of buccal films 
In order to determine film thickness, three circles of 3 cm
2
 were cut from each film. The 
average thickness of the buccal films was determined using a Mitutoyo pocket thickness 
gauge; Mitutoyo Mfc. Co. Ltd, Tokyo, Japan.  
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For determination of weight uniformity, circles of 3 cm
2
 of each film were randomly 
selected and accurately weighted using an electronic balance. The results are expressed as 
the mean values of three determinations. 
Drug content was calculated as follows: three circles of 3 cm
2
 were dissolved in 10 mL of 
phosphate buffer (pH 7.4) containing 2 mL of HCl 0.1M solution, in order to determine 
the amount of propranolol hydrochloride in the films. The amount of drug was 
determined with chromatographic system, composed of a Shimadzu (Milan, Italy) LC-
10ATVP chromatographic pump and a Shimadzu SPD-10AVP UV-Vis detector set at 
254 nm. Separation was obtained on a Phenomenex (Torrance, CA, USA) Sinergy 
Fusion-RP 80A (150 x 4.6 mm I.D., 5 µm) coupled to a Phenomenex (Torrance, CA, 
USA) SecurityGuard C18 guard cartridge (4 x 3.0 mm I.D., 5 µm). The mobile phase was 
composed of a mixture of acetonitrile-pH 3.0 solution of triethylamine (0.5%) 30:70 
(v/v). The flow rate was 0.4 mL/min and manual injections were made using a Rheodyne 
7125 injector with a 50 μL sample loop. Data processing was handled by means of a 
CromatoPlus computerised integration system (Shimadzu Italia, Milan, Italy). Calibration 
curve of concentration versus peak area ratio was plotted at concentration range of 
0.1μg/mL-10μg/mL; good linearity was found (r2 = 0.9998). Repeatability assays were 
carried out on propranolol hydrochloride standard solutions, at concentrations 
corresponding to the lower and upper limit and the middle point of the calibration curve. 
Method precision was satisfactory: RSD% values of 3.1, 3.0 and 1.3 were obtained for 
propanolol hydrochloride concentrations of 0.1, 1.0 and 10.0 μg mL−1, respectively. 
The results were expressed as milligrams of drug for square centimetre (mg/cm
2
). All 
determinations were carried out in triplicate. 
 
2.5   Scanning electron microscopy (SEM) 
The morphological structure of buccal films was studied by SEM analysis. Buccal films 
were fixed on supports and coated with gold-palladium under an argon atmosphere using 
a gold sputter module in a high-vacuum evaporator. Samples were then observed with 
LEO 420 (LEO Electron Microscopy Ltd, England) using secondary electron imaging at 
15 kV in order to examine the structure of the films. 
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2.6  In vitro water-uptake studies 
In vitro water-uptake studies were performed in phosphate buffer at pH 6.8 that simulated 
human saliva and measuring the increase of weight for predetermined periods of time. 
Circles of 3 cm
2
 of each films were weighted (W1) and dipped in simulated saliva fluid 
for predetermined periods of time. Then, the circles were wiped off from the excess 
surface water using filter paper and weighted (W2). Water-uptake (WU) ability was 
determined as a weight increase of the films after 5 h, according to the follow equation:  
WU (%) = [(W2-W1) x 100/W1 ], 
where W1 was the initial weight of dry film and W2 is the weight of hydrated films. 
 
2.7 In vitro and in vivo mucoadhesion properties 
For these studies porcine buccal mucosa was used as biological membrane due to the 
similarity to the human buccal tissue (Shojaei, 1998; Hoogstraate et al., 1992).Porcine 
buccal mucosa was removed from a freshly killed male pig obtained from a local 
slaughter house. The buccal cavity was placed in phosphate buffer at pH 7.4; then buccal 
mucosa was surgically removed from the oral cavity using fine-point forceps and surgical 
scissors to turn away the connective tissue. Finally, buccal mucosa was cleaned in 
phosphate buffer at pH 7.4 and immediately used for tests. 
The in vitro mucoadhesion was measured in terms of the force needed to pull out a 
freshly excised buccal mucosa (surface area 1 mm
2
) from a film with an adapted 
tensiometer (Krüss 132869; Hamburg, Germany). As reported in Luppi et al. (2010b), the 
mucosa was fixed to a support with cyanoacrylate adhesive and then suspended from the 
tensiometer spring. The mucosa was lowered until it just contacted the surface of the 
film, previously hydrated with phosphate buffer at pH 6.8 for 5 minutes. A 20 dyne force, 
measured by the torsion balance of the instrument as a negative force, was applied to the 
films for 60 seconds. Then the mucosa was raised until it was separated from the film. 
The assay was performed for three different circles from each film and it was calculated 
the average. 
The in vivo mucoadhesion properties of buccal unloaded films were tested in five healthy 
volunteers aged 25–40 years. The volunteers were instructed to press the films against the 
gingival mucosa above the canine tooth for 60 seconds (Perioli et al., 2004; Yehia et al., 
2008).The films were observed for 5 h. The volunteers were refrained from food and 
drinks during the test and were asked to monitor for irritation and to record the residence 
time which was taken as the time for the film to dislodge completely. 
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2.8 In vitro release of propranolol hydrochloride from buccal films 
The release studies of propranolol hydrochloride were performed in 10 mL of phosphate 
buffer at pH 7.4 at 37±0.5°C under magnetic stirring. Aliquots of 0.2 mL were withdrawn 
at different time intervals, filtered through cellulose acetate membrane (0.45 μm), and 
replaced by fresh medium. The studies were carried on for 5 h. The release studies were 
conducted in triplicates and the mean values were plotted versus time.  
 
2.9 In vitro permeation studies 
In vitro permeation studies through buccal porcine mucosa were conducted in a Franz-
type permeation cell with a diffusional area of 1.76 cm
2
. At time zero, films were placed 
in the donor compartment and 20 µL of phosphate buffer at pH 6.8 simulating human 
saliva were placed on mucosa. The receiver phase (6.0 mL of a phosphate buffer solution, 
pH 7.4, maintained at 37 °C by means of a surrounding jacket) was stirred constantly and, 
at predetermined time intervals, samples of 100 µL were taken and replaced by fresh 
medium, in order to assess the amount of drug permeated. As control formulation, the 
permeation study of propranolol hydrochloride from 50 µL of solution containing 5 mg 
of drug was performed. The studies were carried on for 6 h. The permeability coefficient 
(P) was calculated using the following equation: P = (dM/dt)/(M0A), where dM/dt 
represents the permeability rate and M0 stands for the initial concentration in the donor 
chamber, while A is the effective surface area of the mucosa. 
 
2.10 Antimicrobial activity assay 
The antimicrobial activity was evaluated against Gram-positive bacteria (Lactobacillus 
acidophilus LA14, Bifidobacterium infantis BI07, Bacillus subtilis ATCC 6633 and 
Staphylococcus aureus ATCC 29213), Gram-negative bacteria (Escherichia coli ATCC 
11105, Pseudomonas aeruginosa ATCC 9027) and yeasts (Candida albicans ATCC 
10231). L. acidophilus LA14 and B. infantis BI07 are probiotic strains purchased by 
Danisco Inc. (Madison, WI). B. subtilis, S. aureus, E. coli and P. aeruginosa were grown 
aerobically in LB medium (Difco, Detroit, MI) at 37°C for 24 h. L. acidophilus and B. 
infantis were cultured in MRS medium (Difco) supplemented with 0.05% L-cysteine at 
37°C for 18-36 h under an anaerobic atmosphere by using Anaerocult A (Merck, 
Darmstadt, Germany). C. albicans was grown aerobically in SD medium (Difco) at 30°C 
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for 48 h.  The disc-agar diffusion method was used to test the antimicrobial activities of 
unloaded and loaded films (6 mm diameter) containing different concentrations of 
chitosan and gelatin (r=0.2, r=0.4, r=0.6). In parallel, the antimicrobial activity was 
evaluated for: (i) chitosan solutions (1%, w/v), without and with propranolol 
hydrochloride (25 mg/mL) in order to simulate polymer and drug amounts in the films; 
(ii) chitosan/gelatin (1%, w/v) solutions, without and with drug. Suspensions of the test 
microorganisms (10
8
 colony-forming units [CFU]/mL) were spread on the agar plates 
containing the appropriate culture media (LB, MRS or SD). Sterile paper discs of 6 mm 
diameter (Schleicher and Schuell, Dassel, Germany) were impregnated with 20 μL of 
each solution. These paper discs and the circular films with the same diameter were 
placed on the surface of the agar plates. Plates were incubated at the appropriate 
conditions and the diameter of the inhibition zone around the paper discs and films were 
measured. The experiments were performed in triplicate.  
The minimal inhibitory concentration (MIC) of propranolol hydrochloride was 
determined by the agar dilution method. A stock solution of 20 mg/mL of drug in water 
was used to prepare agar plates containing scalar concentrations of the drug (3.75–120 
μg/mL). Pure propranolol hydrochloride was used to obtain agar plates containing 25 
mg/mL of the drug. Microbial suspensions of 10
5–106 CFU/mL, prepared from broth 
cultures in log phase growth, were used to inoculate plates containing propranolol 
hydrochloride. Plates were made in triplicate and incubated at the appropriate conditions.  
 
2.11 Statistical analysis 
All the experiments were done in triplicate. Results are expressed as mean ± SD. 
Kruskal–Wallis and Anova tests were used to determine statistical significance of 
permeation studies and of all other studies, respectively. Differences were considered to 
be significant for values of P < 0.05. 
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3. Results and discussion 
 
3.1FT-IR spectroscopy, Thermogravimetric analysis (TGA) and Differential Scanning 
Calorimetry (DSC) 
 
 
 
Fig. 1. FT-IR of chitosan (a), gelatin (b), chitosan/gelatin physical mixture (c), F1 film 
r=0.6 (d). 
 
Fig. 1 shows the FT-IR spectra of chitosan (a), gelatin (b), chitosan/gelatin physical 
mixture (c) and F1 film, r=0.6 (d).  
The FT-IR spectra of chitosan showed bands at 1654 cm
-1
 relative to the vibration of the 
carbonyl group of acetylated amide and at 1580 cm
-1
 relative to stretching of the free 
amino group. Gelatin showed the bands at 1654 cm
-1
 and 1535 cm
-1
 relative to the 
vibration of the amide carbonyl and stretching of the free amino groups, respectively; it 
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also showed band at 1704 cm
-1
 relative to undissociated carboxyl group. These 
characteristics bands were also in the FT-IR spectra of physical mixture of chitosan and 
gelatin. The FT-IR of film showed the shift in amide carbonyl group to 1640 cm
-1
 and the 
shift in amino group of chitosan to 1564 cm
-1
, confirming the interaction between 
chitosan and gelatin, also reported in Yin et al. (1999). 
 
 
Fig. 2. Thermogravimetric analysis of gelatin (a), chitosan (b), chitosan/gelatin physical 
mixture (c), F1 film r=0.6 (d). 
 
Fig. 2 shows the thermograms of chitosan (a), gelatin (b), chitosan/gelatin physical 
mixture (c) and F1 film, r=0.6 (d).  
Chitosan and gelatin degraded at about 285 °C (inflection point temperatures). The 
degradation of polyelectrolyte complex film showed one event at 250 °C that can be 
considered as a proof of chitosan and gelatin complexation. The shift to a lower 
temperature in the thermal degradation of the complex indicated a loss of organization, 
probably due to the formation of ionic bonds between chitosan and gelatin. 
As can be seen from the Fig. 3, propranolol hydrochloride showed a melting point at 
165.6  0.2 °C. DSC analysis of all films showed the absence of exothermic melting peak 
of propranolol hydrochloride and consequently the absence of crystal drug in the films. 
EXPERIMENTAL SECTION-PAPER N°1 
Angela Abruzzo-University of Bologna Pag. 120 
 
 
Fig. 3. DSC of propanolol hydrochloride and F1 films. 
 
3.2  Characterization of buccal films 
Table 1 reports drug content, thickness and weight of loaded and unloaded films.  
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Formulation type 
 
 
Drug content 
(mg/cm
2
) 
 
 
Film thickness 
(µm) 
 
 
Weight films 
(mg/cm
2
) 
 
 
F1 unloaded 
 
 
- 
 
50 ± 3 
 
7.08 ± 0.06 
 
 
F2 unloaded 
 
 
- 
 
70 ± 5 
 
 
10.12 ± 0.13 
 
Fm unloaded 
 
 
- 
 
62 ± 3 
 
10.01 ± 0.02 
 
 
F1 loaded 
 
 
1.67 ± 0.05 
 
 
70 ± 8 
 
 
8.53 ± 0.32 
 
F2 loaded 
 
 
1.68 ± 0.03 
 
100 ± 9 
 
 
11.73 ± 0.36 
 
Fm loaded 
 
 
1.70 ± 0.04 
 
82 ± 7 
 
 
11.48 ± 0.33 
 
 
Table 1. Characteristics of the different films (mean ± S.D., n = 3). 
 
All loaded films consisting exclusively of chitosan did not show uniformity of drug 
content, weight and thickness (data not reported) and they were not considered for the 
subsequent tests. The others films showed weight uniformity and different thickness that 
can be related to the different polymeric concentration (for F1 and F2) and to the 
presence of mannitol in the Fm formulations.  
Moreover, the experimental drug content of loaded films was close to the theoretical one 
(1.67 mg/cm
2
 for all films) with low standard deviation, suggesting that the method 
employed for their preparation was capable of giving an uniform drug distribution.  
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3.3  Scanning electron microscopy (SEM) 
Fig. 4 show the morphology of unloaded F1 film (r=0.6, a) and all loaded F1 films (r= 
0.2, b; r=0.4, c; r= 0.6, d; r=0.8, e; r=1, f) which showed a homogeneous structure and 
devoid of crystals.  
Moreover, loaded films containing an excess of gelatin (d, e, f) did not show a continue 
structure but an increasingly evident convex pattern on the top surface. 
 
 
 
b 
c d 
f e 
a 
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Fig. 4 Scanning electron micrographs of unloaded F1 film r=0.6 (a) and of loaded F1 
films: r= 0.2 (b), r=0.4 (c),  r=0.6 (d), r=0.8 (e), r=1 (f).  
 
3.4 In vitro water-uptake studies 
In vitro water-uptake studies, performed at pH 6.8 on unloaded F1 films, showed the 
highest water-uptake ability % at 30 minutes.  
In particular, film consisting exclusively of gelatin completely solubilised in the medium 
in 10 minutes, while in the complex based films, the presence of a greater amount of 
gelatin provided a higher water-uptake ability % than films with an excess of chitosan (P 
<0.05). In fact, for films with r=0, r=0.2, r=0.4, r=0.6 and r=0.8 the water-uptake ability 
% values were 190.0±7.9, 235.1±5.3, 254.1±4.3, 286.5±6.4, 352.7±8.7, respectively. This 
behaviour can be correlated to the presence of a great number of ionized amino acids in 
gelatin structure and consequently to the presence of free charges favouring the entry of 
water.  
This trend was also observed for loaded F1 films. However, the presence of propranolol 
hydrochloride provided the formation of loaded films characterized by a lower water-
uptake ability % than unloaded films (P<0.05). In particular, water-uptake ability % was 
as follows: 193.8± 8.4 for film r=0.2; 209.3± 7.0 for film r=0.4; 237.5±8.3 for film r=0.6; 
295.3±4.5 for film r=0.8. We must consider that at pH 6.8 propranolol hydrochloride is 
present in its ionized form (pKa 9.5) and its positive charge can interact with free 
negative charges of acidic amino acids of gelatin. These possible drug/protein ionic 
interactions can reduce free charges on gelatin structure thus determining the lower 
tendency of film hydration.  
Fig. 5 showed the water-uptake ability after 60 minutes for all loaded films (F1, F2 and 
Fm).  
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Fig. 5 Water-uptake ability after 60 minutes of different film formulation (F1, F2 and 
Fm) at pH 6.8 (n = 5, the SD did not exceed the 5%). 
 
 As can be seen, the presence of a higher amount of polymer (F2 films) increased water-
uptake ability % respect to F1 films. As previously described the presence of free charges 
in the formulations is extremely important for film hydration and greater amount of 
polymers in the films can improve water-uptake ability % (P< 0.05). 
As can be expected, films with the addition of mannitol (Fm) showed a greater water-
uptake ability % than F1 and F2 films (P< 0.05), due to the presence of a hydrophilic 
molecule able to favour a major entry of water in the system. 
 
3.5 In vitro and in vivo mucoadhesion properties 
Table 2 reports the results of in vitro and in vivo mucoadhesion testsfor unloaded and 
loaded F1 films.  
 
r 0 0.2 0.4 0.6 0.8 1 
 
In vitro force detachment (dyne) 
 
 
18.7  0.4 
 
 
15.8  0.3 
 
 
14.6  0.5 
 
13.8  0.3 
 
11.4  0.5 
 
10.3  0.2 
 
 
In vivo residence time (min) 
 
 
270  15 
 
240  13 
 
230  12 
 
 
220  11 
 
 
150  7 
 
 
50  4 
 
Table.2 In vitro mucoadhesive capacity (expressed as detachment force, mean ± SD, n = 
3) and in vivo residence time in buccal cavity (mean ± SD, n = 3) of unloaded films (F1).  
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As can be seen, films with an excess amount of chitosan showed the bestin vitro 
mucoadhesive properties among all films. In fact, amino groups of chitosan chains were 
positively charged and could interact with sialic acid (pKa 2.6) and sulphate residues of 
mucin glycoprotein, that, at pH 6.8, were negatively charged (Peppas and Sahlin, 1996).  
F2 films showed higher mucoadhesion values than F1 films; in fact, for film with r=0, for 
example, the detachment force increased until a value of 22.8±0.5 (other data were not 
reported). This behaviour can be explained with the presence of a greater amount of 
polymer respect F1 film and consequently, with a greater presence of positively charged 
amino groups.  
Moreover, Fm films, containing mannitol, showed the best mucoadhesion properties 
(30.7±0.9 for film with r=0); in fact, in addiction to ionic interaction, mannitol promoted 
the entry of water, a more efficient chain mobility and physical entanglement with mucus. 
Despite loaded films showed a lower significant water-uptake ability than unloaded films, 
as a consequence of interaction between drug and gelatin (see section 3.5), the ionic 
interaction between chitosan and mucus provided not significantly different 
mucoadhesion properties respect mucoadhesion of unloaded films. 
In vivo mucoadhesive tests were performed to assess the ability of films, without drug, to 
adhere to the gingivae and to study the potential irritant effect. Films did not have 
irritating effects on the buccal mucosa; in fact, after the removal of the film, buccal tissue 
revealed no signs of damage to the mucosa. Volunteers reported no irritation during or 
after the study. 
Moreover, films with an excess of chitosan showed the best in vivo mucoadhesive 
properties, confirming in vitro mucoadhesion studies, while films with an excess of 
gelatin showed a lower residence time respect to films with an excess of chitosan 
(p<0.05). For F1 and Fm films (r=0) the residence times were 300±12 minutes and 320±5 
minutes, respectively (other data were not reported). 
 
3.6  In vitro release of propranolol hydrochloride from buccal films 
In vitro release studies showed that propranolol hydrochloride release stopped in the first 
30 minutes for all films analysed.  
In particular, only film based on gelatin alone (r=1) provided complete drug release due 
to its dissolution. Films with an excess of chitosan (r=0.2 and r=0.4) showed a higher 
release of drug with respect to films with a greater amount of gelatin (P<0.05) allowing 
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83% and 66% of drug released in 30 minutes, respectively. On the contrary, films 
containing an excess of gelatin, r=0.6 and r=0.8, provided a percentage drug release of 
54% and 48% respectively in 30 min.  
Propranolol hydrochloride was not completely released from all the formulations 
containing chitosan/gelatin complexes; this behaviour can be related to the presence of 
possible interactions between drug and gelatin, which, proportionally to gelatin increase 
in the films, limit drug diffusion through the chitosan/gelatin polymeric network.  
Differently, all films containing mannitol provided a complete drug release (100%) in 30 
minutes, due to a greater entry of water favouring polymeric chain mobility and thus drug 
diffusion through the hydrated films. 
 
3.7 In vitro permeation studies 
Fig. 6 showed the permeation profiles and permeability coefficients P (cm/min) of 
propranolol hydrochloride across porcine buccal mucosa, after application of loaded F1 
films.  
 
 
 
 
Fig. 6. Permeation profiles (mean ± SD, n = 3) and permeability coefficients P (cm/min) 
of  propranolol hydrochloride across the porcine buccal mucosa from F1 films. 
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As can be seen from the figure, control formulation provided the complete permeation of 
the drug in 90 minutes. Films consisting exclusively of gelatin provided the greater 
amount of permeated drug, due to its rapid dissolution. Instead, films containing 
chitosan/gelatin complexes provided a lower amount of permeated drug; in particular, 
films with a higher content of gelatin provided the lower amount of permeated drug. 
This behaviour can be correlated with drug release profiles from buccal films, which 
influenced drug availability at the absorption site.  
While control formulation was rapidly removed from buccal cavity by saliva and 
swallowing, mucoadhesive films, in particular films containing an excess of chitosan 
(r=0.2 and r=0.4), provided a higher buccal residence times, optimizing drug 
bioavailability. 
As can be seen from the Fig. 6, these films provided the permeation of only 46% and 
35% (P= 14*10
-4
 cm/minand P= 12*10
-4
 cm/min) of drug, respectively. Differently, 
permeation studies relative to films (r=0.2 and r=0.4) containing mannitol showed an 
amount of permeated drug around 80% and 68% (P= 28*10
-4
 cm/min), respectively. 
As underlined in section 1, considering drug oral bioavailability of approximately 25%, 
for hypertension treatment and for atrial fibrillation the anticipated buccal doses of 
propranolol hydrochloride are 10 mg twice daily and 7.5-10 mg daily, respectively. The 
application of four and two films containing mannitol and an excess of chitosan could 
allow achieving the proposed daily dose for hypertension treatment and for atrial 
fibrillation, respectively.  
3.8 Antimicrobial activity assay 
Buccal preparations intended for chronic treatment should guarantee the adequate dosing 
regimen avoiding any potential undesirable side effects related to their prolonged 
residence at the administration site. An interesting characteristic of chitosan/gelatin films 
was their compatibility with buccal microflora.  
The disc-agar diffusion test showed an antibacterial activity associated with propranolol 
hydrochloride. Loaded films (r=0.2, r=0.4, r=0.6), chitosan/drug and 
chitosan/gelatin/drug solutions determined growth inhibition zones for the pathogen 
bacteria B. subtilis, S. aureus, E. coli and P. aeruginosa with diameters ranging from 8 to 
28 mm. No growth inhibitory effect was observed against the probiotic species L. 
acidophilus and B. infantis and against the yeast C. albicans.  
Differently, unloaded films, chitosan and chitosan/gelatin solutions did not show any 
noticeable inhibition zone for the microorganisms tested, indicating the absence of 
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antimicrobial activity for chitosan and gelatin at the concentrations used in the 
preparation of the films.  
The MIC of propranolol hydrochloride was evaluated by the agar dilution method. MIC 
resulted > 120 μg/mL, indicating that propranolol hydrochloride can not be considered a 
strong antimicrobial agent. Since drug concentration in the films was 25 mg/mL, the 
antimicrobial activity of this concentration was also evaluated. The antimicrobial effects 
of propranolol hydrochloride at 25 mg/mL was demonstrated for all the microorganisms 
tested, confirming the data related to the inhibitory zones. Notably, the formulation of 
propranolol hydrochloride in the polymeric films counteracted the antibacterial effects of 
this drug against the probiotic species L. acidophilus and B. infantis, suggesting a 
selectiveaction against pathogen bacteria.  
4. Conclusion 
Polyelectrolyte complexes based on chitosan and gelatin can be successfully employed 
for the formulation of buccal films.  
The selection of the appropriate chitosan/gelatin ratio and polymer concentration in the 
film, as well as the addition of mannitol, supports the goalof ensuring the necessary 
dosefor treatment of hypertension and atrial fibrillation.  
Moreover, along with adequate drug release and permeation, desirable film 
characteristics such as suitable hydration and mucoadhesion, were obtained. Finally, film 
tolerability and compatibility with buccal mucosa suggests their possible use as 
formulations intended for treatment of chronic diseases. 
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Abstract 
 
Chitosan/alginate complexes were prepared at different polycation/polyanion molar ratios 
and freeze-dried vaginal inserts were obtained for chlorhexidine digluconate local 
delivery in genital infections. Complex yield, FT-IR spectra and TGA thermograms were 
studied to confirm the interaction between the two polyions. The influence of different 
complexes on physical handling, morphology and drug distribution in the samples were 
evaluated by friability test, scanning electron microscopy (SEM) and energy dispersive 
X-ray spectroscopy (EDS), respectively. In vitro water-uptake, mucoadhesion and release 
tests were performed as well as microbiological tests towards pathogenic vaginal 
microorganisms. The results showed that the selection of suitable chitosan/alginate molar 
ratio and drug loading allowed modulate insert ability to hydrate, adhere to the mucosa 
and release chlorhexidine digluconate. The insert containing an excess of alginate was 
found to be the best performing formulation and showed good antimicrobial activity 
towards the pathogens Candida albicans and Escherichia coli.     
 
 
 
 
 
Keywords: chitosan/alginate complex, chlorhexidine digluconate, vaginal delivery, 
mucoadhesive inserts. 
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1. Introduction 
 
Disturbances in the vaginal environment due to abnormal vaginal flora and vaginal 
infections are highly prevalent among reproductive-aged women. Vaginal candidiasis is 
ranked as one of the most common gynaecological infections, and it has been estimated 
that about 75% of women experience an acute episode once in their lifetime. It has been 
reported that 30-35% of vaginitis episodes are due to Candida albicans (Nyririesy et al., 
2001; Sobel, 1988; Nitin et al., 2009; Das Neves et al, 2008). Aerobic vaginitis is another 
frequent form of abnormal vaginal flora which has been considered an important cause of 
pregnancy complications, such as ascending chorioamnionitis, preterm rupture of the 
membranes and preterm delivery. Aerobic vaginitis is defined as a disruption of the 
lactobacillary flora, accompanied by signs of inflammation and the presence of a 
predominantly aerobic microflora, composed of enteric commensals or pathogens, 
especially Escherichia coli and Streptococcus agalactiae (Donders et al., 2002; Donders 
et al., 2011). 
Topical imidazoles are considered standard treatments of candidiasis, while kanamycin or 
quinolones are a good choice for the therapy of aerobic vaginitis (Tempera and Furneri, 
2010). In the case of mixed vaginitis, the use of a monotherapy becomes ineffective, 
whereas treatment with a wide-spectrum antibacterial and antifungal substance, such as 
chlorhexidine digluconate, may be promising for a more rapid healing (Molteni et al., 
2004).  
Several drug delivery systems are used for treatment of vaginal infections (Alamdar et al., 
2005). Indeed, conventional vaginal formulations (suspensions, pessaries, cream and 
solutions) are characterized by short residence time at the site of administration, due to 
washing action of physiological secretions of vaginal fluids. Bioadhesive vaginal drug 
delivery systems, such as tablet, inserts and gels, may adhere to vaginal mucosa in order 
to bring drug in contact with target tissues for sufficient period of time and prevent 
expulsion of formulation (Ceschel et al., 2001; Dobaria et al., 2007; Kast et al., 2002; 
Valenta, 2005, Woodley, 2001). Tablets and some gel-based vaginal delivery systems are 
associated with problems like messiness and leakage of formulations causing 
inconvenience to users and leading to poor patient compliance (Dobaria et al., 2007). For 
this reason, in this study we focused the attention on the possibility to formulate a new 
suitable delivery system, able to overcome these limitations and characterized by a 
convenient application and easy handling. To achieve this goal, the vaginal insert was 
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chosen as final dosage form, easily applicable and able to deliver a unique dose of drug in 
the vaginal cavity, while chitosan and sodium alginate were selected in order to obtain 
good insert mucoadhesion ability. Furthermore, different chitosan/alginate molar ratios 
were tested in order to obtain a system releasing the suitable chlorhexidine digluconate 
amount, accordingly to the therapeutic needs and providing the complete inhibition of 
pathogens, such as Candida albicans and Escherichia coli. 
Chitosan, a N-deacetylated product of the polysaccharide chitin, shows interesting 
biological properties, including biocompatibility, non-toxicity, biodegradability and 
mucoadhesivity (Koga, D., 1998; Kumar Ravi, M., 2000; Dutta et al., 2004; Muzzarelli 
R.A.A,  1997 and 2010). It was also widely used for different type drug delivery systems 
(Dodane et al., 1998, Luppi et al., 2010a) and largely employed to prepare vaginal 
mucoadhesive dosage forms (Bonferoni et al., 2008, Perioli et al., 2008, Valenta, 
2005, Rossi et al., 2003). Chitosan can also interact with anionic polymers in order to 
prepare ionically crosslinked hydrogels (Remuñán-López and Bodmeier, 1996; Hamman, 
2010; Berger et al., 2004; Meshali and Gabr, 1993). Sodium alginate, an anionic, 
biocompatible, hydrophilic and biodegradable polymer, derived primarily from brown 
seaweed and bacteria, is a linear polysaccharide that consists of β-D-mannuronic acid and 
α-L-guluronic acid repeating units in various ratios (Hanne and Jan, 2002). 
Chitosan/alginate complexes were obtained mixing polymeric solutions with different 
molar ratios of chitosan and alginate and then freeze-drying the precipitates. Complex 
yield, FT-IR analysis, TGA thermograms were studied to investigate the interaction 
between the two polyions.  The complexes were used to prepare vaginal inserts loaded 
with chlorhexidine digluconate.Physical handling, morphology and drug distribution in 
the samples were studied by friability test, scanning electron microscopy (SEM) and 
energy dispersive X-ray spectroscopy (EDS) analysis. In vitro water-uptake, 
mucoadhesion, release and microbiological tests were performed in order to investigate 
the polyelectrolyte complexes ability to adhere to mucosa, to release chlorhexidine 
digluconate and to study the antimicrobial activity towards Candida albicans and 
Escherichia coli. 
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2. Materials and methods 
 
2.1 Materials 
Sodium alginate low viscosity (Mw ≈140000 Da, viscosity 100-300 cP, 2 %),chitosan 
low molecular weight (Mw ≈ 150000 Da, viscosity 20-300 cP, T=20°C, 1% in 1% acetic 
acid; deacetylation degree 97%) and chlorhexidine digluconate used for this study were 
obtained commercially from Sigma-Aldrich (Milan, Italy). All other chemicals and 
solvents were of analytical grade and purchased from Carlo Erba (Milan, Italy). Complex 
preparation, water-uptake, mucoadhesion and release studies were carried out in aqueous 
buffers with the following compositions per liter of distilled water: 8.99 mL CH3COOH 
2N and 2.62g CH3COONa for acetate buffer at pH 5.0; 13.61g KH2PO4, adjusted with 
hydrochloric acid to pH 4.5, for buffer simulating vaginal secretions. 
 
2.2 Preparation of chitosan/alginate complex and solid complex weight measurement 
Chitosan/alginate was prepared according to a method reported in a previous work 
(Bigucci et al.,  2008) with some modifications. Briefly, chitosan(1.50 mmol of monomer 
in 200 ml) and alginate (1.50 mmol of monomer in 200 ml)were separately dissolved in 
acetate buffers at pH 5.0 at the same ionic strength (50 mM). Different volumes of 
chitosan solutions were added to alginate solutions and stirred at room temperature for 24 
h, in order to obtain different chitosan/alginate molar ratios (1:9, 3:7, 1:1, 7:3 and 9:1). 
The precipitate was separated by ultracentrifugation at 10,000 rpm for 10 min (ALC 
4239R centrifuge; Milan, Italy). Then it was washed with deionized water and 
homogenized at 17,500 rev min
-1
 for 5 min (Ultra-Turrax, T 25 basic homogenizer; IKA, 
Dresden, Germany) for three times in order to eliminate sodium acetate. Finally, the 
precipitate was suspended again in deionized water and freeze-dried (Christ Freeze Dryer 
ALPHA 1-2, Milan, Italy), obtaining five different chitosan/alginate complexes: 
CH/ALG(1:9), CH/ALG(3:7), CH/ALG(1:1), CH/ALG(7:3) and CH/ALG(9:1).  
Each precipitate was weighted for the determination of solid complex weight. 
 
2.3 FT-IR spectroscopy and thermogravimetric analysis (TGA) 
To verify interactions between chitosan and alginate, FT-IR spectroscopy (FT-IR-4100 
spectrophotometer recorded with a Jasco, 650-4000 cm
−1
) and TGA (STA 409 PC Luxx® 
Netzsch, temperature range: 5-1700 °C, heating and cooling rates: 0.01 K/min-50 K/min, 
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inert atmospheres) of unloaded complex, chitosan and alginate powders and their 
physical mixture were performed. The IR spectra for the test samples were obtained using 
KBr disk method. Measurements were carried out at least in triplicate (relative standard 
deviation ± 5%). 
 
2.4 Preparation of chitosan/alginate complex vaginal inserts 
The freeze-dried chitosan/alginate complexes were used to prepare vaginal inserts. For 
unloaded inserts (average diameter 0.6 cm, height 1.0 cm) 200 µl of phosphate buffer at 
pH 4.5 were added to 20 mg of different complex/mannitol mixtures (9:1; w/w). Mannitol 
was added, as a bulking agent in order to improve mechanical strength of lyophilized 
vaginal inserts when handled (Luppi at al., 2009; McInnes et al., 2005). Loaded 
insertswere prepared in the same way adding 200 µl of chlorhexidine digluconate 
solutions (in phosphate buffer at pH 4.5) at different concentration in order to obtain three 
different complex/drug weight ratios (2:0.5, 2:1 and 2:2) for every type of complex. The 
resultant suspensions, filled into polypropylene microcentrifuge tubes, were allowed to 
settle to swell and remove air and finally lyophilized, obtaining cone-like shaped solid 
inserts. The inserts were stored in a desiccator until use (Luppi et al., 2010b). 
Moreover, control formulations were prepared, without chitosan/alginate complexes, 
using 20 mg of mannitol and 200 µl of chlorhexidine digluconate solutions at different 
concentration (mannitol/drug weight ratio 2:0.5, 2:1 and 2:2). 
 
2.5 Scanning electron microscopy (SEM) and energy dispersive X-ray spectroscopy 
(EDS) 
The morphology of vaginal inserts was studied by SEM analysis. Inserts were cut with a 
razor blade to expose the inner structure, fixed on supports and coated with gold–
palladium under an argon atmosphere using a gold sputter module in a high-vacuum 
evaporator. Samples were then observed with LEO 420 (LEO Electron Microscopy Ltd., 
England) using secondary electron imaging at 15 kV in order to examine the surface 
morphology and structure of the inserts. 
Moreover, drug distribution in the samples was evaluated by energy dispersive X-ray 
spectroscopy (EDS).     
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2.6 Friability studies 
Friability tests were conducted by subjecting at least 10 inserts to repeat revolutions using 
a friability tester. Inserts were weighted before and after the testing and % friability was 
measured as a percentage of weight lost during a standardized abrasion.  
 
2.7 Water-uptake ability 
Water-uptake studies were performed in phosphate buffer at pH 4.5 that simulate vaginal 
fluids and with the procedure reported in our previous work (Luppi et al., 2010b).  
The water-uptake behavior of loaded inserts with different complex/drug weight ratios: 
2:0.5, 2:1 and 2:2 was also investigated. 
 
2.8 Insert mucoadhesion properties 
For these studies, vaginal mucosa obtained from freshly slaughtered pig was used. In fact, 
porcine vaginal mucosa was found to be very similar to human one in many 
characteristics, such as lipid compositions and histological properties (Kremer et al., 2001 
and Van Eyk AD, 2005).The in-vitro mucoadhesion was measured in terms of the force 
needed to pull out a freshly excised porcine vaginal mucosa (surface area 1 mm
2
) from 
the inserts with an adapted tensiometer (Krüss 132869; Hamburg, Germany) as reported 
in a previous work (Luppi et al., 2010c).  
The mucosa, suspended from the tensiometer spring, was lowered until it just contacted 
the surface of the insert, previously immersed in phosphate buffers at pH 4.5 for 15 
min.A 500 µN force, measured by the torsion balance of the instrument as a negative 
force, was applied to the inserts for 30 s. Then, the vaginal mucosa was raised until it was 
separated from the formulations. This point represents the adhesive bond strength 
between these elements and is expressed as a positive force in dyne.  
 
2.9 In-vitro release studies 
In-vitro release studies were performed as reported in Luppi et al., 2010b. Briefly, loaded 
inserts were placed on the sintered-glass filter plate of a Borosil glass filter crucible and 
the whole system was closed with Parafilm to avoid evaporation of release medium 
(filled with 10 ml of pH 4.5 phosphate buffer) and adjusted exactly to the height of the 
release medium surface so that the porous glass membrane was wetted but not 
submersed. The experiments were performed at 37 °C under magnetic stirring. Samples 
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of 200 µl were taken at predetermined time points and replaced by fresh medium and 
analyzed using UV- spectrophotometer set at 254 nm. 
 
2.10  Microbiological assays 
The antimicrobial activity was evaluated against Escherichia coli ATCC 11105 and 
Candida albicans ATCC 10231. E. coli was grown aerobically in LB medium (Difco, 
Detroit, MI) at 37°C for 24 h. C. albicans was grown aerobically in SD medium (Difco) 
at 30°C for 48 h.   
Viability of E. coli and C. albicans in phosphate buffer (pH 4.5) was compared with 
viability of the respective bacterium and yeast cultured in the presence of vaginal insert 
based on CH/ALG (1:9) complex and containing chlorhexidine digluconate 
(complex/drug weight ratio 2:1). A microbial suspension, prepared from a broth culture 
in log phase growth of E. coli or C. albicans, was used to inoculate the Erlenmeyer flasks 
containing 120 ml of phosphate buffer. The initial concentration of E. coli and C. 
albicans was about 6 log of colony forming unit (CFU) per ml of experimental medium, 
corresponding to the physiological amounts in cases of infection. Counts of viable E. coli 
and C. albicans were carried on LB and SD agar plates, respectively, at the inoculum 
time (T0) and after 6 h (T6), and 24 h (T24) of incubation at 37°C (physiological 
temperature). LB plates were incubated aerobically at 37°C for 24 h. SD plates were 
incubated aerobically at 30°C for 48 h. All plates were made in triplicate. Microbial 
concentration was expressed as a mean of log CFU/ml ± standard deviation (SD).   
 
2.11 Statistical analysis 
All the experiments were done in triplicate. Results are expressed as mean ± SD. Anova 
tests were used to determine statistical significance of studies, respectively. Differences 
were considered to be significant for values of P < 0.05. 
 
3. Results and discussion 
 
3.1 Chitosan/alginate polyelectrolyte complex weight measurement 
Fig. 1shows the effect of chitosan/alginate molar ratio on complex formation at pH 5.0.  
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Fig. 1. Solid complex weights as a function of chitosan/alginate molar ratio at pH 5.0 
obtained from 400 mlof final polymeric solutions. 
 
The molar ratio for maximum insoluble complex formation at pH 5.0 was 1:1. In fact, at 
pH 5.0 most of the chitosan amino groups and alginate carboxylic groups were charged 
(pKb value of chitosan= 6.3 and pKa value of alginate= 3.5), thus providing the greater 
interaction between the polymers. Moreover, the amount of precipitated complexes 
CH/ALG(7:3) and CH/ALG(9:1) was lower with respect to that of CH/ALG(3:7) and 
CH/ALG(1:9), respectively (P<0.05); this suggest that greater moles of alginate were 
charged with respect to chitosan and that the presence of greater amount of alginate 
provided the formation of major amount of complex. For this reason, the amount of 
positively and negatively charges was evaluated. In particular, NH3
+
 and COO
-
 
theoretical concentration (mM) was calculated considering a complexation reaction 
between chitosan (5mM) and alginate (5mM) as a function of pKa values of the two 
polysaccharides and molar ratio chitosan/alginate at pH 5.0. NH3
+
  and COO
-
  theoretical 
concentration (mM) was 4.28 and 0.49 for CH/ALG(9:1), 3.33 and 1.45 CH/ALG(7:3), 
2.38 and 2.42 for CH/ALG(1:1), 1.43 and 3.39 CH/ALG(3:7), 0.48 and 3.36 for 
CH/ALG(1:9), respectively, thus demonstrating the greater ionization of alginate with 
respect to chitosan. 
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3.2. FT-IR spectroscopy and thermogravimetric analysis (TGA) 
Fig. 2 showed the FT-IR spectra of chitosan and alginate powders, physical mixture and 
CH/ALG(1:1) complex. 
 
 
 
Fig. 2. FT-IR of chitosan (a), alginate (b), chitosan/alginate physical mixture (c) and 
complex CH/ALG (1:1) (d) 
 
The FT-IR spectra of chitosan showed bands at 1654 cm
-1
 relative to the vibration of the 
carbonyl group of acetylated amide and at 1580 cm
-1
 relative to stretching of the free 
amino group. Alginate showed the typical band at 1620 cm
-1
relative to the vibration of 
C=O group. These characteristics bands were also in the FT-IR spectra of physical 
mixture of chitosan and alginate.The FT-IR of complex CH/ALG(1:1) showed the shift in 
amide carbonyl group to 1626 cm
-1
 and the shift in amino group of chitosan to 1554cm
-1
, 
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confirming the interaction between chitosan and alginate, also reported in Muzzarelli C., 
2003. 
Fig. 3shows thermograms of chitosan, alginate, physical mixture and CH/ALG(1:1) 
complex.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. Thermogravimetric analysis of chitosan (a), alginate (b), chitosan/alginate 
physical mixture (c), CH/ALG (1:1)  (d). 
 
Chitosan and alginate degraded at 293 and 238 °C, respectively. In the physical mixture  
there were two peaks at 238 and 293 °C that could be related to the weight loss of 
alginate and chitosan, respectively. The complex CH/ALG(1:1) showed one event at 202 
°C that can be considered as a proof of chitosan and alginate complexation. The shift in a 
lower temperature in the thermal degradation of the complex indicates that there was a 
loss of organization, due to the formation of ionic bonds between chitosan and alginate. 
 
3.3 Scanning electron microscopy (SEM) and energy dispersive X-ray spectroscopy 
(EDS) 
The structure of the inserts, observed by scanning electron microscopy (SEM), depends 
on the composition of chitosan/alginate complexes.  
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Fig. 4.  Scanning electron micrographs/EDS of the different chitosan/alginate complexes: 
A/1: CH/ALG (9:1), B/2: CH/ALG (7:3), C/3: CH/ALG (1:1), D/4: CH/ALG (3:7), E/5: 
CH/ALG (1:9) with complex/drug molar ratio 2:1. F/6: CH/ALG (1:9) with 
complex/drug molar ratio 2:0.5, G/7: CH/ALG (1:9) with complex/drug molar ratio 2:1, 
H/8: CH/ALG (1:9) with complex/drug molar ratio 2:2. 
 
Fig 4(A-E)show the morphology of vaginal inserts based on the different complexes with 
10 mg of chlorhexidine digluconate (complex/drug weight ratio 2:1). The presence of 
drug in the complexes produced a rough and less porous surface rather than smooth as 
unloaded complexes (images of unloaded complexes are not reported). 
Moreover, the complexes structure was more rough with the increase of the content of 
alginate in the complexes (Fig. 4D e 4E), probably due to the interaction between alginate 
and chlorhexidine digluconate. This interaction was studied measuring the turbidity (UV 
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spectrophotometer set at 500 nm) of alginate solutions (2% w/w) with increasing 
chorhexidine digluconate content (Bertram and Bodmeier, 2006). The drug concentration, 
at which precipitation started, was determined by extrapolating the linear correlation of 
the measured data points to an absorption of zero. Drug polymer interaction was observed 
as precipitation in polymeric solutions at concentration >0.06mg/ml.   
Fig. 4 (F-H) show the influence of different amount of drug on CH/ALG(1:9) complex. 
As can be seen, inserts based on complex/drug weight ratio 2:0.5 provided a more smooth 
surface with respect to inserts based on complex/drug weight ratio 2:1 and 2:2. 
Fig. 4 (1-8) shows the drug distribution in the inserts. As can be seen, the drug was 
homogeneously distributed in all the inserts based on the different complexes and also in 
the case of CH/ALG(1:9) inserts with complex/drug weight ratios 2:0.5,  2:1 and 2:2.     
 
3.4 Friability Studies 
Inserts should be hard enough to be easily removed from their packaging and to be placed 
intact into the vaginal cavity. Friability is a function of the hardness of a solid form and 
was measured in order to assess insert tendency to chip, crack or crumble due to friction 
and abrasion resulting from physical handling. The lower the friability, the more resistant 
the solid dosage form is to handling. In general, friability is affected by factors such as 
the size, shape and weight of the dosage form, as well as the formulation. In particular, 
friability values of loaded inserts based on CH/ALG(1:9), CH/ALG(3:7), CH/ALG(7:3) 
and CH/ALG(9:1) were 9.3±0.6, 10.1±0.3, 9.5±0.5, 9.8±0.4 %, while complex 
CH/ALG(1:1) provided a friability of 80±1.7%. All loaded inserts, except CH/ALG(1:1), 
were handled without damage and can be considered as promising formulations for 
vaginal application. 
 
3.4 Water-uptake ability 
Water-uptake was influenced by the medium (phosphate buffer pH 4.5) and by 
chitosan/alginate molar ratio. All the complexes showed the highest water-uptake ability 
at 120 minutes. In particular, the complex CH/ALG(1:1) showed the lower water-uptake 
ability among all the complexes (404.4 ± 11.2); while a large excess of chitosan and 
alginate allowed a greater water-uptake ability. In fact, water-uptake ability % of  
CH/ALG(9:1), CH/ALG(1:9), CH/ALG(7:3) and CH/ALG(3:7) were 686.2 ± 9.5, 767.9 
± 10.2, 484.9 ± 7.1, 548.7 ± 7.6 . This behavior is due to the presence of major charges in 
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the complexes CH/ALG(9:1) and CH/ALG(1:9)  that provided the entry of major amount 
of water in the systems. Moreover, in the complex CH/ALG (1:1), the ionization of the 
same amounts of polymers provided a system with a major interaction between chitosan 
and alginate and a minor amount of charges, thus limiting water-uptake ability. 
Furthermore, the complexes CH/ALG(1:9) and CH/ALG(3:7) showed a major water-
uptake ability (P<0.05) with respect to CH/ALG(9:1) and CH/ALG(7:3), due to the major 
ionization of alginate at pH 4.5 (see section 3.1).  
The influence of chlorhexidine digluconate on the water-uptake ability of the insert was 
also investigated (Fig. 5).  
 
 
 
 
Fig. 5. Water uptake ability after 120 minutes of differently loaded (complex/drug weight 
ratios: 2:0.5, 2:1, 2:2 and 2:4) complexes at pH 4.5 (n = 3, the SD did not exceed the 5%).  
 
As can be seen,  the presence of the drug in the vaginal inserts gradually reduced water-
uptake. In fact, for the preparation of loaded inserts, the drug was dissolved in phosphate 
buffer at pH 4.5 and the amino group of chlorhexidine (pKb 10.3) and the carboxylic 
groups of gluconic acid (pKa 3.6) were positively and negatively, charged, respectively. 
When drug solution was added to complex/mannitol mixture, these groups can interact 
with negative (alginate carboxylic groups) and positive (chitosan amino groups) charges, 
respectively, thus reducing the amount of free charges in the inserts.  
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3.5 Insert mucoadhesion properties 
The presence of different amounts of chitosan or alginate in the formulations influenced 
significantly theinsertsmucoadhesion properties. In particular, chitosan hydrochloride 
insert showed a higher detachment force value with respect to that of alginate insert (150 
± 7 µN and 55±3 µN, respectively). This behaviour can be due to the presence of chitosan 
amino groups that at pH 4.5, were positively charged and could interact with the 
negatively charge of sialic acid (pKa 2.6) and sulphate residues of mucin glycoprotein 
(Peppas and Sahlin, 1996). For the same reason, a decrease in the mucoadhesion values 
was observed with reduction of chitosan amount in the inserts. In fact, the detachment 
force for CH/ALG(9:1) and CH/ALG(7:3) was higher with respect to that for 
CH/ALG(1:9) and CH/ALG(3:7) inserts (88±4, 70±6, 55±3, 57±4 µN, respectively). 
Moreover, in the complex CH/ALG(1:1) the high interaction between chitosan and 
alginate limited the presence of the positively charges, and, consequently, the detachment 
force (27±2 µN). There was no significant difference in mucoadhesion results between 
loaded and unloaded inserts (P>0.05). 
 
3.6 In-vitro release studies 
Release profiles from loaded vaginal inserts (complex/drug weight ratio 2:1) at pH 4.5 
are shown in Fig. 6.  
 
 
 
Fig. 6. Fractional amount of chlorhexidine digluconate released over time at pH 4.5 from 
the different chitosan/alginate complexes (Mt drug amount released over time, M0 drug 
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amount in the formulation at t=0). Each datum represents the average of three 
determinations ± SD. 
 
 
 
 
Fig. 7. Fractional amount of chlorhexidine digluconate released after 6 h from differently 
loaded (complex/drug weight ratios: 2:0.5, 2:1 and 2:2) chitosan/alginate complexes at 
pH 4.5. Each datum represents the average of three determinations ± SD. 
 
In the case of the control formulation, the total amount of loaded drug was released after 
30 minutes, due to the fast dissolution of the mannitol insert (data not reported in Fig. 6). 
On the other side, a sustained drug release can be observed for all the complex based 
formulations, due to the interaction of chlorhexidine digluconate with alginate and 
chitosan. Among all the inserts based on the different complexes, CH/ALG(1:1) showed 
the higher drug release due to the higher degree of interaction between chitosan and 
alginate in the complex and the lower free charges amount able to interact with 
chlorhexidine digluconate. Surprisingly, despite the comprovate interaction between 
alginate and chlorhexidine digluconate suggesting a major sustained release, 
CH/ALG(1:9) insert allowed higher drug release with respect to CH/ALG(9:1) insert. 
As previously described, drug-complex interaction provided a decreased water-uptake. 
However the same interaction determined a decrease of density from unloaded to loaded 
inserts, indicating the capability of the hydrogel network to extend the polymeric chains 
in a greater way in presence of drug. In particular, the density values for unloaded and 
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loaded (complex/drug weight ratio 2:1) inserts based on CH/ALG(1:9) and CH/ALG(9:1) 
were 0.54 ± 0.02 g/cm
3
, 0.65 ± 0.03 g/cm
3
, 0.45 ± 0.02 g/cm
3
 and 0.52± 0.03 g/cm
3
, 
respectively.From these data we can also observed that the decrease in density was more 
evident for the insert with the excess of alginate, thus resulting in a major drug release 
from the polymer matrix, due to a greater drug diffusion ability. Finally in the case of the 
complex/drug ratio 2:2 the all inserts were unable to control drug release (Fig. 7).   
 
3.7 Antimicrobial activity of the vaginal insert containing chlorhexidine digluconate 
Viability of E. coli and C. albicans in phosphate buffer at pH 4.5 in the absence and 
presence of unloaded and loaded vaginal insert based on CH/ALG(1:9) complex 
(complex /drug weight ratio 2:1) is shown in Table 1. 
 
a
 Counts of viable E. coli and C. albicans were carried at the inoculum time (T0) and 
after 6h (T6) and 24h (T24) of incubation at 37°C. 
b 
Microbial concentration was expressed as a mean of log CFU/ml ± SD. 
 
Table 1. Viability of Escherichia coli and Candida albicans in phosphate buffer at pH 4.5 
with and without the vaginal insert containing chlorhexidine digluconate. 
 
Cell concentration of E. coli decreased after 6 h (T6: 4.38 log CFU/ml) and 24 h (T24: 
3.15 log CFU/ml) of incubation at 37°C, compared to the baseline value (T0: 6.15 log 
CFU/ml), with a survival of 71.2% and 51.2% at T6 and T24, respectively. Loaded insert 
exerted a strong antibacterial activity against E. coli as evidenced by the bacterial 
concentrations that were below the detection limit (< 2 log CFU/ml) at the time points T6 
and T24.  
A good viability in phosphate buffer was demonstrated by C. albicans, as its 
concentration remained approximately constant after 6 h (T6: 5.85 log CFU/ml) and 
 Microbial concentration (log CFU/ml ± SD)
b 
 Escherichia coli Candida albicans 
Time point 
(h)
a 
Unloaded insert  Loaded insert Unloaded insert  Loaded insert 
T0 6.15 ± 0.24 6.18 ± 0.15 5.90 ± 0.19 5.90 ± 0.23 
T6 4.38 ± 0.28 < 2 5.85 ± 0.20 5.00 ± 0.31 
T24 3.15 ± 0.19 < 2 4.86 ± 0.16 < 2 
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decreased about one logarithmic unit after 24 h (T24: 4.86 log CFU/ml) of incubation, 
compared to the baseline value (5.90 log CFU/ml). The survival of the yeast was found to 
be 99.2% and 82.4% at T6 and T24, respectively. The addition of the loaded vaginal 
insert to the experimental medium caused the loss of almost one logarithmic unit in the 
viability of C. albicans at T6 (5.00 log CFU/ml; survival: 84.7%) and a strong reduction 
of the yeast count at T24 (< 2 log CFU/ml). 
The present microbiological data demonstrated the inhibitory activity of the 
chlorhexidine digluconate formulated in vaginal insert against the principal pathogens 
which are responsible for aerobic vaginitis and candidiasis. 
 
Conclusions 
This investigation verified the formation of polyelectrolyte complexes between chitosan 
and sodium alginate in the vicinity of the pKa interval of the two polymers and confirmed 
the potential of these complexes, able to hydrate and adhere to vaginal mucosa. 
Moreover, these complexes can be used to prepare new suitable carrier system capable to 
overcome limits of the conventional delivery formulations, such as messiness and leakage 
of formulations, thus increasing patient compliance. The selection of the appropriate 
chitosan/sodium alginate molar ratio as well as the drug amount allowed the modulation 
of insert water-uptake behavior and chlorhexidine digluconate release. In particular, 
inserts based on the complex CH/ALG(1:9) provided the higher amount of released drug 
and microbiological data demonstrated that chlorhexidine digluconate released from this 
insert can inhibit the principal pathogens responsible of aerobic vaginitis and candidiasis.  
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Abstract 
The purpose of this work was to investigate the potential of a new chitosan nanocarrier 
composed of cyclodextrins and two excipients (C) with the capacity to modify insulin 
bioavailabity. In particular, the selected excipients, C1 and C2, were included in the 
chitosan/cyclodextrins nanocarriers in order to study their influence on nanoparticles 
physico-chemical properties and on insulin bioavailability upon nasal administration. 
Nanoparticles were obtained with the ionic gelation method, adding cyclodextrin/C 
solutions, with or without TPP, to the chitosan phase. The size of the resulting 
nanoparticles,ranging between 260 and 398 nm, was affected by the nature and the 
amount of the cyclodextrins and Cwhereas the zeta potential of the NPs was always 
positive.Nanoparticles in vitro stability was evaluated in different media and the 
empirical amount of C in nanoparticles was quantified using a kit. Finally, in vitro release 
and in vivo studies were performed in order to evaluate loaded nanoparticles ability to 
release insulin and to modify its bioavailability. Results showed good nanoparticle 
stability and capacity to decrease blood glucose levels in rats after nasal administration. 
 
 
 
 
 
Keiwords: nanoparticles, chitosan, cyclodextrin, insulin nasal delivery. 
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1.Introduction 
 
Peptides and proteins administration through oral route is characterized by a low drug 
absorption and bioavailability, due to the gastrointestinal environment and first-pass 
metabolism that lead to chemical and enzymatic drug degradations (Woodley, 1994; 
Saffran et al., 1997; Ram et al., 2003; Singh et al., 2008, Sood and Panchagnula, 2001; 
Chen et al., 2011). Other conventional administration routes, such as the intravenous 
route, are no convenient and show a poor patient compliance, due to the repetitive 
injections, generally necessary for a chronic treatment. In the recent years, nasal route has 
been studied as an alternative administration route thanks to the interesting properties of 
nasal mucosa. In fact, the large surface area, the porous endothelial membrane, the 
avoidance of first-pass metabolism and the ready accessibility of the nasal cavity can 
allow to obtain faster and higher level of drug absorption and a good patient compliance 
(Ugwoke et al., 2005; Costantino et al., 2007; Prego et al., 2005a). On the other hand, the 
mucociliary clearance mechanism removes rapidly the formulations from the nasal 
cavity, thus determining their low residence time and, consequently, low drug 
permeability and bioavailability (Merkus et al., 1998; Illum, 2003; Andersen and Proctor, 
1983; Inagaki et al., 1985; Harris et al., 1986). In order to overcome this limitation, in the 
past years many mucoadhesive materials were analyzed to evaluate their ability to adhere 
to nasal surface and to increase the contact time of drug systems with the nasal mucosa 
(Duchene et al., 1988). Different studies have shown that chitosan nanocarriers can 
facilitate the interaction of the drug with mucosa (Csaba et al., 2006; Felt et al., 1998; 
Prego et al., 2005b; Luppi et al., 2010), thanks to the interactions between positively 
charged chitosan amino groups and the sialic acid and sulphate aminoacidic residues of 
the mucus layer, thus providing a longer contact time for drug absorption (Lehr et al., 
1992). Moreover, another limitation with nasal route administration is the low 
permeability of polar and large molecular weight drugs, that generally cross the epithelial 
cell membrane by the paracellular route through the tight junctions between the cells. 
Although the tight junctions are dynamic structures, their mean size channels limit the 
transport of large molecules (Illum, 2003). Recent studies have demonstrated that 
chitosan can transiently open the tight junctions of the human barrier thus increasing drug 
permeability (Smith et al., 2004; Garcia- Fuentes and Alonso, 2012).  
In this study, in order to improve insulin bioavailability through nasal route, two 
excipients were used (C1 and C2) for nanoparticles formulation. Nanoparticles (NPs) 
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were obtained with the nanoprecipitation technique and were characterized with regard to 
their size, surface charge, C1/C2 experimental amount and stability in different media. 
Finally, in vitro release and in vivo studies were performed in order to study nanoparticles 
ability to drug deliver and to modify insulin bioavailability.  
 
2.Materials and methods 
 
2.1. Materials 
The following chemicals were obtained from commercial sources and used as received. 
Ultrapure chitosan (CS) hydrochloride salt (Protasan UP CL 113, Mw = 110 KDa and 
deacetylation degree = 86%) was purchased from FMC Biopolymers (Norway). 2-
hydroxypropyl-β-cyclodextrin (HP-β-CD, Mw = 1540, substitution degree = 4.69), 
pentasodium tripolyphospate (TPP), C1 and C2 were all purchased from Sigma-Aldrich 
(Spain). Sulphobutyl ether-β-cyclodextrin sodium salt (SBE-β-CD, Mw = 2163, 
substitution degree = 6.40) was obtained from CyDex, Inc. (USA). Recombinant human 
free Zn insulin (27.4 units/mg, isoelectric point = 5.8) was kindly donated by Novo 
Nordisk A/S (Målov, Denmark). The kit for xcipients C1 and C2 amount determination 
was purchased from Cayman Chemical (Michigan, USA). All other chemicals were 
reagent grade or higher. 
 
2.2 Preparation of cyclodextrin/C 
The two selected excipients (C) and CDs (CD/C molar ratio of 1:1) were solubilized in an 
ethanol/water mixture (1:11 v/v) with the adding of an equimolar amount of NaOH with 
respect to C. We obtained HP-β-CD/C1, SBE-β-CD/C1, HP-β-CD/C2 and SBE-β-CD/C2 
solutions with different C concentrations. In particular, for C1 and C2the concentrations 
ranges were 0.01-2mg/ml and0.01-1mg/ml, respectively. These solutions were 
evaporated with rotavapor until a volume reduction of tree times. In order to obtain 
control formulations, solutions without C were prepared with the same procedure.  
 
2.3 Preparation of NPs 
NPs were prepared according to the procedure previously described by our group (Calvo 
et al., 1997a; Calvo et al., 1997b). CS/TPP nanoparticleswere spontaneously formed upon 
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addition of 1 ml of TPP aqueous solution (0.15% w/v, polyanionic phase) to 3 ml of the 
CS solution (0.20% w/v, polycationic phase) under stirring. For CS/CD/C NPs, different 
volumes of CD/C1 andCD/C2 solutions, prepared as described above, were added to the 
polycationic phase, with or without TPP, obtaining NPs with different components 
weight ratio (table 1a, 1b and 2).In particular, in the case of nanoparticles based on HP-β-
CD, TPP was added maintaining a CS/TPP weight ratio of 4/1; while in the case of SBE-
β-CD NPs, the weight ratio CS/TPP was 4/0 or 4/0.5. Using the same procedure, CS/CD 
control NPs were obtained using solutions composed of only CD. 
The resulting NPs were isolated by ultracentrifugation (16000 × g, 30 min, 15°C; 
Beckmann Avanti 30, Beckmann, USA) and resuspended in ultrapure water. For loaded 
NPs, human insulin was added to the anionic phase until a final concentration in 
nanoparticles suspension of 0.25 mg/mL.  
 
2.4 Physicochemical and morphological characterization of NPs 
The mean particle size and the size distribution (PDI) of the NPs were determined by 
photon correlation spectroscopy (PCS) using a Zetasizer 3000 HS (Malvern W 
Instruments, Malvern, UK). The ζ-potential determination was performed by laser 
Doppler anemometry (Zetasizer 3000 HS, Malvern Instruments, Malvern, UK) after 
dilution with KCl 1 mM.  
The morphological examination of NPs was performed by transmission electron 
microscopy (TEM) (CM12 Philips, Eindhoven, Netherlands). All samples were stained 
with 2% (w/v) phosphotungstic acid and placed on copper grids with Formvar
®
 film for 
TEM observation. 
 
2.5 Stability in different media 
Unloaded and insulin loaded nanoparticles were tested for their stability in different 
media: water, phosphate buffer at pH 6.8 and at pH 6.0, simulating nasal secretions. 
Nanoparticles stability was evaluated taking into account the change of nanoparticles size 
and their possible precipitation. Aliquots of fresh suspensions of nanoparticles were 
diluted in these media reaching a concentration of 1 mg/mL, and the evolution of size 
was assessed using photon correlation spectroscopy (Zetasizer 3000HS, Malvern 
Instruments, UK) for 2 h at 37°C (n=3). The size and PDI of the nanoparticles in the 
fluids were measured after 30, 60 and 120 min by photon correlation spectroscopy.  
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2.6  Determination of Process Yield 
For the calculation of the nanoparticles production yields, the nanoparticles suspensions 
were centrifuged (30000g, 15 °C, 40 min), and the supernatant was discarded. The 
sediments were dried at 50°C until constant weight, and the difference of the theoretical 
solid weights and the actual dried nanoparticles weights were obtained (n = 3). The yield 
of the process was calculated as follows: process yield (%) = nanoparticles weight x 100/ 
total solids weight. 
 
2.7. Determination of excipients (C)experimentalamount 
The Cexperimental amount was investigated using a kit. First, nanoparticles composed of 
CD/C and of CDs (used as control formulations) were isolated as described in section 2.2 
and resuspended in ultrapure water. Then, chitosanase-RD was added to NPs suspensions 
(1:2 chitosanase-RD/NPs w/w ratio, 1 h, 37°C) in order to promote chitosan degradation. 
Following this process, the experimental amount of C in the nanoparticles were 
calculated using a kit.  
 
2.8 Loading and encapsulation efficiency of nanoparticles 
For the calculation of loading % and encapsulation efficiency, loaded nanoparticles were 
isolated by centrifugation as described in Section 2.2. The amount of unbound insulin 
was determined in the supernatant by HPLC analyses (Agilent1100 Series, Santa Clara, 
CA, USA), with a method described by Marsüchtz, M.K. and Bernkop-Schnürch (2000) 
that was thereby modified. Briefly, 20 µL of the supernatant was injected into HPLC. 
Insulin and/or degradation products were separated on a protein and peptide C18 column 
(Grace Vydac, W.R. Grace & Co., Columbia, MD, USA) at room temperature. Gradient 
elution was performed as follows: flow rate 1.0 mL/min, 0-10 min; linear gradient from 
70% A/30% B to 39% A/61% B (eluent A: 0.1% trifluoroacetic acid in water; eluent B: 
80% of acetonitrile and 20% of eluent A). Insulin and/or degradation products were 
detected by absorbance at 220 nm with a diode array absorbance detector. Insulin 
concentration was quantified from integrated peak areas and calculated by interpolation 
from an according standard curve. 
The loading % and the encapsulation efficiency of insulin, respectively, were calculated 
as follows: 
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Loading % = (Total amount of drug −Amount of unbound drug) x 100/ Nanoparticles 
weight 
Encapsulation efficiency (EE) = (Total amount of drug −Amount of unbound drug)x 100/ 
Total amount of drug 
 
2.9 In vitro release studies 
Insulin release studies were performed by incubating 0.1 mg insulin-loaded nanoparticles 
in 1mL of phosphate buffer at pH 6.0, simulating nasal secretions, at 37 °C. At 
appropriate intervals, the samples were filtered and the amount of released insulin was 
evaluated by HPLC analysis. Insulin concentrations were quantified and calculated by 
interpolation from an according standard curve. 
 
2.10 In Vivo Studies 
Male Sprague-Dawley rats (160-190 g) from the Central Animals House of the 
University of Santiago de Compostela (Spain) were fasted for 12 h before experiments 
but allowed water ad libitum. Animals were kept conscious during the experiments. The 
following formulations were administered intranasally to rats: (1) insulin aqueous 
solution, (2) CS/SBE-β-CD/C1/TPP (4/2/0.17/0.5) and (3) CS/SBE-β-CD/TPP (4/2/0.5) 
NPs. In all cases the insulin dose administered was 5 UI/kg and the volumes of 
formulations used were 40 µl (20 μL/nostril). Formulations were intranasally 
administered using a polyethylene tubing inserted about 1 cm into the nostril. Blood 
samples were collected from the tail vein 30 min prior the nasal administration (t) -30 
min, in order to establish the baseline glucose levels, and at different times after dosing 
(t) 0, 30, 60, 120, 180, 240 and 300 min. Glycaemia was determined in plasma samples 
by the glucose-oxidase method (Glucose-TR, Spinreact S.A, Spain). Results are shown as 
the mean values of plasma glucose levels % of initial level of six animals. 
 
2.11 Statistics 
Pairs of groups were compared by performing one-tailed Student‘s t-test and multiple 
group comparison was conducted by one-way analysis of variance (ANOVA). All data 
are presented as a mean value with its standard deviation (mean ± SD). p-Values less than 
0.05 were considered to be statistically significant.  
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3. Results and discussion 
 
3.1 Preparation of NPs 
In previous works, we have demonstrated the interesting properties of nanoparticles 
based on chitosan and cyclodextrins for insulin delivery (Fernandez-Urrusuno et al., 
1999; Maestrelli et al., 2006; Trapani et al., 2008; Teijeiro- Osorio et al., 2009). These 
nanocarriers combine the enhancement effect and the mucoadhesion properties of 
chitosan and the cyclodextrins capacity to load molecules with high efficiency, to protect 
drugs from enzymatic degradation and to promote their transport across mucosal 
surfaces. In the present work, in order to improve insulin bioavalability, we designed 
CS/CDs nanocarriers containing two excipients (C),C1 and C2, with the capacity to 
modify insulin bioavailabity. Moreover, for this study, we selected a neutral and a 
polyanionic cyclodextrin, HP-β-CD and SBE-β-CD. 
 
3.1.1. Conditions for NPs formation. 
First of all, we prepared CDs/C solutions with different C concentrations and then we 
formulated CS/CD/C/TPP nanoparticles with the ionic gelation technique, developed in 
our laboratory (Calvo et al., 1997a; Calvo et al., 1997b). 
CDs/C solutions were prepared with 1:1 molar ratio between cyclodextrins and C and in 
order to increase C solubility, an equimolar amount of NaOH was added in the solutions. 
Transparent solutions with the higher amount of C were selected for the preparation of 
nanoparticles. In particular, in the case of C1, Cconcentrations were 1.0 and 0.25 mg/ml 
for HP-β–CD/C1 and SBE-β-CD/C1 solutions, respectively. For solutions based on C2, 
C2concentration was lower (0.1 mg/ml) due to its lower solubility. These concentrations 
allowed us to evaluate the optimal conditions, in terms of components amount, for 
nanoparticle formulations. In fact, as reported in previous studies (Trapani et al., 2008), 
the formation of the different types of CS/CDs NPs were clearly influenced not only by 
the TPP and CS concentrations, but also by the nature of CDs and their amount added 
during the preparation process.  
3.2 Physicochemical and morphological characterization of NPs 
Tables 1a, 1b and 2 show the physicochemical properties of the different NPs: CS/TPP 
NPs, CS/CD/C/TPP NPs and CS/CD/TPP NPs, for every cyclodextrin and C. 
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Ratio  
CS/CD/C/TPP 
(w/w/w) 
Size (nm) Polydispersity δ (mV) 
CS/TPP 
4/1 
361 ± 20 0.36-0.44 +35.1 ± 0.3 
CS/ HP-β-CD-C1/ TPP 
4/ 3/ 0.33/ 1.0 
340 ± 4 0.30-0.35 +27.8 ± 1.4 
CS/ HP-β-CD / TPP 
4/ 3/ 1.0 
398  ± 2 0.28-0.31 +32.8  ± 0.4 
CS/ HP-β-CD- C1/ TPP 
4/ 6/ 0.67/ 1.0 
291  ± 5 0.26-0.29 +27.4 ± 0.3 
CS/ HP-β-CD / TPP 
4/ 6/ 1.0 
383  ± 5 0.30-0.33 +33.6  ± 1.2 
CS/ HP-β-CD- C1/ TPP 
4/ 12/ 1.34/ 1.0 
260  ± 5 0.29-0.34 +35.5 ± 1.0 
CS/ HP-β-CD/ TPP 
4/ 12/ 1.0 
360  ± 4 0.28-0.32 +31.0  ± 0.5 
Table 1a. Physicochemical properties of CS/HP-β-CD/C1/TPP NPs and their respective 
control formulations (NPs without C1), means ± S.D., n = 3. 
 
Ratio  
CS/CD/C/TPP 
(w/w/w) 
Size (nm) Polydispersity δ (mV) 
CS/TPP 
4/1 
361 ± 20 0.36-0.44 +35.1 ± 0.3 
CS/ HP-β-CD-C2/ TPP 
4/ 0.76/ 0.13/ 1.0 
322  ± 9 0.34-0.38 +34.3 ± 0.3 
CS/ HP-β-CD / TPP 
4/ 0.76/ 1.0 
335  ± 7 0.27-0.39 
+31.0  ± 1.8 
 
CS/ SBE-β-CD-C2/ TPP 
4/ 1/ 0.13/ 0.5  
375  ± 19 0.23-0.28 +33.9  ± 2.9 
CS/ SBE-β-CD/ TPP 
4/ 1/ 0.5 
b - - 
b = transparent solution 
 
Table 1b. Physicochemical properties of CS/HP-β-CD/C2/TPP and CS/SBE-β-
CD/C2/TPP NPs and their respective control formulations (NPs without C2), means ± 
S.D., n = 3. 
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Ratio  
CS/CD/C/TPP 
(w/w/w) 
Size (nm) Polydispersity δ (mV) 
CS/TPP 
4/1 
361 ± 20 0.36-0.44 +35.1 ± 0.3 
CS/ SBE-β-CD- C1/ TPP 
4/ 1/ 0.08/ 0.5 
381  ± 5 0.23-0.30 +31.5  ± 1.7 
CS/ SBE-β-CD / TPP 
4/ 1/ 0.5  
b - - 
CS/ SBE-β-CD- C1/ TPP 
4/ 2/ 0.17/ 0.5 
290 ± 7 0.22-0.28 +33.6  ± 1.6 
CS/ SBE-β-CD / TPP 
4/ 2/ 0.5 
337 ± 6 0.37-0.39 +31.4  ± 1.0 
b = transparent solution  
 
Table 2. Physicochemical properties of CS/SBE-β-CD/C1/TPP NPs and their respective 
control formulations (NPs without C1), means ± S.D., n = 3. 
 
It is well known that the NPs size largely depends on the cyclodextrins nature (Maestrelli 
et al., 2006; Trapani et al., 2008).  
In particular, data reported in the tables confirmed that the presence of HP-β-CD has no 
critical impact in the NP formation process and, therefore, no particular limit of CD 
amount needs to be respected for the preparation of these NPs, while SBE-β-CD can 
readily interact with CS, and an excess of cyclodextrin can lead to aggregates formation 
(data were not reported). In the case of nanoparticles based on HP-β-CD, the sizes 
decreased with the increase of the cylcodextrin amount, probably due to the formation of 
a more compact structure. For SBE-β-CD nanoparticles a reduction in size was also 
evident; this behavior can be explained with the formation of ionic interaction between 
chitosan and the anionic cyclodextrin that lead to smaller particles size, as demonstrated 
in our previous work (Trapani et al., 2008). 
Tables 1a and 2 report the sizes, polydispersity and potential zeta of nanoparticles with 
C1, in which it was possible to relate CS/CDs/C1/TPP NPs with the respective control 
NPs. In particular, for nanoparticles based on HP-β-CD, a decrease in size (p < 0.05) 
from CS/CDs/TPP to CS/CDs/C1/TPP was observed. This behavior has been attributed 
mainly to the presence of C1 that in the nanoparticles suspensions, was negatively 
charged and could interact with the positively charged amino group of chitosan; this ionic 
interaction could lead to the formation of a more compact structure. For SBE-β-CD 
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nanoparticles, CS/CDs/C1/TPP also showed a lower size than the control nanoparticles 
(without C1). In this case, the reduction in size of CS/CDs/C1/TPP was mainly attributed 
to the presence of the anionic cyclodextrin that can interact with chitosan, thus reducing 
nanoparticle size in a greater way with respect to HP-β-CD that weakly interacts with 
chitosan. 
In the case of NPs containing HP-β-CD and C2 (table 1b), the low amount of C2 
contained in the formulation did not provide a significant reduction in nanoparticles size. 
On the other hand, nanoparticles based on SBE-β-CD and C2 showed size in the 
nanometer range, but control preparations lead to transparent solutions. 
NPs composed of SBE-β-CD can be prepared also without TPP by direct incorporation of 
the SBE-β-CD/C solutions into the CS phase; in this case it was possible to incorporate a 
greater amount of cyclodextrin, because the cyclodextrin/TPP cooperative effect in the 
ionic interaction was absent. Moreover, we also observed a reduction of nanoparticles 
size with the increase of cyclodextrin and C amounts (data not showed).  
With respect to the zeta potential of the four series of NPs, it was interesting to observe 
that all the series exhibited positive charge values (tables 1a, 1b and 2). The fact that all 
the NPs showed positive zeta potential suggests that CDs and also the excipients C are 
mainly entrapped inside the NP matrix and do not mask the inherent charge of CS on the 
surface. Moreover, for NPs containing HP-β-CD/C1 a reduction of zeta potential was 
observed with respect to control formulations, probably due to the presence of the 
negative charges of C1 that, interacting with chitosan, reduced the positive charge of the 
surface. 
In all cases, the size, ranging between 260 and 398 nm, can allow nasal administration 
and promote an efficient drug transport through biological barriers, while the presence of 
a positive surface can improve the interaction between the formulations and the mucosal 
surface, ensuring a good mucoadhesion properties. 
Loaded NPs (table 3) showed a higher size with respect to unloaded NPs probably due to 
the incorporation of insulin inside the NPs, while a zeta potential decrease was observed. 
This zeta potential reduction could be explained by the interaction between CS and 
insulin that leads to a positive charge reduction in the NPs surface. 
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Ratio  
CS/CD/C/TPP 
(w/w/w) 
Size (nm) Polydispersity δ (mV) EE% Loading % 
CS/ HP-β-CD- C1/ TPP 
4/ 12/ 1.34/ 1.0 
308 ± 2 0.28-0.33 +27.6 ± 0.6 89.5 ± 1.1 25.3 ± 1.1  
CS/ HP-β-CD-C2/ TPP 
4/ 0.76/ 0.13/ 1.0 
340 ± 3 0.29-0.32 +30.7 ± 0.6 71.5 ± 5.2 19.3 ± 0.7 
CS/ SBE-β-CD-C1/ TPP 
4/ 2/ 0.17/ 0.5 
370 ± 4 0.19-0.27 +29.7  ± 0.9 46.7 ± 4.3 6.1 ± 0.4 
CS/ SBE-β-CD-C2/ TPP 
4/ 1/ 0.13/ 0.5  
387 ± 7 0.23-0.29 +30.5  ± 1.0 21.0 ± 1.1 7.1 ± 0.3 
Table 3. Physicochemical properties, EE% and Loading % of loaded nanoparticles 
(means±S.D., n=3). 
 
 
 
Fig. 1. Morphological Characterization performed by transmission electron microscopy  
of  blank NPs: CS/ HP-β-CD/C1/TPP (4/12/1.34/1) (a/c) and CS/SBE- β-CD/C1/TPP 
(4/2/0.17/0.5) (b/d). 
 
Fig. 1 shows the morphological appearance of CS/CD/C1/TPP NPs.In general, particles 
size measured by TEM is smaller than that determined by photon correlation 
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spectroscopy, which is attributed to the loss of water during the drying step prior to 
electron microscopy. It can also be observed that NPs containing HP-β-CD showed an 
irregular morphology (figure 1(a/c)), whereas those containing SBE-β-CD exhibits a 
round shape (figure 1(b/d)). 
 
3.3  Stability in different media 
In order to evaluate whether nanoparticles size changed in the different tested media and 
to predict their suitability for administration, NPs stability was investigated. Fig. 2 shows 
the stability of the following nanoparticles composed of C1: CS/HP-β-CD/C1/TPP 
4/12/1.34/1.0, CS/SBE-β-CD/C1/TPP 4/2/0.17/0.5, CS/SBE-β-CD/C1/TPP 4/4.3/0.33/0. 
 
 
 
 
Fig. 2. Stability of nanoparticles composed of C1  in different media (mean ±SD., n=3) 
 
As can be seen, all NPs were stable in water with small changes in size and DI values 
(PDI values are not reported). Furthermore, NPs with TPP were also stable in phosphate 
buffer at pH 6.8 and 6.0, while NPs without TPP aggregate and cannot be used for nasal 
administration. For this reason, for the next studies we selected NPs with the higher 
amount of C and with TPP. 
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3.4 Determination of Process Yield 
In order to study the influence of C on drug absorption through nasal mucosa, we selected 
the formulations with the higher amount of C. In table 4 we report the selected 
nanoparticles and the results of the process yield determination. 
 
Ratio  
CS/CD/C/TPP 
(w/w/w) 
Process yield (%) Theoretical C 
content(%) 
Experimental C content 
(%) 
CS/ HP-β-CD-C1/ TPP 
4/ 12/ 1.34/ 1.0 
11 ± 1 7.29 2.89 ± 0.14 
CS/ HP-β-CD-C2/ TPP 
4/ 0.76/ 0.13/ 1.0 
26 ± 2 2.28 0.17 ± 0.02 
CS/ SBE-β-CD-C1/ TPP 
4/ 2/ 0.17/ 0.5 
42 ± 2 2.56 3.53 ± 0.17 
CS/ SBE-β-CD-C2/ TPP 
4/ 1/ 0.13/ 0.5  
24 ± 1 2.36 0.58 ± 0.05 
 
Table 4.  Yield percentage for the prepared  nanoparticles and theoretical and 
experimental amount of C in nanoparticles (mean ± S.D., n = 3). 
 
As can be seen, for NPs containing HP-β-CD the yield was lower with respect to 
nanoparticles containing SBE-β-CD. In fact, HP-β-CD weakly interact with chitosan and 
its incorporation efficiency within the NPs was very low (about the 3% as demonstrated 
in another study (Trapani et al., 2008). In this work, we can also suppose that Cwere 
included in the hydrophobic cavity of the cyclodextrinandthat their  extremities,  
negatively charged, was located outside of the cyclodextrin andcan interact with chitosan. 
For this reason, we hypotized that also the incorporation efficiency of C was lower for 
NPs based on HP-β-CD with respect to SBE-β-CD nanoparticles. On the other side, the 
ionic interaction between chitosan and SBE-β-CD can lead to the formation of a great 
number of precipitation nuclei, increasing the incorporation efficiency of the cyclodextrin 
and consequently, of the excipients C, and leading to a greater process yield. 
3.5 Determination of excipients C experimental amount 
Table 4 reports the theoretical amount of C with respect to the total amount of 
nanoparticle components, while the C experimental amount was correlated to the weight 
of nanoparticles obtained after ultracentrifugation. As can be seen, in SBE-β-CD 
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nanoparticles, the amount of C was higher compared to that of HP-β-CD nanoparticles. 
As described in section 3.4, the incorporation efficiency of HP-β-CD was around the 3% 
and lead to a low process yield; for the same reason, the experimental amount of C, that 
was incorporated in the hydrophobic cavity of the cyclodextrin, was lower with respect to 
the theoretical amount. Moreover, the experimental content % of C1 was higher with 
respect to that of C2, although for Nps with HP-β-CD/C2 the process yield was higher 
than the yield of HP-β-CD/C1 NPs, thus demonstrating an higher incorporation capacity 
of C1. For the same reason, C1 was also mainly incorporated in nanoparticles with SBE-
β-CD with respect to C2; moreover, SBE-β-CD incorporation efficiency was very high 
through its interaction with chitosan and this aspect can allow to incorporate a great 
amount of C1 into nanoparticles. 
We concluded that the presence of the excipients in the formulations was influenced by 
the incorporation efficiency of cyclodextrin and by the capacity of the excipients to be 
included in the cyclodextrins and consequently, into the nanoparticles. In particular, data 
demonstrated that C1 can be incorporated in a higher amount inside the nanoparticles, 
with respect to C2. Moreover, in the case of SBE-β-CD/C1 nanoparticles, this aspect, 
together with the high incorporation efficiency of cyclodextrin, led to a greater C1 
experimental amount with respect to that theoretical. 
 
3.6  Loading and encapsulation efficiency of nanoparticles 
In the table 3 the loading % and the encapsulation efficiency of loaded nanoparticles were 
reported. As described in our previous study (Fernandez-Urrusuno et al., 1999), the 
association of insulin to chitosan nanoparticles is primarily based on electrostatic 
interaction such as hydrophobic interactions. As can be seen, nanoparticles with HP-β-
CD showed a very high encapsulation efficiency (>70%), leading to insulin loading 
values of 25%. Moreover, as discussed before, the incorporation efficiency of  
cyclodextrin and the C experimental amount were lower in the case of HP-β-CD based 
NPs than SBE-β-CD NPs; this aspect leads to a greater presence of chitosan in HP-β-CD 
NPsthat can interact with insulin. On the other hand, the insulin encapsulation efficiency 
in NPs composed of SBE-β-CD was lower; in fact, the anionic cyclodextrin and C, 
included in cylcodextrin, can interact with chitosan leading to a reduction of positive 
charges, able to bind insulin.  
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3.7. In vitro release studies 
In order to study the influence of the excipients C on drug release, we tested 
nanoparticles with and without C. In particular, fig. 3 shows the insulin amount released 
in phosphate buffer at pH 6.0 during 2 hours from CS/SBE-β-CD/C1/TPP (4/2/0.17/0.5) 
andCS/SBE-β-CD/TPP (4/2/0.5).  
 
 
Fig. 3. Insulin release from loaded nanoparticles CS/SBE-β-CD/CA/TPP (4/2/0.17/0.5) 
and CS/SBE- β-CD/TPP (4/2/0.5) in phosphate buffer, pH 6.0, 37 ◦C (means ± S.D., n = 
3). 
 
As can be seen, the 80 % of loaded insulin was rapidly released from nanoparticles, 
confirming that the insulin release depends on a simple dissociation mechanism based on 
the ionic interaction between the chitosan amino group and insulin negative charges. 
Significant difference between formulations with C1 and without C1 can not be found. 
 
3.8. In Vivo Studies 
Fig. 4 shows the reduction of plasma glucose concentration after intranasal administration 
of different formulations. In particular, the figure reports the plasma glucose levels 
achieved following administration of loaded CS/SBE-β-CD/C1/TPP andCS/SBE-β-
CD/TPP NPs, unloaded CS/SBE-β-CD/C1/TPP NPs as well as insulin solution instilled to 
conscious rats.  
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Fig. 4. Plasma glucose levels achieved in rats following nasal administration of: insulin 
solution, CS/SBE-β-CD/C1/TPP (4/2/0.17/0.5) unloaded nanoparticles and CS/SBE-β-
CD/C1/TPP (4/2/0.17/0.5) and CS/SBE- β-CD/TPP (4/2/0.5) loaded nanoparticles (mean 
± S.D, n=6).  
 
As shown in the figure 4, the administration of unloaded nanoparticles to rats did not 
provide any modification in plasma glucose levels during the experimental period, thus 
indicating the absence of stress that could be caused by the administration procedure or 
the blood sampling. The same figure shows that the administration of insulin control 
solution (5IU/Kg) resulted in a decrease blood levels less than 10 % at 30 min post 
administration. The blood glucose level fell to 87 % basal levels when insulin was 
associated with CS/SBE-β-CD/TPP NPs, confirming CS/CD nanoparticles properties to 
promote the nasal insulin absorption. In particular, chitosan ability to adhere to the 
mucosa and to transiently open the tight junctions and cyclodextrins properties to protect 
drugs from enzymatic degradation and to disrupt the epithelial membrane by extraction of 
phospholipids and proteins (Marttin et al., 1998; Fernandez-Urrusuno et al., 1999; 
Teijeiro- Osorio et al., 2009) can improve insulin absorption. Moreover, these results 
indicate that the nanoparticles preparation method not influenced insulin structure and 
activity.  
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Interestingly, a greater response was achieved after the administration of insulin loaded 
CS/SBE-β-CD/C1/TPP NPs. In fact, the blood glucose concentration decreased to about 
72% respect to the baseline levels at 30 minutes post-administration. This plasma glucose 
concentration reduction was the maximum and it was significantly different from that 
induced by the insulin control solution at least 1 hour and from that induced by 
nanoparticles without C1 at least 30 minutes post-administration. Indeed, the presence of 
C1 in nanoparticles could improve the pharmacological effect of the formulation, 
probably due to the bioavailability enhancement effect of C1.  
It is also interesting to note that the decrease in plasma glucose level obtained in this 
study with the administration of CS/SBE-β-CD/TPP loaded nanoparticles was lower with 
respect to the decrease observed with a similar formulation (CS/SBE-β-CD/TPP4/3/0.25) 
in our previous study (Teijeiro- Osorio et al., 2009). These differences can be explained 
by the different experimental approach: different animal model  (rabbits vs. rats) and 
different insulin (insulin from bovine pancreas vs. Zn-free human insulin).  
According to our previous studies, we can summarize the interesting results obtained 
when insulin was associated with CS/CD and CS/CD/C/TPP nanoparticles. First, CS/CD 
nanoparticles can enhance the absorption of macromolecules, such as insulin, thanks to 
chitosan and cyclodextrin ability to adhere to the epithelium and to open the tight 
junctions, to disrupt the epithelial membrane, as well as to protect drug from enzymatic 
degradation. Second, as demonstrated in this study, the presence of C1 in the formulation 
can promote a systemic absorption of insulin, leading to a reduction in plasma glucose 
level that was significant different from that induced by the same formulation but without 
C1.  
On the other hand, in our previous works, we hypothesized another mechanism that can 
influence drug nasal absorption. In fact, these nanocarriers can act as a true 
macromolecule carriers, internalizing in the nasal epithelium (as shown in the CLSM 
cross section of a previous work, Teijeiro- Osorio et al., 2009), thus operating 
simultaneously with the mucoadhesion and penetration enhancements mechanisms.  
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4.Conclusions 
 
In this work, CS/CD nanoparticles containing two excipients, C1and C2, able to improve 
insulin bioavailabilitywere prepared. Nanoparticles showed size in the nano range and a 
positive charge due to the presence of chitosan, that allows the interaction with the nasal 
epithelium. Nanoparticles with SBE-β-CD and C1 showed the higher content of the 
excipient C1 and interesting properties in terms of encapsulation efficiency and drug 
release. In vivo studies showed that the presence of the C1 modify insulin bioavailability, 
as demonstrated by the significant glucose decrease in the plasma rats.  
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Concluding remarks 
Chitosan represents a multifunctional polymer, featuring both mucoadhesive and 
permeation-enhancing properties and therefore is a widely studied excipient for 
transmucosal drug delivery. Chitosan have been used for the preparation of gels, solid 
inserts, powders and nanoparticles in which ionic interactions with anionic molecules can 
be recognized. This thesis have contributed to a deeperinvestigation of the properties of 
some chitosan based formulations. 
In particular, the paper 1 have demonstrated that chitosan and gelatin can be successfully 
employed for the formulation of buccal films that ensure the necessary dosefor treatment 
of hypertension and atrial fibrillation.Moreover, along with adequate drug release and 
permeation, desirable film characteristics such as suitable hydration, film tolerability and 
compatibility with buccal mucosaand mucoadhesion, were obtained.  
In the paper 2, polyelectrolyte complexes between chitosan and sodium alginate were 
obtained in the vicinity of the pKa interval of the two polymers. The complexes were able 
to hydrate and adhere to vaginal mucosa and can be used  to prepare vaginal inserts for 
local deliver of chlorhexidine digluconate. The selection of the appropriate 
chitosan/sodium alginate molar ratio as well as the drug amount allowed the modulation 
of insert water-uptake behavior and chlorhexidine digluconate release and provided the 
inhibition of the principal pathogens responsible of aerobic vaginitis and candidiasis.  
In the last paper, CS/CD nanoparticles loaded with insulin and containing two excipinets 
with the capacity to modify the bioavailabity of drug, C1 and C2, were prepared and 
characterized. Results demonstrated that  nanoparticles with SBE-β-CD and C1 showed  
interesting properties in terms of encapsulation efficiency and drug release. In vivo 
studies showed that the presence of C1 improve insulin bioavailability, as demonstrated 
by the significant glucose decrease in the plasma rats.  
I hope that these works will stimulate further investigations in the fieldtransmucosal drug 
delivery using chitosan based formulations and thatresearchers will collect further data 
and concrete clinical perspectives for a real application in the pharmaceutical industry. 
 
 
 
